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Abstract 
Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are 
major health burdens on the global population. To treat diseases of the lung, topical 
therapies using dry powder inhalers (DPIs) have been employed. However, a relatively small 
amount of dose (5.5 – 28 %) reaches the lung during DPI therapy leading to high inter-
patient variability in therapy response and oropharyngeal deposition. Strategies were 
assessed to take patient variability in inhalation performance into account when developing 
devices to reduce throat deposition and to mitigate flow rate dependency of the emitted 
aerosol. A cyclone-spacer was manufactured and evaluated with marketed and in-house 
manufactured formulations. An in vivo study showed that a high resistance inhaler would 
produce longer inhalation times in lung disease patients and that a spacer with high 
resistance may prove a suitable approach to address inter-patient variability. Two spacer 
prototypes were evaluated with cohesively- and adhesively-balanced particle blends. The 
data suggested that the throat deposition dramatically decreased for the emitted particles 
when the spacers were used with the inhalers (e.g. 18.44 ± 2.79% for salbutamol sulphate, 
SS 4 kPa) due to high retention of the formulation within the spacer (87.61 ± 2.96%). 
Moreover, variation in fine particle fraction and dose was mitigated when increasing the flow 
rate (82.75 ± 7.34 %, 92.2 ± 7.7 % % and 77.0 ± 10.1 % at 30, 45 and 60 Lmin-1, 
respectively). The latter was an improvement over previous proposed DPI spacers, where 
variability in emitted dose due to airflow rate was a major issue. Due to the different 
physicochemical properties of the active pharmaceutical ingredients used in the formulation, 
throat deposition and respirable fraction for adhesively-balanced particles (e.g. SS) were 
double that of the cohesively- balanced particles (salmeterol xinafoate, SX) (e.g. 65.83 ± 
8.99 % vs. 45.83 ± 5.04 % for SS:Coarse Lactose (CL) and SX:CL, respectively). Scanning 
electron microscopy revealed that surface-bound agglomerates were more freely removed 
from the carrier, but subject to decreased impaction-type deagglomeration forces in the 
spacer than for carrier-bound drug. An ex vivo study using breath profiles from healthy 
volunteers identified the minimization of differences between adhesively- and cohesively-
balanced blends when full breath profiles were studied compared to square-wave airflow. 
Therefore the use of constant flow for in vitro testing should not be the sole flow regime to 
study aerosolization when developing new inhalation devices and formulations.  
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1. The respiratory system 
The human respiratory system permits us to inhale and exhale air. It is divided 
in two main regions: the conduction and the respiratory zone. The first is represented 
by the airways that deliver air to the second region, where the gas exchange with 
blood occurs. The conduction zone is divided in 2 sections: the upper respiratory 
tract comprised of the nose and sinuses, the pharynges and part of the oral cavity; 
and the lower respiratory tract comprised of the larynx, trachea, bronchi and 
bronchioles. The respiratory zone is represented by the alveoli where the gas 
exchange occurs, providing the oxygen to the systemic circulation. The respiratory 
route maximizes the pharmacological effects of inhaled medication while minimizing 
side-effects. Compared to the oral route, the respiratory system has been used 
widely for the delivery of bronchodilators, anti-asthmatic drugs, and antiviral agents 
[1]. The human lung possesses a large surface area of 126 m2 for drug absorption, 
low metabolic activity compared to the gastrointestinal tract, high permeability of 
alveolar epithelium and a rich blood supply [2]. As the respiratory tract is one of the 
main exposure routes of our body, many drug products have been delveloped for the 
treatment of several diseases [3]. The following sections will discuss in more detail 
the conduction and respiratory airways. 
 
1.1.  Anatomy of the lung 
The air is warmed and humidified when inhaled through the nose, due to the 
nasal epithelium that also removes particulate material. It then passes through the 
conduction airways, which epithelium is composed of ciliated cubic or columnar 
epithelium with goblet cells. The air reaches the trachea that divides into the right 
and left bronchi that branch through the chest into 16 generations of bronchioles as 
proposed by Weibel [4]. All of the branches of the airways have different size and 
diameters. The bronchi have large walls 1 mm in thickness, which are reinforced with 
cartilage, whilst bronchioles do not possess such thickened walls [3]. In the 
manoeuvre of respiration, inspiration occurs more commonly at the right main 
bronchus because of the gentler angle to the trachea compared the left bronchus. 
The lung occupies the thoracic cavity that is a space bounded by the chest wall and 
the diaphragm. This space is lubricated by the fluid present in the pleura (double-
layer membrane of the lung). The lungs connect the internal environment with the 
pulmonary artery, pulmonary vein, lymphatic and vagus nerves [5]. The major 
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functions of the lungs are gaseous exchange, systemic circulation, homeostatic 
maintenance of blood pH, vocal expression. The right lung is further subdivided into 
upper, middle and lower lobes which each connect with the bronchus. The left lung is 
subdivided only into two lobes: the upper and lower. The shape of the lung is 
pyramidal and the height is about 20 cm where the density, when it is fully inflated, is 
0.2 kg dm-3. Approximately, the lungs weigh between 500 g and 600 g in a young 
healthy person [6]. 
 
The bronchi become terminal bronchioles approximately at generation 16, 
where after they are classified as respiratory bronchioles that eventually join with the 
alveolar sacs of the lung. Here the layer of the epithelial cells becomes the lining of 
the alveoli. Macrophages, neutrophilis and eosinophilis can be found and, at the 
level of alveoli, type I epithelial cells allow the gas exchange and form the thin air- 
blood barrier which is 0.5 µm wide. Type II pneumocytes produce a surfactant that is 
stored in the form of lamellar bodies in the cells. Approximately 300 million 
pneumocytes are assembled together among the blood capillaries to create an air – 
blood interface and a surface area of 126 m2. Each acinus has a size of 0.072 cm2 
[3].  In the alveoli capillaries are present and they are connected to a network of 
arteries and veins. The pulmonary artery and its branches deliver blood rich in 
carbon dioxide (CO2, and lacking in oxygen) to the capillaries that surround the air 
sacs. Inside the air sacs, carbon dioxide moves from the blood into the air. At the 
same time, oxygen moves from the air into the blood in the capillaries. The oxygen-
rich blood then travels to the heart through the pulmonary vein and its branches. The 
heart pumps the oxygen-rich blood out to the body [6].  
 
For breathing, muscles including the diaphragm, intercostals and abdominal 
muscles and muscles in the neck and collarbone area are required. The diaphragm, 
the main muscle, is located below the lungs and it separates the chest cavity from 
the abdominal cavity. The intercostal muscles are located between the ribs that 
create the thoracic cavity. Abdominal muscles are located below the diaphragm. 
They help to breathe out when fast breathing occurs, for example during physical 
activity [6]. Muscles located in the neck and collarbone area are involved when the 
muscles mentioned above do not work well or when lung disease impairs breathing. 
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1.2.  Physiology of the lung 
The three main physiological functions of the respiratory zone are ventilation, 
diffusion and perfusion [3]. The ventilation (inspiration and expiration) brings the air 
from the external environment to the alveoli and vice versa. The elasticity of the 
lungs permits the inspiration and expiration due to a pressure differential. The 
positive internal pressure is made by airways and alveoli, while the negative external 
pressure is made by the thoracic cavity (within the interstitial liquid). LaPlace's law 
and tension explain how the alveoli work. When inhalation occurs, the thoracic cavity 
pressure decreases and the alveoli become filled with air. LaPlace’s law (Equation 1) 
describes how the pressure changes with regards to the surface tension and radius 
of the alveoli, necessary to create the positive pressure [5]. 
P =
2T
r
      (1) 
Where P = pressure, T=surface tension and r= radius. 
 
During inhalation the radius of the alveoli increases from about 0.05 mm to 0.1 mm 
with surface tension of 50 dynes/cm. Therefore, the pressure shifts from 15 to 7.5 
mmHg. However, the surfactant present in the alveoli reduces the surface tension by 
a factor of 15 in order to maintain the normal respiratory pressure difference of 1 
mmHg [5]. According to LaPlace’s law, the pressure created by the surface tension 
would be greater in the smaller alveoli than in the big ones. If the surfactant was not 
present, the small alveoli would empty the air into the bigger ones and would 
therefore collapse. However, the presence of surfactant avoids the latter occurrence 
by reducing surface tension. The surfactant is a mixture containing phospholipids 
and proteins and, therefore, it positions itself between water molecules reducing 
hydrogen bonds (the main feature of aqueous surface tension).  
 
The diffusion (gas exchange) is measured by diffusion capacity for CO2 which 
tests how well the gas can cross the wall of alveoli and enter the capillary. Diffusion 
occurs in the lungs and in the cells. CO2 diffuses out of the cell and into the blood 
whereas oxygen diffuses into the cell from the blood. Smokers or patients affected 
by asthma show high values of CO2 [5]. 
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The final function of the respiratory tract is perfusion. Each division of the 
respiratory tract has its own blood supply. The pulmonary artery capillaries that 
surround the alveoli transport the oxygen and other gases into the blood and CO2 
from the blood back to the lung to be expelled [3]. 
 
Several terms have been developed to describe the various physiological 
capacities of the respiratory tract. Total lung capacity (TLC) is the volume of gas in 
the lungs following maximal inspiration, while the functional residual capacity (FRC) 
is the volume of the gas in the lungs at the end of normal expiration and it is 
comprised of the expiratory reserve volume (ERV, the amount of air expelled with 
maximal expiratory effort, approximately 1.2 L in an average weight male) and the 
residual volume (RV, volume of air after maximal expiration, approximately 3.1 L in 
an average weight male). Lung compliance (CL) is also very important to assess the 
stiffness of the lungs (Equation 2) [5]: 
CL =
∆V
∆P
      (2) 
Where ΔV = volume of air in the lung and ΔP = the difference between alveolar 
pressure and intrapleural pressure. In a young male, the CL is about 1.5-2.0 L kPa
-1. 
 
1.3.  Mechanics of inhalation and airflow 
When breathing, the diaphragm muscles contract, pulling the diaphragm 
downwards. The lung volume increases and the inta-alveolar pressure decreases 
causing air to flow into the lungs. During exhalation, the diaphragm relaxes and rises 
decreasing the lung volume. The pressure within the alveoli rises and the air is 
pushed out. Lung function testing measures the ability of the lung to work properly. 
The test gives an instant idea of any breathing problem such as shortness of breath 
[5]. 
1.3.1. Lung function testing 
Lung function tests measure the lung capacity (e.g. how much air can be taken 
into the lung and the amount of air that can be exhaled). Doctors use lung function 
tests to help diagnose conditions such as asthma, pulmonary fibrosis (scarring of the 
lung tissue), and COPD (chronic obstructive pulmonary disease). Also, these tests 
might be used to check how well treatments, such as asthma medicines, are 
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working. The breathing tests commonly used are: body plethysmography, spirometry 
and lung diffusion capacity. 
 
The term ‘‘lung volume’’ usually refers to the volume of gas within the lungs, as 
measured by body plethysmography. It assesses the FRC (Functional Residual 
Capacity), the specific airways resistance (sRaw), RV and TLC [7]. FRC is the 
volume of gas present in the lung at end expiration during tidal breathing. The ERV 
is the volume of gas that can be maximally exhaled from the end-expiratory level 
during tidal breathing (i.e. from the FRC). The maximum volume of gas that can be 
inspired from FRC is the inspiratory capacity (IC). The inspiratory reserve volume 
(IRV) is the maximum volume of gas that can be inhaled from the end-inspiratory 
level during tidal breathing. RV refers to the volume of gas remaining in the lungs 
after maximal exhalation (regardless of the lung volume at which exhalation was 
started). IVC is the inspiratory vital capacity that is the inhaled volume from the point 
of maximum expiration. VC (volume capacity) is the volume change at the mouth 
between the positions of full inspiration and complete expiration [7, 8].  
Spirometry is the assessment of the pulmonary function and measures the 
inhalation and exhalation volumes of air as a function of time [9]. Lung function 
markers, such as Peak Expiratory Flow (PEF), FEV1 (forced expiratory volume in 1 
sec) and Forced Vital Capacity (FVC), are assessed by spirometry. The ratio 
between FEV1 and FVC predicts the severity of lung obstruction [10, 11]. FEV1 is 
effort independent and highly repeatable for patients affected of mild asthma [11]. A 
reduced FEV1/FVC below the 5
th percentile of the predicted value shows narrowed 
airways (obstruction) during exhalation. In fact, a ratio < 0.7 typically occurs in those 
subjects affected with asthma [1]. When % FEV1 predicted is used as marker, 5 
classes of degree severity of airways obstruction can be distinguished [11]:  
- Mild >70 % 
- Moderate 60–69 % 
- Moderately severe 50–59 % 
- Severe 35–49 % 
- Very severe <35 % 
The graph below represents the normal volume - time dependent curve to show the 
FEV1 (Figure 1.1). 
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Figure 1.1.Volume-time loop of a healthy male showing the FEV1 (forced expiratory volume in 1 sec). 
 
Peak expiratory flow (PEF) is another marker used to monitor asthma and 
define the severity of obstruction. It is also, used as a reference value for monitoring 
the effects in changing the treatments. PEF is the highest flow achieved from a 
maximum forced expiratory manoeuvre and it is effort dependent. PEF (expressed 
as % of the predicted value) is usually compared to patients’ own previous best 
measurements when they used their own peak flow meter [10]. If the PEF is between 
50-75%, the obstruction is moderate [11]. On the other hand, if PEF is between 33-
50%, then the obstruction is severe.  
 
Another marker for asthma is the peak inspiratory flow (PIF) as it depends upon 
the patient’s ability to draw air into their lungs (e.g. through inhalers) [12]. It 
measures the highest flow that a patient is able to perform when s/he inhales. The 
PIF can be measured using the In-Check® system. [12, 13].  
 
1.3.2. Inspiratory flow loop 
Using the spirometer to assess lung function, a flow-volume loop can be drawn 
(Figure 1.2). It is generated by plotting the inspiratory (negative values) and 
expiratory flow (positive values) against the volume of air. It can predict early stages 
of obstructions and one advantage is that it shows whether the airflow is appropriate 
for a particular lung volume [14]. The flow-volume loop graph starts with a curve that 
FEV1 
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reaches a peak (PEF). After PEF is reached, the curve decreases (flow decreases) 
and more air is expired. After 25% of the total expired volume, FEF25 is reached. At 
half way FEF50 is calculated (FEF at 50% of FVC). At 75%, FEF75 is achieved. The 
mean flow between FEF25 and FEF75 is called FEF25-75. After the expiratory 
manoeuvre the patient has to make a complete and forced inspiration to close the 
flow volume loop [9].  
 
 
Figure 1.2. Flow-volume curve. On the x-axis volume of air is represented. On the y-axis inspiratory 
(negative values) and expiratory (positive values) is reported. 
 
The shape of the loop depends on the mechanical properties of the lung and 
different diagnoses can be made:  
 Normal - on exhalation the maximal expiratory flow is rapidly reached followed 
by a linear decline until exhalation is complete (as per Figure 1.2).  
 Asthma - typically the curve is a smooth concave shape as airway obstruction 
is relatively constant throughout expiration [9]. 
-10
-8
-6
-4
-2
0
2
4
6
8
10
0 1 2 3 4 5 6 7 8
Flow-volume curvePEF
FEF50
FEF75
FEF25
FVC
PIF
Fl
o
w
 (L
/s
)
Volume (L)
26 
 
In patients with obstructive lung disease such as COPD, the small airways are 
partially obstructed. A patient with obstructive lung disease typically has a concave 
flow-volume loop (Figure 1.3) [9].  
 
 
Figure 1.3. Flow-volume in obstructive lung disease. 
 
The air in the large airways can be exhaled without problems, so the PEF will 
be normal. However, when the lung is obstructed the small airways are partially 
blocked, so the air will escape more slowly. This will result in a lower flow and a 
sharp fall in the flow-volume. FEV1 and FEF25-75 will be low compared to healthy 
subjects. Typically the patient will have a normal FVC [14]. 
  
Restrictive lung disease means that the total lung volume is too low (Figure 
1.4). Since the airways are normal, the flow volume loop will have a normal shape: 
the curve will descend in a straight line from the PEF to the X-axis.  
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Figure 1.4. Flow-volume in restrictive lung disease: shape normal with low FVC. 
 
Often patients will show signs of both obstructive and restrictive lung disease 
showing a flow-volume loop with characteristics of both syndromes (Figure 1.5) [14]. 
 
 
Figure 1.5. Volume-time curve in mixed lung disease: FVC, FEV1 and FEF25-75 are too low. 
 
1.4. Pathophysiology of lung disease 
Diseases that affect lung function can cause obstructive or restrictive 
dysfunction. Obstructive diseases are characterised by a reduction in airflow and 
airflow limitation such as asthma, chronic bronchitis, COPD and emphysema. 
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Restrictive lung diseases are characterised by a reduction in lung size or an increase 
in lung stiffness resulting in a decrease in the maximum volume of air can be 
breathed (e.g. pulmonary fibrosis, asbestosis). Airway obstruction may be due to 
obstruction inside the airway lumen (e.g. secretion of mucus in chronic bronchitis), 
obstruction in the wall of the airway (e.g. inflammation in asthma), and obstruction 
outside the airways in the per bronchial region (e.g. destruction of the lung 
parenchyma in emphysema or tumour) [15]. 
 
1.4.1. Asthma and chronic obstructive pulmonary diseases 
Asthma and COPD are a major disease burden worldwide. In developing 
countries between 6.5 to 7.7 % of the population suffers from chronic bronchitis due 
to open-fire cooking with high child mortality [16]. In the United States, more than 22 
million people are known to have asthma and nearly 6 million of these people are 
children. The diseases are a major burden also in the UK with 7 million people 
suffering from asthma and 800,000 from COPD and with more than 1,200 deaths per 
year [11]. There is no a standard definition for asthma, however, it is characterised 
by inflammation and narrowing of the airways that lead to breathlessness, coughing 
and wheezing [11]. The inflammation is due to increased airway 
hyperresponsiveness to various stimuli and manifests by widespread narrowing of 
the airways that changes in severity either spontaneously or a result of treatment. 
Symptoms of asthma are commonly encountered in childhood but the disease can 
occur at any age. A variety of "triggers" may initiate or worsen an asthma attack (e.g. 
antigen, pollen, animal fur or tobacco smoke) [17]. It has been found that also the 
enzyme tryptase (found in mast cells, a type of white blood cell important for fighting 
infection) may cause asthma and other inflammation disorders. Progression of 
asthma needs to be controlled because exacerbation (during which symptoms 
worsen over-and-above the baseline respiratory function decline of the disease, 
typically requiring a change in therapy [11]) leads to poor quality of life characterized 
by reduced physical activity, increased mortality and morbidity, increased health 
costs and hospitalization rates [18]. Exacerbations can also have a significant impact 
on the patient’s long-term condition; it has been reported that repeated episodes 
result in faster decline in lung function, thereby contributing to disease 
progression.The exacerbations can have different classification of severity:  
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- mild, which involves an increase in respiratory symptoms that can be 
controlled by the patient with an increase in the usual medication;  
- moderate, which requires treatment with systemic steroids and/or antibiotics; 
- severe, which describes exacerbations that require hospitalization [19]. 
 
Similar effects of this disease are present in COPD a disease of the lungs most 
frequently associated with smoking (9 out of 10 COPD-related deaths) [20]. People 
with COPD suffer shortness of breath, they sometimes have spasms of airways of 
the lung (especially of bronchial branches), and suffer with cough and wheeze. 
Symptoms and lung damage slowly deteriorate over time and the lung function 
rapidly declines [21]. Cardiovascular diseases are often associated with COPD and 
are the causes of mortality in COPD [22]. Donaldson et al [23] analysed 25,857 
patients with COPD over a 2 year time period. They correlated the risk of 
cardiovascular disease with episodes of COPD exacerbation. Risk of myocardial 
infarction or stroke 1-5 days and 1-49 days after an exacerbation episode were 
reported, respectively [23]. The mechanisms linking COPD and heart disease are 
still unclear but systemic inflammation might be an explanation of the increased risk 
of vascular events [24, 25]. 
 
1.4.2. Pulmonary remodelling 
Chronic inflammation and airway hyperresponsiveness damage the epithelium of 
the lung, leading to smooth muscle and mucus gland hypertrophy (an increase in 
size of airway smooth muscle cells) and hyperplasia (an increase in the number of 
airway smooth muscle cells) [26]. The thickening of the airway wall causes 
irreversible airflow limitation as the tract will be narrowed and, therefore, increasing 
airway resistance [27]. This would lead to difficulties in breathing for the patient and 
a rescue therapy of bronchodilators is needed. The remodelling is also driven by 
inflammatory mediators such as interleukins, histamine, eosinophils, mast cells, 
metallo-proteases that have destructive, restorative and chemiotaxic properties [19, 
28, 29]. All the structures of the bronchi are involved in asthma and inflammation. 
The separation of the mucosal cells in bronchial epithelium could be observed, 
leaving an intact basal cell layer. Ebina et al [30] preformed 3-D morphometry of 
airway muscle cells on serial sections of autopsied lungs from 10 asthmatic patients. 
In some cases the thickened muscles were found only in the central and larger 
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bronchi without hypertrophy, while there were some cases where thickened muscles 
were found everywhere in the tract and hyperplasia was mild and localized only in 
the bronchi. Moreover, airway macrophages were found in increased numbers in 
asthmatic bronchi. They appear to be in an activated state and release enzymes, 
mediators that cause bronchoconstriction and mucus secretion, eicosanoids, 
platelet-activating factor (PAF), oxygen free radicals and cytokines, including tumour 
necrosis factor (TNF) that might be deleterious to the bronchi. Macrophages can also 
synthesize and secrete elastase and a group of metallo-proteases having the 
capacity to degrade various extracellular macromolecules such as elastin [26]. 
Moreover, macrophages in addition to fibroblasts are responsible for the production 
of collagen, leading to fibrosis [26, 31].  
 
1.4.3. Changes in the airflow anatomy 
It has been shown that airway remodelling is an important mechanism that 
leads to fixed airflow obstruction in asthma [27]. This is due to the inability to reach 
the predicted lung function levels after bronchodilator therapy. The airways structure 
in asthma is altered due to the thickening of the walls of the conducting airways. 
Moreover, the lumen narrows and excessive mucus is produced. This narrows the 
airways further, leading to a high resistance to airflow [32]. Studies have found that 
increased airway inflammation was strongly correlated with destruction of alveolar 
attachment, suggesting a role for leukocyte-derived proteases in alveolar disruption 
[33, 34]. The obstruction in the small airways is caused by epithelial changes (e.g. 
goblet cell hyperplasia and squamous cell metaplasia), and fibrosis [15]. Airway 
inflammation increased with the severity of airflow limitation, and was correlated to 
increased numbers of macrophages, neutrophils, B and T lymphocytes and lymphoid 
follicles [15]. Therefore, small airways are major contribution to airflow limitation in 
asthma and COPD [35]. 
 
1.4.4. Ventilation, mucus and lung function test changes 
Studies reported that asthmatic patients with recurrent exacerbations and with 
stable condition had increased closing volume and closing capacity (CC) in the same 
manner, even after bronchodilator therapy [36]. Therefore, narrowing of the small 
airways is a risk in severe asthmatic patients with frequent exacerbation episodes. 
The lumen mucus is secreted in large quantities by cells and mucus-secreting 
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submucosal glands. Goblet cell hyperplasia is a feature of the large airways in both 
asthma [37] and chronic bronchitis [38]. 
 
It has been reported that asthma and COPD are associated with a rapid decline 
in FEV1 [21]. The ratio of FEV1  and FVC is a criterion of the presence of airflow 
limitation and should be the primary guide for distinguish obstructive from non-
obstructive patterns [31]. It was shown that [32] the wall area internal to the muscle 
was significantly thickened over the entire range of cartilaginous airways measured 
and that this was associated with a reduction in FEV1/FVC ratio. 
 
1.5. Particle - lung interactions 
Understanding the deposition of particles is important to improve the efficiency 
in drug delivery for inhalation therapies, but also to understand risks of inhalation 
toxicology [39].  Deposition is the process by which an inhaled particle separates 
from the airflow stream and contacts the respiratory surface from which there is no 
re-suspension [40].  
 
1.5.1. Mechanisms of deposition of the particles 
Deposition is a very complicated process and it is divided in five mechanisms, 
depending on particulate structure, size, chemistry, shape, physiological factors of 
the environment. The five different mechanisms are: impaction, sedimentation, 
diffusion, interception and electrostatic precipitation. 
 
Inertial impaction occurs when a particle that has a specific momentum cannot 
follow the airstream and thus deviates from the airflow during inhalation and impacts 
on any anatomical structures in its path [40]. The probability of a deposition of a 
particle by impaction is a function of Stokes number (Equation 3) [40], which is a 
dimensionless number that describes the behavior of particles in a suspension and it 
is defined as the ratio of the stopping distance of a particle to a characteristic 
dimension of the obstacle: 
 
𝑆𝑡𝑘 =  
𝜌𝐶𝑉𝐷𝑝
2
9𝜇𝐷𝑗
      (3) 
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Where Stk is Stokes number; ρ is the particle density (g/cm3); C is the 
Cunningham slip correction factor; V is the velocity (cm/sec); Dp is the particle 
diameter (cm), µ is the fluid viscosity (Pa sec); Dj is the jet diameter (cm) [40]. The 
higher is Stokes number, the more readily the particle will impact. When air is 
inhaled, large particles with high momentum will deposit in the upper airways where 
impaction commonly occurs [40]. 
 
Sedimentation is a time-dependent process where particles travel under 
gravitational force and it is dominant in the smaller airways (i.e. the bronchiolar 
region where the flow velocity is low and airway diameter is small). Stokes Law 
determines the velocity of sedimentation (Equation 4) [40]: 
 
 V=
2
9
(ρp−ρf)
μ
gR2     (4) 
  
Where V is the velocity of sedimentation, ρp is the density of the particle, ρf is the 
density of the air, g is the gravital acceleration, µ is the dynamic viscosity, R is the 
radius of the particle. 
 
For particles of smaller size (< 1 µm), the motion becomes random and diffusion, 
or Brownian motion, occurs. This motion increases as the particle size is reduced 
and it occurs in the deepest part of the lung. 
 
Interception takes place when the centre of gravity of a particle is in the gas 
phase while one of its ends comes in contact with the airway or alveolar wall. 
Deposition by interception is important when the dimension of the airways is 
comparable with one of the particles’ dimensions. For similar volume, elongated 
particles are likely to deposit by this mechanism [40]. 
 
A charged particle may induce an image charge of opposite sign on the surface 
of the airways that are electrically conducting and then deposit by electrostatic 
precipitation [40]. This mechanism contributes less that 10% of overall deposition 
[41]. Thus, the deposition due to charge is usually small compared to deposition by 
the previously mentioned mechanisms [42] (Figure 1.6). 
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Figure 1.6. Diagram of the mechanisms of deposition of the particles: impaction, sedimentation and 
diffusion, interception and electrostatic deposition. 
 
From a toxicological point of view, all particles smaller than 10 µm in geometric 
diameter have the potential of being biologically active in susceptible individuals [43]. 
Deposition is dependent on particle size so it would be useful to predict where the 
particles may deposit in the respiratory tract considering their size. Particles larger 
than 10 µm in diameter are likely to deposit in the  mouth and throat [40].  
 
Pharmaceutical inhalation technology suggests that particles smaller than 5 µm 
deposit in the lower airways (bronchiolar-alveolar level) therefore, pharmaceutical 
powders are required to be of this size [40, 44, 45]. In fact, particles with size range 
of 1-5 µm will deposit in bronchi and bronchioles by impaction, whilst particles with 
size range of 1.0-2.5 µm will deposit in alveoli and bronchioles by sedimentation [46]. 
Particles with a diameter below 1 µm deposit by diffusion and the one with 0.5 µm 
size are exhaled as they do not have enough mass and momentum to deposit by 
impaction and sedimentation [40].  
Impaction
Sedimentation
Diffusion
Interception
Electrostatic deposition
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The target of inhaled drugs for treatment of asthma and COPD is the lower 
areas of the respiratory tract, in particular the bronchioles and the alveolar region. 
The target region for deposition of the active agents is related to the location of the 
receptor sites. For example, β-adreno receptors are located in lower respiratory tract 
in small conducting airways [47], whereas the cholinergic receptors (e.g. M3 
muscarinic receptors) are located on the airway smooth muscle [48]. Thus, in order 
to have a better local effect, β-agonists should be deposited in peripheral as well as 
central airways of the lower regions of the lung [46-48]. 
 
1.5.2. Physicochemical properties: aerodynamic diameter and particle size 
distribution 
Although particle size is probably the major factor affecting particle deposition in 
the lung, several other factors affect the total and the regional deposition of particles. 
These factors can be particle characteristics (e.g. particle density), physiological 
factors, lung anatomy, and environmental factors. Also the shape can have an 
important effect on the aerodynamic behaviour of the particles and therefore on 
deposition efficiency. The airways have a particle-size selective system as a function 
of the aerodynamic diameter of the particles. Aerodynamic diameter is the diameter 
of a hypothetical spherical particle of unit density that settles in air at the same falling 
velocity as the physical particle (Equation 5) [49]. 
 
dae = dg√
ρ
χ
      (5) 
            
where dae= aerodynamic diameter, dg= geometric diameter,  ρ= particle density and 
χ= shape factor. 
 
Thus, it is important to measure the particle size and density in order to 
predict the deposition of the released particles from an inhaler as an indicator of the 
efficacy of the device. The term "aerodynamic diameter" has been developed in 
order to provide a simple means of categorizing the sizes of particles having different 
shapes and densities with a single dimension. Also, aerodynamic diameter is 
suitable to describe the deposition behavior for non-spherical particles [46]. The 
aerodynamic diameter is useful for: 
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- Predicting the behavior of particle in air 
- Determining site of deposition in lung 
- Optimizing air sampling characteristics 
 
In Figure 1.7 a representation of particle deposition in the respiratory tract based on 
the aerodynamic diameter is reported. 
 
 
Figure 1.7. Deposition of particles according to the aerodynamic diameter [50]. 
 
Aerodynamic size is important when porous particles are used for aerosol 
medication [51]. The density of porous particles is lower than for non-porous ones. 
Therefore, according to the definition, if the density of a particle is reduced the 
aerodynamic particle size would decrease. For appropriate porous particle delivery, 
the correct size should be created and the relationship between geometric diameter, 
aerodynamic diameter and particle density has to be taken into consideration. To 
deliver large particles, the density can be reduced, i.e. increasing its porosity [51]. 
The porous structure permits deep lung delivery of relatively large diameter 
therapeutic aerosols, for example greater than 5 µm [52]. Because of their rough 
surface, particle agglomeration can be reduced and a powder with high dispersibility 
can be provided, which is ideal for aerosolization via DPIs (dry powder inhalers), 
leading to lower deposition in the mouth and throat. One of the problems with porous 
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particles is that they are more likely to be deformable than non-porous particles 
during powder processing and also, due to a high specific surface area, they can 
uptake water vapour and so increase their density and aerodynamic diameter, 
thereby, decreasing their dispersibility [40]. 
 
The aerodynamic diameter is important for predicting lung deposition and 
bioavailability, formulation of inhaled medication, flow and packing properties. 
Therefore, particle size analysis has been developed to obtain quantitative data on 
the mean size, particle size distribution (PSD) and shape of the particles to be used 
in pharmaceutical formulation to assure the quality of the final dosage forms and 
drug delivery systems. The PSD is the particle frequency distribution that shows the 
percentage of particles found in each size range [53]. The PSD can be related to: the 
number-weighted, surface-weighted and volume (or mass)-weighted. However, the 
volume (mass)-weighted PSD is the most appropriate description for pharmaceutical 
materials. The number-weighted PSD is useful for determining the size of primary 
particles in agglomerated systems as well as the tightness of a PSD. The closer the 
number weighted and volume weighted PSDs, the greater the monodispersity of the 
particle size [53]. Accordingly to the definition of PSD, frequency or cumulative 
distribution can be plotted (on the Y-axis) by number count, surface area, or 
mass/volume and the graph showed in Figure 1.8 will be obtained. 
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Figure 1.8. Particle size distribution of fine lactose (LH 300) at 5 bar using the laser diffraction 
instrument (Rodos, Sympatec GmbH). 
 
The mode (value that occurs most frequently in a distribution) diameter corresponds 
to the peak of the distribution and for a symmetric distribution is equivalent to the 
mean and median diameter. The median diameter represents 50% (particle diameter 
that divides the frequency distribution in half, DV50) of the particle population. The 
width of the PSD (or span) is calculated from lower and upper fractions of the 
cumulative PSD as Equation (6) [54]: 
 
span =
Dv90−Dv10
Dv50
     (6) 
 
Most aerosols are polydisperse and have a wide range of diameters. Therefore, 
it can be said that most particles in a powder sample with a narrow distribution have 
a similar particle size, while a sample with a wide distribution may possess the same 
median diameter as the narrow sample but possess a wider range of particle sizes 
[53].  Aerosol size distribution (for dry powder inhalers (DPIs) and metered dose 
inhalers (MDIs)) is better described by a log normal distribution. Therefore, when the 
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fraction of particles (of a particle size) is plotted against the logarithm of the particle 
diameter, a Gaussian distribution will result (Figure 1.8) [55]. 
 
1.6. Pulmonary drug delivery 
Orally-inhaled products (OIPs) are used for local treatment lung diseases due 
to the large surface area and the lack of hepatic first - pass effect. Moreover, delivery 
of drugs for inhalation can also lead to a systemic delivery (e.g. insulin). Small 
molecules can be delivered with very rapid action, low metabolism and high 
bioavailability; and macromolecules can be delivered without injections, as 
highlighted by the first inhaled insulin product [56]. 
 
1.6.1. Medications to treat asthma 
The principal medications used in asthma are corticosteroids and 
bronchodilators. Corticosteroids can suppress inflammation of the airways, even in 
very low doses. However, they have poor clinical effect for COPD as they treat 
inflammation that is often absent in obstructed lungs. In both asthma and COPD, 
corticosteroids are commonly given as combination inhalers with long acting β2-
agonists (LABA, such as salmeterol xinafoate and formoterol fumarate) [57]. At a 
cellular level inhaled corticosteroids reduce the numbers of inflammatory cells in 
asthmatic airways, including eosinophils, T-lymphocytes, mast cells and dendritic 
cells [58]. Corticosteroids include budesonide, fluticasone propionate, becometasone 
dipropionate and they exhibit similar chemical structures as they are derivatives of 
cortisone.  Patients with mild asthma treated with a low dose of corticosteroids 
(budesonide 400 μg daily) showed fewer symptoms and a progressive improvement 
in lung function [59] with fewer episodes of exacerbation [60]. Combination of 
corticosteroids and LABA (becomethlasone propionate 200 μg and salmeterol 50 μg) 
led to an improvement of the lung function in asthmatics  [61]. Therefore, adding a 
LABA is more effective than increasing the dose of corticosteroids [11] in terms of 
improving asthma control and reducing exacerbations [62]. 
 
 
1.6.2. Difficulties in delivering pulmonary medications 
The conduction zone of the respiratory tract is composed of bronchi and 
bronchioles. The bronchiolar diameter decreases further down towards the 
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respiratory zone whereas the number of airways for each generation increases at a 
much higher rate. Moreover, in the upper airways the air stream is subject to a sharp 
change in direction and deposition by impaction may occur [3]. Furthermore, the 
tracheo-bronchial region ciliated cells are present which facilitates mucociliary 
clearance of any deposited particles [29]. Delivery of inhaled drug, therefore, might 
be difficult [41, 63]. In the alveoli, the columnar epithelial cells are replaced primarily 
by Type I cells alongside their progenitor Type II cells that also produce lung 
surfactant. In this region the alveolar macrophages and proteases are found too [3]. 
They are one of the most important mechanisms of defence presents into the lung 
when particles of 1-6 µm size are inhaled. They can dispose of particles either by 
transporting them along the alveolar surface to the mucociliary escalator, or by 
translocation to tracheo–bronchial lymph or by internal enzymatic degradation (for 
protein and peptide drugs) [64]. Lombry et al [65] demonstrated that alveolar 
macrophages comprise one of the major barriers to the transport of macromolecules 
from the lungs into the bloodstream, particularly for moderate-sized to large proteins. 
Therefore, strategies to increase systemic absorption of macromolecules over the 
last decade have been developed: chemical or physical alternatives for minimizing 
alveolar macrophages; inhibition of endocytosis using physiological modulators; co-
administration of ligands competing with proteins for binding on membranes of 
macrophages; and the preparation of large porous particles combined with various 
excipients to enhance absorption and/or retain the drug at the site of deposition. 
 
1.6.3. Inhalation therapies 
MDIs (metered dose inhalers) and DPIs (dry powder inhalers) have been used 
widely with historical improvements in the delivered dose. Inhaler use is common in 
Europe with MDIs comprising 75% of all sales in the UK [66]. Nevertheless, the NHS 
bulletins show an increase in hospitalization of asthmatic and COPD patients. For 
example, between 2009-2010 there were more than 100,000 emergency admissions 
to hospital in England for exacerbations of COPD [67]. This is due to multiple causes 
such as poor patient concordance, compliance and competence. Many patients 
display poor inhalation technique, having received inappropriate training from the 
medical staff and the prescription of unsuitable inhalers [11, 68, 69]. Constant design 
and formulation changes are made to improve the aerosolization of the particles from 
inhalers. GlaxoSmithKline (GSK) manufactured the Gemini® DPI, that has a similar 
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design to the Diskus™, but instead of having a single strip of blisters, there are two 
stripes of blisters containing one a corticosteroids and one a LABA. At actuation, the 
two strips come in contact with each other for a better aerosolization of the drug. 
Moreover, GSK together with Theravance, manufactured the Relvar® to deliver 
vilanterol and fluticasone. Acton Pharmaceuticals also developed a new pMDI 
(Aerospan®) to deliver flunisolide [70, 71]. 
 
1.7. Dry Powder Inhalers 
The first dry powder inhaler for treatment of lung disease was the 
Abbot/Spinhaler® developed in 1970. Seven years later the Rotahaler® (a single 
dose DPI) was used with salbutamol. Subsequently, the Turbuhaler® and 
Diskhaler®, the first multidose DPIs were employed, followed by GlaxoSmithKline's 
Diskus™ [72]. DPI doses can be loaded with a single capsule (Cyclohaler®), or multi 
single unit dose (Diskus™) or as reservoir device (Turbuhaler®) [73]. DPIs have 
been designed to be able to deliver a dose in the range of inhalation flow rate 
between 30 and 90 Lmin-1 [74]. There are differences between MDIs and DPIs. DPIs 
are propellant free (in comparison to MDIs); can deliver a high dose of drug particles 
and are breath-actuated so they avoid the hand-lung coordination required for MDIs 
[75]. Thorsson et al. [76] and Borgstrom et al. [77] showed that twice the dose is 
delivered to the lungs when emitted from the Turbuhaler® than from a MDI [76]. 
However, the efficiency of delivery of medicaments to the target regions of the lung 
is typically low and variable for DPIs. Less than 15 % of the emitted budesonide 
reached the lung in healthy volunteers (n=10) [78] and when the inhalation rate 
increased, aclidinium bromide emitted from Genuair® DPI showed 34 % of lung 
deposition [79]. The same trend was previously shown for MDIs with only 5.5 – 28 % 
of a dose depositing in the lung [80]. Patients with obstructive lung disease are 
unable to generate an aerosol cloud effectively from DPIs [81]. In particular a high 
fraction of the emitted dose deposits in the oropharynx, and the latter fraction cannot 
be therapeutically active and contributes to side-effects [82]. Borgstrom et al. [77] 
showed that the lung deposition from a Turbuhaler of terbutaline sulphate (nominal 
dose of 0.25 mg) in thirteen asthmatic patients was 20.8 %. When a MDI was used 
for the same drug, the lung deposition was only 4.8 % for 0.25 mg. Therefore, in this 
study, an improved lung deposition has been shown and that the use of a DPI has 
greater potential. DPIs, therefore, are overtaking the MDI market [66]. 
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DPIs are termed passive inhalers because they employ the patient’s own 
inhalation for the aerosolization of the drug product [83]. The design of the DPI helps 
the deagglomeration of the formulation within the device. The design of each DPI is 
optimised to emit the formulation as a respirable dose during inhalation. However, 
each DPI has different resistance due to a different design and this plays a major 
role on the magnitude and properties of the delivered dose. For example, the size of 
the internal diameter of the device mouthpiece might affect the turbulence to air flow 
through each device [84]. Rotahaler®, Spinhaler® have low resistance, Diskus™ 
and Cyclohaler® have medium resistance, and Easyhaler™  and Turbuhaler® have 
high resistance [85]. Al-Showair et al. [81] showed that the higher the internal 
resistance of DPI, the lower is the flow rate generated for a given pressure drop. 
Therefore, it has been suggested that patients with obstructed lungs require a low to 
medium resistance inhaler, to be able to generate sufficient airflow rate foe effective 
aerosolization. 
 
Single-unit dose inhalers such as the Cyclohaler® consist of a capsule that 
must be replaced after each actuation. The patient presses the buttons on the side of 
the inhaler that are connected with pins that pierce the capsule (Figure 1.9, A). Upon 
inhalation the velocity of the particles increases and more collisions occur between 
the drug and the grid which also creates more energetic turbulence [86]. A multiunit-
dose inhaler such as the Accuhaler™, contains prepared unit dose drug powder in 
sealed blisters, which are pealed open by lifting the mouthpiece lid and the powder is 
dispersed by the turbulent shear upon inhalation (Figure 1.9, B) [87]. Multi-dose 
reservoir inhalers (e.g. Easyhaler™) have been designed to minimize the flow 
dependency between patients. The Easyhaler™ consists of a bulk supply of drug 
from which individual doses are metered with each actuation (Figure 1.9, C) [88]. In 
this way, up to 200 doses can be delivered. The Easyhaler™ has a protective case 
and the hopper is designed so that is impossible for the patients to blow inside the 
inhaler. 
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Figure 1.9. Design of three different dry powder inhalers: Cyclohaler® (A), Accuhaler™ (B) and 
Easyhaler™ (C). 
 
The change in dimension of the airflow path between DPIs maximizes the 
particle separation. As a result, the fine particle fraction (FPF), and the lung 
deposition ratio of drug particles are enhanced [86]. The literature [89] highlights that 
dose emission from an Easyhaler™ is fairly consistent irrespective of the flow rates 
compared to other DPIs (Figure 1.10). Easyhaler™ also is easy to use therefore, 
more suitable for patients [90]. 
 
 
Figure 1.10. Dose delivery (% of the nominal labelled dose) from three salbutamol-containing multi-
dose powder inhalers at different flow rates in asthmatic patients: Buventol Easyhaler (200 µg/dose), 
Inspiryl Turbuhaler (100 µg/dose) and Ventolin Diskus (200 µg/dose) [89]. 
 
A B C
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The design of the DPIs has been improved over 40 years, and a modern device 
has been developed and marketed (the Conix™) that shows a greater delivery of the 
dose compared to the Accuhaler™ [91] because it contains a miniature reverse flow 
cyclone that helps the deagglomeration of the particles. Another DPI with a cyclone 
system has been developed: the AirMax™ (Figure 1.11). 
 
 
Figure 1.11. Design of the novel dry powder inhalers AirMax™ (A) with the cyclone system (B) [92]. 
 
The design of the AirMax™ is similar to a pMDI for patients’ convenience. Tests 
using either budesonide or salbutamol on the FPF (fine particle fraction) and total 
emitted dose from the AirMax™ demonstrated significant improvement compared to 
that of the Turbuhaler® and more constant dose delivered regardless of the 
inhalation flow rates used [93] . 
 
1.7.1. Fluidisation of inhalation powders 
Most DPI formulations are composed of micronized drug and coarse carrier, 
which is typically lactose monohydrate (size of 63-90 µm), that improves the 
flowability of cohesive particles and therefore, minimizes the interparticulate forces 
caused by their micronized size. It is also necessary as a bulking agent as the dose 
of the drug is typically small [75]. The patient’s inhalation airflow causes fluidisation 
within the device and creates turbulence that should be sufficient to de-aggregate 
drug/carrier mixture [75, 85] into fine particles with the potential to deposit in the lung 
(i.e. the respirable dose). The principal forces leading to powder de-agglomeration in 
inhalers can be divided into frictional forces, drag and lift forces, and internal forces 
Inlet
Cyclone separation 
that collects the 
lactose carrier
Fine particles escape
A B
Air
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[94]. The deagglomeration of drug particles to form a fine, respirable aerosol cloud is 
caused by particle interaction with shear flow and turbulence, particle-device and 
particle-particle impaction [95]. In the formulation sometimes, ternary agent (e.g. fine 
lactose) is added to enhance dispersion of the active pharmaceutical ingredient 
(API). 
 
There are two theories that explain the attachment of the API to the carrier: the 
active site theory and the agglomeration theory (Figure 1.12). It has been suggested 
that due to the rough surface of the carrier, there are sites with high energy to which 
the API is likely to be attached. Therefore, the presence of fine carrier particles is 
required to compete with the API. Thus, when the dose is delivered, the API is 
dislodges easily [75, 96]. Other studies suggested that the API with the fine particle 
carrier creates agglomerates on the surface of the coarse lactose and, upon 
aerosolization, the agglomerates are released from the carrier, therefore the drug is 
liberated from the fine carrier particles [83].  
 
Figure 1.12. Diagram of active site and agglomeration theories for the attachment of the drug to the 
carrier 
 
In order to deliver the dose to the lung, passive inhalers employ patients’ 
inspiratory flow that creates turbulence that should be sufficient enough to allow the 
transition of the powder bed from a static to a suspended state in the airstream, and 
to deaggregate the fluidised particles into smaller ones due also to impaction of 
particles on the device components (e.g. capsules, walls and outlet). This process is 
called fluidisation [75]. 
 
carrier
carrier carrier
Active pharmaceutical 
ingredient (API)
Fine carrier particles
Active Sites 
Theory
Agglomeration 
Theory
carrier
carrier carrier
Active pharmaceutical 
ingredient (API)
Fine carrier
particles
Active Sites 
Theory
Agglomeration
Theory
45 
 
1.7.2. Powder and blend structure of the formulation 
The micronized drug particles required for pulmonary delivery (1-5 µm) show 
cohesive behaviour, and dispersion upon inhalation can be difficult [97]. To 
overcome this issue, lactose monohydrate or other type of carrier (with size between 
63-90 µm) is added to the formulation, and improve the flowability of micronized 
drug. Marketed formulations often contain carrier with the drug (Ventolin™ and 
Seretide/Accuhaler™, Easyhaler™). In vitro studies have shown also that different 
types and % of lactose might affect the aerosolization of the formulation [98-101]. 
 
A small carrier size has been demonstrated to increase the fine particle fraction 
of budesonide from 26.36 ± 0.79% to 37.46 ± 0.15% when carrier size decreased 
from 120-180 µm to 32 µm [102]. Moreover, increasing the API dose load on the 
carrier surface increased the emitted dose with a linear relationship [96]. 
 
It has also been shown that the aerosolization of the drug and coarse lactose is 
improved when a fine ternary agent is added. Zeng et al [103] showed that adding 
fine lactose to the formulation of salbutamol sulphate/lactose monohydrate 
decreased the pre-separator deposition from 55.6 % for blends without micronized 
lactose to 36.1 % for blends with the ternary agent. Adi et al [104] showed that 
adding fine lactose to the formulation of salmeterol xinafoate/coarse lactose 
increased almost three-fold the FPF of the drug than when fine lactose was absent 
(11.7% and 4.0%, respectively). Therefore, it seems that the introduction of a small 
amount of micronized lactose to the formulation improves drug detachment from the 
carrier particles and consequently, improves the FPF of the API. In fact, as per the 
theory described in Section 1.7.1, adding micronized lactose particles may reduce 
the drug/carrier interactions as the fine lactose competes with the API and occupies 
possible drug binding sites on the carrier lactose particle surface. Some studies 
suggested that the presence of fine lactose is sufficient to enhance the respirable 
fraction most probably due to the fact that the API, not adhering to the coarse lactose 
surface, is more available for dispersion. Srichana et al. [105] showed an 
improvement in the fine particle fraction of SS when micronized lactose was added 
to the drug rather than when only coarse lactose was used (44.29 ± 1.30 % vs. 29.76 
± 0.69 %). 
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There is an increasing interest in formulations that do not need the coarse 
carrier to aid the flowability of micronized drug. The Turbuhaler®, for example, 
consists of a carrier-free formulation. Here, micronized drug particles are loosely 
agglomerated into larger particles with improved flowability such that the 
agglomerates can flow from the drug reservoirs into metering chambers of the 
inhaler [106]. During the patient’s inspiratory action, shear and collision forces 
provided by the turbulent air stream generated within the device disperse the 
agglomerates and break them up into smaller particles that can penetrate into the 
lung.  
 
1.7.3. Physicochemical proprieties affecting formulation performance 
When a formulation is manufactured, particle size, shape, morphology and 
chemistry need to be taken in consideration. Also the surface rugosity of the carrier 
plays an important role. The high energy areas on the carrier surface provide sites to 
which drug particles adhere leading to poor dispersion. On the other hand, when the 
surface of the carrier is smoother, the particles are more exposed. It has been 
demonstrated that smooth carrier particles facilitate higher respirable fractions [107]. 
Moreover, irregular drug particle shape can also reduce the ease of dispersion as it 
increases the area of inter-particle contact. Furthermore, very big carrier size affects 
the drug dispersion: larger particles are subject to greater aerodynamic drag forces 
and can enhance the drug dispersion from the surface [103]. 
 
1.7.3.1. Cohesive and adhesive behaviours 
The surface electrostatic forces associated particles in the inhalable size range 
overcome gravitational force, resulting in the development of cohesive powders 
(drug-drug interaction) with poor flow [40]. Therefore, micronized particle behave as 
agglomerates. However, when carrier is added, micronized particles may exhibit two 
different behaviours: they evenly spread on its surface (e.g. salbutamol sulphate, 
SS), leading to an adhesive behaviour (drug-carrier interaction) [108, 109] or create 
agglomerates (e.g. salmeterol xinafoate, SX  [98, 104]) as a result of a more 
cohesive behaviour. The drug particles are bound by physical forces to active sites 
on the surface of the carrier particles [73]. The interaction between lactose and drug 
molecules provides a degree of resistance to segregation, but must not be so great 
as to prevent the deaggregation of the drug from the carrier during drug delivery. Any 
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drug still adhering to the lactose after the aerosol has been generated will be 
deposited in the oropharyngeal region, which has the potential to cause local side-
effects, as in the case of inhaled corticosteroids [82]. 
 
1.7.3.2. The nature of interparticulate forces driving cohesive and 
adhesive formulations 
The degree of drug dispersion depends upon the forces of interaction within the 
powder formulation and the mechanical forces of dispersion from the device and 
patient’s inspiration. The adhesion forces between drug and carrier consist mainly of 
Van der Waals forces but also Columbic forces and capillary forces [40]. Studies 
demonstrated that strong adhesion of the drug to coarse carrier reduced the extent 
of dispersion of the micronized particle [99, 110]. Factors affecting interparticulate 
forces within the powder formulation include the drug and carrier properties, drug-
carrier ratio, ternary components, mixing process conditions, presence of 
electrostatic charges, moisture content, carrier surface rugosity and storage 
conditions [111, 112].  Adi et al. [99] showed that adding fine lactose improved the 
dispersion process of the salmeterol xinafoate from the coarse carrier, because the 
interaction between the fine lactose and the SX produced mixed agglomerates with 
enhanced dispersion efficiency, and more easily broken up during inhalation. 
 
The adhesion of fine particles to the carrier varies when the roughness of the 
carrier varies. Increasing the surface roughness of lactose particles improves 
delivery efficiency. Kawashima et al. [110] showed that increasing the surface 
rugosity of the carrier increased the emitted dose of the drug as the lactose can carry 
more drug particles, but it decreases the respirable fraction. However, mixing fine 
lactose particles improved deaggregation, as well as the fine particle fraction. 
Smaller particles have a lower degree of surface roughness and smaller 
interparticulate contact area than big particles. Therefore,  the liberation of the drug 
from the surface of fine lactose can occur with more efficiency than from the coarse 
carrier [101]. Thus, the respirable fraction is enhanced when fine lactose is present, 
while the flowability of the powder is maintained by the coarse lactose. Other studies 
showed that the presence of coarse carrier is not necessary [113]. Behara et al. 
[113] showed that SS and fine lactose mixtures with increased lactose content (1:4 
to 1:8) improved powder aerosolisation. However, at high flow rates, a negative 
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effect on SS aerosolization was found. The deagglomeration of the mixture was 
greater than for individual powders, indicating that adhesive interactions overcome 
forces that otherwise reduced deagglomeration. 
 
1.8. In vitro formulation performance analysis 
In order to predict deposition in the lungs, impaction studies have been widely 
proposed [114-116]. DPIs and MDIs are meant to aerosolize drug particles and the 
deposition of the latter inside the pulmonary regions is a function of the aerodynamic 
diameter. Laser diffraction analysis has been proposed to assess the particle size 
distribution based on the number or volume of particles. However, many studies 
have used monodisperse aerosol to study deposition mechanisms [117, 118] and 
therefore, a generator that can create monodipserse aerosol has been proposed. 
Moreover, it is essential to validate, device and impactor stage cut-off diameters and 
monodisperse aerosol are necessary to achieve this. 
 
1.8.1. Monodisperse aerosol generator 
Several studies [117, 118] have used monodisperse aerosol in order to deliver 
a specific sized particle to a particular lung region. The monodisperse aerosol 
generator uses a liquid jet to create the particles. Therefore, the solid has to be 
dispersed and diluted in an appropriate solvent before coagulation occurs. The 
vibrating orifice aerosol generator (VOAG, model 3540) used in the current project 
was composed of four major parts (Figure 1.13): 
- the liquid feed system 
- the droplet generator 
- the droplet dispersion system 
- the aerosol flow system 
 
The liquid feed system consists of a syringe pump that feeds the droplet generator 
with liquid at a constant flow rate. The droplet generator consists of a stainless steel 
cup, an orifice disc placed inside the bottom of the cup, a Teflon O-ring on top of the 
orifice disc and a stainless steel cap placed onto the O-ring to hold the orifice disc in 
place. There is also a ring-shaped piezoelectric ceramic that vibrated when the 
aerosol is generated. The liquid, from the liquid feed system, is fed through the cap 
into the cup and is then sprayed through the orifice. A voltage is applied to the 
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piezoelectric ceramic which vibrates the cup and create a single liquid jet at a 
constant frequency. The frequency helps to create a uniform jet leading to emission 
of monodisperse aerosol [119]. When the frequency is either too high or too low, the 
jet splits in two leading to more than one size of droplet (called “satellites”) [120]. The 
droplet stream enters the dispersion system. The droplet dispersion system consists 
of a Perspex steel holder and cover for the droplet generator, a pressure regulator, a 
flow meter, and an absolute filter. The cover has a dispersion orifice through which 
both the droplet stream and a turbulent air jet pass. When the droplet stream 
reaches the turbulence of this air jet, it is dispersed into a conical shape. The 
dispersed droplets (aerosol) then enter the aerosol flow system.  
 
 
Figure 1.13. Diagram of a monodisperse aerosol generator. 
The aerosol flow system consists of a blower and flow meter for the main dilution air, 
an absolute filter, a perforated plate which supports the droplet generator assembly, 
and a vertical plastic tube for diluting and drying the volatile liquid droplets. Air from 
the blower passes through the absolute filter, through the perforated plate, and then 
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mixes with the dispersed droplets. This clean air dilutes and transports the aerosol, 
and, in the case of a non-volatile solute in a volatile solvent, the clean air also 
evaporates the volatile solvent. The monodisperse aerosol then leaves at the top of 
the plastic tube [119].  
 
1.8.2. Impaction analysis of aerosol particle size 
Cascade impactor is the technique based on inertial impaction of particles and 
is used to measure the particle distribution based on the aerodynamic size [115]. 
Cascade impactors group together Multi Stage Impinger, Andersen Cascade 
Impactor (ACI) and Next Generation Impactor (NGI). Cascade impaction is based on 
a simple principle: when the airflow changes direction, particles in the airstream are 
subjected to two forces. The first one is the momentum derived when the particles 
travel along the streamline; the second one is the hydrodynamic force (i.e. friction) 
with the surrounding air stream as the particle changes direction. The momentum 
keeps the particle in its original flow trajectory, whilst the friction created between the 
particle and the air makes the particle accelerate in a new direction in the air. 
Therefore, until the particle loses the inertia, it will keep travelling in the original 
direction. Then it will change direction within a characteristic time. The latter 
determines whether or not a particle will deposit in a specific collection surface [40]. 
The technique is used widely because the emitted dose from the inhaler is divided 
into aerodynamic size classes that characterize the potential region for deposition in 
the respiratory tract [121]. The aerosol is guided by the air stream at  a defined flow 
rate through a model mouth, throat and to the next stages where the particles are 
deposited depending on their size; therefore each stage represents a specific 
particle size range [115]. The whole system is described by the flow rate of the air 
and the geometry of the nozzles in each stage and these parameters are used for 
calculating the size cut-off of a stage [116, 122]. In an impactor, the particle is drawn 
through the nozzle, which accelerates the air and the particle to high speed. The 
surface of the impaction plate deflects the air which makes a sharp turn. The 
particles with sufficient inertia continue their movement to the collection surface and 
impact into it [115]. At each stage if the nozzle diameter or the number of nozzles is 
decreased, then the air velocity will increase as a consequence in order to keep the 
volumetric flow constant and thus the inertia of the particles is increased 
progressively. If a small particle does not have sufficient inertia to deposit in one 
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stage, it will deposit onto a later stage due to increased inertia at that stage. Thus, 
each stage collects particles that have diameter larger than its cut off size. The cutoff 
point is defined as the point of 50% collection efficiency [115]. 
 
1.8.3. Laser diffraction analysis of aerosol particle size 
The difference between laser diffraction analysis (LDA) and impaction 
techniques is that LDA provides information of the geometric particles size, whereas 
impaction gives information on the aerodynamic particle size of aerosolized particles. 
Therefore, the impaction technique is widely accepted as an in vitro prediction of 
how particles will deposited in the lungs based on their aerodynamic size.  
 
Along with cascade impaction, laser diffraction analysis (LDA) has been 
evaluated to investigate aerosol particle distributions [116]. LDA measures the 
particle size that corresponds closely to the volume equivalent diameter for a near 
spherical powder [116, 123]. In the LDA, a monochromatic laser beam hits the 
aerosol cloud that scatters the light into a Fourier lens. This lens focuses the 
scattered light into a multi-element detector and, using an inversion algorithm, a 
particle size distribution is calculated from the collected diffracted light intensity data 
[44]. Therefore, the particle size is a function of the angle of the diffracted light and 
thus, the particle volume. LDA uses an optical model to interpret the scattering data 
and hence calculate a particle size distribution and the Dv10,  Dv50 and Dv90 that 
correspond to the particle diameter (by volume) below which 10%, 50% and 90% of 
the particles exist [123]. There are two optical methods that convert the light energy 
diffraction pattern into a size distribution: the Fraunhofer approximation and the more 
rigorous Lorenz - Mie theory [124]. The first is simpler and describes diffractions of 
light at the contour of the particles. It does not require knowledge of the optical 
proprieties (such as refractive index including light absorption coefficient) of the 
particles and it works well with uni-modal size distribution and for particles that are 
bigger that 5 µm. Therefore the assumption is that particles of all the dimensions 
scatter the light with the same efficiency. It assumes that particles being measured 
are opaque and scatter light at narrow angles. This is why it is only applicable for 
large particles. The Mie theory is more rigorous and predicts scattering intensities for 
all particles (small, large, transparent and opaque). It assumes a homogeneous and 
optically linear material irradiated by an infinitely extending plane wave. It assumes 
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that the scattering of the light by particles approaching the wavelength of incident 
radiation is a function of the angles of scattering, the wavelength of the incident light, 
differences in refractive indices, and the diameter of a sphere [40]. It takes into 
consideration the refractive index between particles and dispersion medium and the 
theory is recommended when the refractive index of the particles is close to that of 
the supporting medium and for particles smaller than 5 µm.  
 
1.8.4. Inhalation simulation 
Cascade impactor analysis uses a constant flow rate. However, it has been 
shown that in patients a constant flow is not achievable [125]. In fact, previous 
studies showed that acceleration of flow influences the peak inspiratory flow rate and 
the time when it is reached [12, 126]. Many in vitro studies have now started to utilize 
real inhalation profiles for a better comparison with in vivo results. The electronic 
lung device (ELD), the inhalation manager and the breath simulator in combination 
with the NGI (Next Generation Impactor) are few examples of cascade impactor 
techniques with real inhalation profiles. The dispersion of the aerosol will be 
generated by the inhalation profiles and not by an unrealistic constant flow rate. The 
electronic lung device is an inhalation simulator and it separates the dose dispersion 
system for the particle size process. The dose dispersion occurs during the 
simulation of the patient inhalation, whilst the particle size process occurs thanks to 
an additional constant flow rate [127]. 
 
1.9. Clinical efficacy and adherence studies 
Inhalation therapy plays a major role in asthma and COPD. However, it has 
been established that there is poor adherence by the patients. Around 60% of COPD 
patients [128, 129] and between 30 to 70 % of asthmatics  [130] do not adhere to 
their therapy. The main reason of the poor adherence is the patients’ fear of the side 
effects caused by inhaled corticosteroids. Moreover, they reported that there was 
lack of information from the medical staff and the increasing cost of the medications 
became a burden [131]. However, lack of communication, poor adherence and 
incorrect inhalation techniques lead to a progression and poor management of the 
disease [132].  
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1.9.1. Poor management of asthma 
Achieving and maintaining the control of asthma are the aims of asthma 
management. However, many patients show poor asthma control and this increases 
the cost of management [133, 134]. “Control of asthma” is defined as the fluctuations 
or lack of symptoms and lung function over a period of time [132]. Minimal or no 
symptoms of asthma during day and night, absence of asthma attack, no 
hospitalization or no requirement for rescue therapies (such as bronchodilators) are 
the targets for a good control and management of the disease [68]. However, many 
patients require a change in the medication due to a poor response to corticosteroids  
as the inflammation may persist [69]. In Table 1.1 the main factors that cause 
inadequate control of asthma are listed and how they can be avoided [74, 132, 135]. 
 
Table 1.1. List of causes of poor asthma control and possible solutions. 
Cause of poor control asthma Possible solutions 
Exposure for prolonged time to triggers of 
asthma 
Avoid unnecessary exposure to triggers 
Underestimated symptoms Correct diagnosis 
Lack of adherence of the patients to the therapy Awareness of patients of the early stage of the 
disease 
Incorrect usage of the inhalers Adequate training in use of inhalers 
Inadequate dose reached the peripheral lungs Change of the medication 
 
In order to identify poor management, alongside clinical measurements such as 
lung function, peak expiratory flow (PEF) and forced expiratory volume in 1 second 
(FEV1), inflammatory markers are widely used [68, 136]. Many studies have been 
performed using hyperreactivity to methacholine or histamine, markers in sputum 
such as the number of eosinophils and nitric oxide (NO) [137-140]. Remodelling of 
the airways (hypersensitiveness of the airway where the constriction of the muscles 
in the airways is accentuated) and increase in neutrophils are good markers to 
identify poor response to glucocorticosteroid therapy, and therefore, to poor asthma 
control [69]. Variability in clinical markers represents a poor control of the disease, 
but a distinction needs to be made between poor control and severity of asthma. 
These two definitions do not replace each other, but the severity of the disease might 
be a consequence of the poor management. Whilst poor control reflects the 
inadequacy of treatment, severity reflects the disease process and the irregularity in 
the pathology [141].  
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1.9.2. Progression of asthma 
Poor management of asthma can lead to a progression of the disease. To 
identify disease progression, persistent symptoms, impaired lung function, high 
bronchodilator use, unscheduled consultations, hospitalisations, and rescue therapy 
are the markers that need to be taken in consideration [132]. Progression of asthma 
needs to be controlled because exacerbation, during which symptoms worsen over-
and-above the baseline respiratory function that shows decline of the disease 
leading to  a change in therapy [142]. This leads to poor quality of life characterized 
by reduced physical activity, increasing mortality and morbidity, increasing in the 
health cost and hospitalization. Prevention of exacerbation and disease progression 
are, therefore, the key components of management’s strategy for asthma [11, 68]. 
 
1.9.3. Clinical inhaler use issues 
Studies have been reported that patients don’t feel the need to talk about their 
lung diseases as they underestimate the symptoms [131]. This is because most of 
the patients do not take the medications and they have incorrect inhalation 
technique. Constant improvement to the inhaler design has been made helping the 
patient to achieve a better inhalation technique. MDIs contain propellant that 
complicates effective inhaler use by paediatric patients and the elderly. The impact 
of the aerosol on the throat leads the patient to stop breathing. Moreover, patients 
find it difficult to coordinate the actuation of the device and the inhalation of the 
aerosol or they breathe too rapidly. Spacers have been used widely to overcome this 
issue [143]. Clement Clarke International has manufactured a training device that 
can teach the patients the correct inhalation technique. The Flo-Tone is attached to 
the MDI and, on inhalation, it will make a sound that informs the patient when to 
actuate the inhaler [144]. 
 
Some patients are prescribed with DPIs which lack the requirement of hand-
lung coordination. However, it is their inhalation strength that aerosolizes the 
formulation. Studies reported that there is a high inter-patient variability in the flow 
rate [77, 85] and the medication is inhaled before the peak inspiratory flow is 
reached [12, 125, 126]. The inter-patient variability leads to a variable and low 
emitted dose of the medication and high dependency on the flow rate. Moreover, 
their lungs are obstructed therefore, the inhalation strength is low and the medication 
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impacts on the throat. As seen for the Flo-Tone, with DPIs the pharmaceutical 
companies provided some design features to help the patient to achieve the 
appropriate technique. The Novolizer® for example has multiple feedback signals 
which inform the patient that sufficient drug has been delivered to the lungs [145]. 
Some of the signals are: colour change in a control window, ‘‘click’’ sound when the 
inhalation is performed correctly. Moreover, the Novolizer® also prevents patients 
from inadvertently overdosing with the preparation because the device cannot be 
reloaded until the previously loaded dose has been correctly inhaled. A similar 
feature is present in the Easyhaler™ that has a hopper so that is impossible for the 
patients to blow inside the inhaler [88]. 
 
Better technology has been recently used to manufacture novel devices: 
cyclone technology has been used for the Airmax® [92, 93] that has a design similar 
to MDI and a miniature reverse cyclone has been added to the Conix® [91, 146]. 
This technology increases the respirable fraction and capture in the device the big 
particle carrier that otherwise would impact on the throat. However, these are only 
two DPIs with different formulations. Therefore, a generic spacer for DPI that 
achieves the specific benefits of the latter design features is required 
 
1.10. Aims and scope of the thesis 
It is reported that patients struggle with their inhalers and some show 
progression of asthma and COPD diseases despite constant improvement in the 
marketing of novel DPI technologies. The main issues are lack of adherence of the 
patients to the therapy and the inappropriate choice of inhaler prescription based 
solely on the peak inspiratory flow, rather than a full inhalation profile. This is despite 
knowledge that a full profile gives a better understanding on the mechanism of 
aerosolization of the particles based on the device resistance. It has been suggested 
that the ex-vivo studies with either reproduced human inhaler profiles or real patient 
profiles produce more parameters to be considered to predict aerosol deposition, 
such as flow acceleration, time to reach the peak inspiratory flow (PIF), inhalation 
volume and deceleration. Studies have reported that the dose is delivered prior 
reaching the PIF. The primary aim of this thesis is to develop a diagnostic tool to 
guide DPI choice for clinicians based on the ability of inspiration of the patients, and 
therefore on their inhalation profiles through multiple marketed DPIs. Moreover, 
56 
 
differences in the flow achievable through a given inhaler by patients leads to 
variability in the flow rates and, therefore, also of the emitted dose and its particle 
size distribution.  In many cases this is associated with high throat deposition of the 
emitted aerosol.  Therefore, the second aim of the thesis is to investigate strategies 
to decrease throat deposition of the emitted dose and to mitigate the flow 
dependency of the aerosol emitted from DPIs using novel inhaler technologies. 
 
1.10.1. Objectives of the thesis 
I. To design a new test system to collect patients’ inhalation profiles though a 
wide range of marketed inhalers 
II. To estimate the flow rate variability with commercial inhalers. 
III. To test new technologies to mitigate the flow rate dependency of the emitted 
dose 
IV. To assess the difference in aerosol deposition when employing the standard 
metric of square wave peak inhalation flow compared to a full inhalation 
profile. 
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2.1. Development and characterization of reverse – flow cyclones for pulmonary 
delivery 
 
2.1.1  Defining the performance of dry powder inhalers 
The use of dry powder inhalers (DPIs) to deliver aerosol formulations for 
pulmonary delivery has been increasing over the last 25 years [66]. Most DPI 
formulations are composed of micronized drug with a coarse carrier, typically lactose 
monohydrate with a size of 63-90 µm that improves the flowability of cohesive 
particles and therefore, minimizes the cohesive interparticulate forces of micronized 
drugs [83]. The patient’s inhalation airflow causes fluidisation within the device and 
creates turbulence that should be sufficient to de-aggregate the drug/carrier mixture 
[83, 85] into fine particles. The deagglomeration of drug particles to form a fine 
respirable fraction aerosol cloud is caused by interactions of powder and particles 
with shear flow and turbulence, particle – device and particle – particle impaction 
[95]. 
Impaction analysis is the pharmacopoeial test to assess the particle size 
distribution of a formulation based on the aerodynamic particle size [147]. Cascade 
impactor techniques such as Twin Stage Impinger (TSI), Andersen Cascade 
Impactor (ACI) and Next Generation Impactor (NGI) require a constant flow to 
predict the particle size of an emitted particle for potential pulmonary delivery [115]. 
Fine particle mass (FPM), fine particle dose (FPD) and mass median aerodynamic 
diameters (MMADs) are parameters to quantify and asses the aerosolization 
efficiency and particle size in impaction studies [148, 149]. However, they do not 
provide information about induction port deposition in a cascade impactor. 
In vitro testing requires a constant flow rate as per FDA (Food and Drug 
Administration) recommendation [150].The British Pharmacopoeia prescribes testing 
of inhalers at 4 kPa pressure drop [147], but in real inhalation manoeuvres the flow 
rate accelerates [12]. In humans a constant PIF  is generally achieved only with a 
high resistance device, but patients would find it uncomfortable to maintain the 
highest PIFs during aerosolisation [125]. The PIF has been correlated with the force 
available for de-aggregation of DPI blends [85] into fine particles that can potentially 
deposit in the lung (i.e. the respirable dose). However, many patients with 
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obstructive lung disease are unable to generate sufficient force for efficacious 
delivery of medicaments [80, 151].  
 
2.1.2  Pulmonary and oropharyngeal deposition: the impact of flow rate 
The performance of DPIs depends on the inhalation strength of the patient 
leading to variable and low deposition in the lungs. The force of the patient’s 
inhalation flow through the DPI creates turbulence leading to high deposition through  
impaction of the emitted particles in the extra thoracic region leading to side effects 
[82].  A study on the lung deposition of budesonide emitted from the Turbuhaler® in 
healthy volunteers reported that only 14.8 % of the dose deposited in the lung and 
66.6 % in the oropharynx region at 35 L min-1 [78]. A more recent study [79] showed 
that at high flow rates (80 L min-1), lung deposition of aclidinium bromide emitted 
from the Genuair® DPI was 34.0 % of the delivered dose but the oropharyngeal 
deposition was still substantial, being  61.9 % of the delivered dose. 
Lung deposition depends on aerosolization of the formulation to an appropriate 
aerosol size distribution, a process depending on the inhalation strength of the 
patient for passive DPIs. Both in vitro and in vivo studies have shown that the higher 
is the flow rate, the greater is the resultant fine particle fraction produced (i.e. the 
respirable fraction the patient would inhale) [125, 149, 152, 153]. A wide range of 
commercial DPIs have been tested and impaction studies have shown that the fine 
particle fraction (FPF) almost doubled from 30 to 90 L min-1 for low resistance 
devices [153]. Munzel at al. [154] showed a similar correlation between variability of 
fine particle dose  (FPD) and flow rates in healthy subjects through in vitro impaction 
studies of budesonide emitted from the Novolizer® and the Turbuhaler®. In vivo lung 
deposition showed that between 45 and 90 L min-1 the fraction of budesonide 
deposited increased from 19.9% to 32.0 % for the Novolizer®, whereas the 
Turbuhaler® showed only 21.4 % at 60 L min-1. However, one study [155] showed 
that at slow (30 L min-1) and fast (60 L min-1) inhalation rates the lung deposition of 
salbutamol (radiolabelled with 99mTc), in healthy volunteers (42.2 µg vs. 52.8 µg) for 
the MAGhaler device did not differ significantly. 
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2.1.3 Cyclone technology for improvement delivery of drug from dry powder inhaler 
In recent years, miniature reverse airflow cyclone technology has been 
suggested and used for DPIs to capture the particles with high momentum in order to 
liberate only the fine particles to achieve higher pulmonary delivery. The Airmax™ 
device design resembles a pMDI (pressured metered dose inhaler) and the FPF and 
total emitted dose from the AirMax™ for both budesonide and salbutamol 
demonstrated significant improvement compared with that of the Turbuhaler®. This 
included greater consistency of delivered dose regardless the flow rates used [93]. 
The Conix™ was developed by Cambridge Consultants Ltd. [156] and licensed by 
3M Drug Delivery Systems (3M Ltd). 3M Ltd showed [91] a greater amount of 
potentially respirable particles from the Conix™ than for the Accuhaler™ due to the 
retention of large agglomerates inside the device. FPD3µm (fine particle dose below 3 
µm) of fluticasone propionate and salmeterol xinafoate delivered from the Conix™ 
was 41.8 % and 40%, respectively, compared to 14% and 12.3% when the Advair 
Diskus® was used [146]. Plasma concentration data showed that the Conix™ 
increased pulmonary deposition compared to the Diskus for both drugs. Considering 
the FEV1 of the asthmatic subjects in the study, the Conix® showed comparable in 
vivo results although the delivered dose was one-third compared to the Advair® 
[146]. The Conix® was tested also with salbutamol sulphate and the device retained 
80% of the drug [91]; which would reduce the mouth and throat deposition in the 
patients [146]. Moreover, the Conix™ almost halved the mass median aerodynamic 
diameter for the drugs compared to the Accuhaler™, thereby promoting a more 
specific pulmonary delivery (1.99 µm for salbutamol sulphate delivered from 
Accuhaler™ compared to 0.99 µm for the Conix™) [91]. 
 
2.1.4 Principles of cyclone separation 
Reverse airflow cyclone technology has been widely employed. The Dekati® 
Cyclone has been used in many applications [157] to remove large particles from 
sampled environmental air. Another example is the Dyson vacuum cleaner that uses 
cyclonic separation to remove dust and other particles from an air stream. Cyclone 
separation is based on centrifugal sedimentation, where particles sediment out of a 
61 
 
helical gas or liquid stream. With a reverse flow cyclone, when a patient inhales, the 
air is drawn into the cyclone chamber (cone section in Figure 2.1) where an axially 
downward-flowing vortex occurs. 
 
Figure 2.1. The reverse flow cyclone principle. 
  
As the diameter of the cyclone body decreases towards the closed bottom, the 
downward flow is radially forced towards the centre, where it reverses direction and 
directs upwards. The core of the cyclone thus forms a second vortex with axially 
upward flow towards the exit orifice. The inhalation creates a vortex field with high 
velocities and energy which is favourable for the process of de-agglomeration. 
Collisions between particles and the cone wall as well as other particles occur as a 
result of the cyclonic flow field [146]. In this way, particles with large mass and size 
(e.g. lactose carrier) will deposit in the bottom of the cone and only the finest particle 
(e.g. 5 µm salbutamol sulphate) will escape the cyclone [91]. Therefore, drug that 
remains adhered to the lactose is retained within the device instead of being 
released into the respiratory tract. This would decrease the deposition in the throat 
that occurs in the traditional DPI, reducing subsequent side effects. However, it has 
been suggested that the efficiency still depends on the patient’s inhalation flow rate 
[93]. 
 
 
Outlet (where patient inhales)
Vortex
Carrier particles 
depositing at the 
bottom of the 
conical section
Small particles escaping 
toward the outlet
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2.2. Aims 
Little information has been reported into the operation of miniature reverse-flow 
cyclones or the formulation factors determining their suitability for inhaled drug 
delivery. Previous work has involved computational fluid dynamic investigations of 
particle behaviour in miniature cyclones [158, 159]. The investigations identified the 
potential of reverse-flow cyclones to restrict particle output to sizes within the 
respirable range, and therefore identified the potential for a generic applicability to 
lung drug delivery. The aim of the current work was to investigate the potential of a 
cyclone spacer to improve in vitro drug delivery for a typical DPI (Cyclohaler®) and 
reduce throat deposition of the emitted particles. 
The objectives of the project were: 
- to manufacture a prototype cyclone spacer (hereafter called Cheng 1); 
- to assess the in vitro throat deposition of Ventolin/Accuhaler™ formulation 
composed of SS (salbutamol sulphate) and coarse lactose when the Cheng 
1 was used  with the Cyclohaler®  
- to compare particle size distribution of the emitted dose of SS from 
Cyclohaler® with and without Cheng 1. 
 
2.3. Materials and methods 
 
2.3.1. Materials 
Micronized salbutamol sulphate (SS, batch number B027798) was obtained from 
GlaxoSmithKline Research and Development (Ware, UK). Lactose monohydrate, 
chromatography grade methanol, hydrochloric acid solution (HCl) 5M, sodium 
hydroxide and n-Hexane were purchased from FisherScientific (Loughborough, UK). 
Hipersolv® grade ammonium acetate was purchased from Lab3 Ltd (Northampton, 
UK). A Luna 3 μm C18 column (150 mm x 4.6 mm x 3 μm) was obtained from 
Phenomenex (Macclesfield, UK). Silicone oil - Dow Corning Corporation 200® fluid 
was obtained from Sigma-Aldrich (Gillingham, UK). Fluorescein disodium salt and 
oleic acid were purchased from Acros organics (Geel, Belgium). The DPIs tested 
were Ventolin/Accuhaler™ 200 µg/dose (purchased from Allen & Hanburys, 
Uxbridge, Middlesex, UK) and a Pulmicort/Turbuhaler® 400 µg/dose purchased form 
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AstraZeneca. A Cyclohaler® device was obtained from AAH Hospital Supplies 
(Coventry, UK). Size 4 hard gelatine capsules were obtained from Meadow 
Laboratories Ltd. (Romford, UK). The cyclone spacer (Cheng 1) was manufactured 
in-house (University of Cambridge, UK) from a Perspex block (Engineering & Design 
Plastics Ltd, Cambridge, UK); the exit duct was cut and polished from stock brass 
tubing (Engineering Department Storeroom, University of Cambridge, UK). The flow 
meter (model number DFM2), next generation impactor (NGI) and a model HCP5 
vacuum pump were all purchased from Copley Scientific Ltd (Nottingham, UK).  
 
2.3.2. Cyclone manufacture 
A miniature reverse-flow cyclone (Cheng 1) was manufactured using empirical 
models [157] from Department of Engineering at Cambridge University to have a 
theoretical particle cut-off diameter below 5 μm for flow rates between 30 and 120 
Lmin-1. The Cheng 1 was machined from Perspex with a circular inlet orifice of 
diameter 4.14 mm to facilitate relatively high inlet velocities with high pressure drops. 
For dimensional accuracy, easy sample collection and interchangability, the Cheng 1 
was manufactured in three separate sections – exit duct (top), inlet and cylinder body 
(mid) and cone (bottom); the bottom of the cone section had a through-hole for 
sample collection, which was sealed during experiment. In Figure 2.2 the dimensions 
of the cyclone are reported. An inlet adapter was also manufactured out of Perspex 
to enable connectivity with the Cyclohaler® (Figure 2.2). 
 
 
 
 
 
 
 
Figure 2.2. Dimensions of simulated cyclone geometries (units in mm) and photograph of reverse 
flow cyclone spacer 
1
Cheng 1 was manufactured with a circular inlet orifice, diameter 4.1mm. 
 
 Cheng 1 
D 20 
De 5.9 
a1 4.1 
b1 4.1 
H 57.9 
h 24.7 
S 17.3 
B 6.2 
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2.3.3. High performance liquid chromatographic assay validation of salbutamol 
sulphate 
Salbutamol sulphate (SS) was analysed using high performance liquid 
chromatographic (HPLC) assay. A stock solution was prepared by weighing 
accurately approximately 0.0025 g of the drug on a weighing scale (Mettler Toledo, 
UK), transferring it into 50 ml volumetric flask and bringing the solution to volume 
with an 80:20 (v/v) mixture of 0.6% (w/v) aqueous ammonium acetate: methanol  
(solution pH adjusted to 4.5 with HCl 1M). The stock solution was used in order to 
prepare a calibration series by pipetting the volumes shown in Table 2.1 and the set 
of calibration standards were run using HPLC (Agilent 1050 Series, Agilent 
Technologies UK Ltd., Edinburgh, UK) with a Luna 3 μm C18 column (150 mm x 4.6 
mm x 3 μm) at 1 ml min-1. The column temperature was 50 °C and injection volume 
was 50 µl. SS was detected by UV at 272 nm. 
 
Table 2.1. Volume of stock solution (ml) required to prepare a calibration series in the concentration 
range of 0.05-50 µg ml
-1
. 
Theoretical concentration 
(µgml-1) 
Volume of stock solution 
(ml) 
Final volume 
(ml) 
25 10 20 
10 5 25 
5 1 10 
1 1 50 
 
2.3.4. Data analysis of high performance liquid chromatography 
 
2.3.4.1. Assay linearity, precision and reproducibility 
The linear regression analysis was performed using the LINEST function of 
Microsoft Excel to establish the relationship between peak area and concentration. 
Three injections were made for each standard and the raw data for each day (n=3) 
were used. The mean peak area response and the relative standard deviation (RSD) 
at each concentration level were determined to assess intra-day variation. To assess 
inter-day variation, the peak area responses of the calibration standards were 
normalized to unit concentration to account for slight variation in the drug 
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concentration from the nominal value. The mean normalized peak area response 
and RSD for each concentration level was considered. 
 
2.3.4.2. Limits of detection (LOD) and limits of quantification (LOQ) 
The LOD and LOQ were calculated to determinate the sensitivity of HPLC of 
analysis using Equation (2.1) and (2.2). 
LOD =3Sy/m      (2.1) 
LOQ = 10Sy/m     (2.2) 
Where “Sy” is the standard deviation of the y-intercept from the linear regression 
analysis and “m” is the linear regression coefficient (gradient). 
 
2.3.4.3. Accuracy determination 
Two sets of five standard solutions were prepared; the first set was prepared 
with 0.002 g of SS dissolved into 20 ml of mobile phase and making a 1:10 dilution in 
order to obtain a 10 µgml-1 solution. The second set was prepared with 0.002 g of 
the API and 0.048 g of lactose monohydrate dissolved into 50 ml of mobile phase 
and 1:4 dilutions were performed to obtain the same concentration mentioned above. 
The peak area response of the standards when analyzed by HPLC according to the 
assay in Section 2.3.2 was determined. The amount of SS recovered was calculated 
using the calibration curve and the percentage recovery of the drug was calculated 
using Equation (2.3). 
 
% recovery = 
calculated concentration (μgml−1)
theoretical concentration (μgml−1)
   (2.3) 
 
2.3.5. Spectrofluorimetric assay for fluorescein disodium salt 
Fluorescein disodium salt (uranine) was tested using a spectrofluorimetric 
assay. A stock solution (100 µM) [160] was prepared by weighing accurately 
approximately 0.004 g of uranine, transferring it into 100 ml volumetric flask and 
bringing the solution to volume with NaOH 0.1 M. The stock solution was used in 
order to prepare a series of calibration standards (1-0.025 µM). The range of 
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calibration standards between 0.5-0.025 µM was analyzed using spectrofluorimetry 
(fluorescence spectrometer, PerkinElmer, LS 55) at 513 nm for emission wavelength 
and 489 nm for absorption wavelength. 
 
2.3.6. Dose content assay 
 
2.3.6.1. Dose content for mixture of salbutamol sulphate and lactose 
recovered from Ventolin/Accuhaler™ 200 µg/dose 
The mixture of micronized SS and lactose was removed from marketed 
Ventolin/Accuhaler™ products. A set of six solutions was prepared by weighing 
accurately approximately 0.0125 g of the blend and dissolving into 10 ml of mobile 
phase. The concentration of SS was determined by HPLC assay. The dose content 
for SS was calculated using Equation (2.4) in order to identify the amount of drug 
contained in each dose (µg/dose). 
 
Dose content = 
mass of the drug determined byHPLC (μg)
mass of the mixture (mg)
   (2.4) 
 
2.3.7. Resistance of Cheng 1 
The resistance of Cheng 1 was measured across the spacer and Cyclohaler® 
in series using a dose uniformity sampling apparatus (DUSA, Copley Scientific Ltd., 
Nottingham, UK). The DUSA was connected to a critical flow controller TPK (Copley 
Scientific Ltd., Nottingham, UK) to adjust the flow rate. Once the flow rate was set 
through the DUSA, the Cheng 1 with the Cyclohaler®   was attached to the DUSA to 
record the pressure drop of the two devices in series. The range of flow rates tested 
was between 17-70 L min-1. The pressure drops obtained were then plotted against 
the corresponding flow rates and the resistance calculated using the equation (2.5): 
 
R =
√∆P
Q
     (2.5) 
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Where “R” is the resistance (kPa1/2 L-1min), “ΔP” is the pressure drop (kPa) and “Q” 
is the flow rate (L min-1).  
 
2.3.8. Impaction studies 
 
2.3.8.1. Impactor plate coating 
In order to have 1% w/v solution for coating the NGI plates, 1 g of silicon oil 
was accurately weighed and dissolved into 100 ml of n-Hexane. Approximately 15 ml 
of the solution was added into the first stage and the stage rotated, excess solution 
transferred into the second stage and so on until the last stage was covered. The 
plates were left under the fume hood in order to allow the hexane to evaporate 
leaving a thin layer of silicon oil as coating. 
 
2.3.8.2. Cyclohaler® capsule filling 
The mixture of micronized SS and lactose was removed from marketed 
Ventolin/Accuhaler™ products. Size 4 hard gelatin capsules were accurately hand-
filled with approximately 0.0125 g of the blend. 
 
2.3.8.3. Aerodynamic deposition assessment using next generation impactor 
Aerosolisation studies were performed using the next generation impactor 
(NGI) with a model HCP5 vacuum pump (both from Copley Scientific Ltd., 
Nottingham, UK). In order to collect the drug-carrier mixture, each plate of the NGI 
was coated with 1% (w/v) silicone oil in n-Hexane, as described in Section 2.3.8.1. 
The NGI was then assembled as per the requirements in the British Pharmacopeia 
(Figure 2.3). 
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Figure 2.3. Scheme of next generation impactor according to the British Pharmacopoeia. 
 
The Ventolin™ formulation was aerosolized using a Cyclohaler® device with 
and without the cyclone spacer. 15 ml of mobile phase was added to the central cup 
of the pre-separator and the flow rate was adjusted with the aid of a flow meter 
(Copley Scientific Ltd., Nottingham, UK) in order to reach 30, 45, 60, 75 or 100 Lmin-
1. When only the Cyclohaler® was employed for aerosolization, 6 Size 4 hard gelatin 
capsules (accurately hand-filled with 0.0125 g of the blend) were actuated. The 
aerosolization studies were performed at 30, 45, 60 and 75 and 100 L min-1 (= 4 kpa) 
with each actuation lasting 8, 5.3, 4, 3.2, 2.5 sec, respectively. A critical flow 
controller TPK (Copley Scientific Ltd., Nottingham, UK) was used to time the duration 
of the actuations. When the cyclone was employed as spacer device 8 filled 
capsules were actuated (12 capsules for 30 L min-1). The aerosolisation studies were 
performed at 30, 45 and 60 Lmin-1 as above (Figure 2.4) and the flow rate measured 
across the Cheng 1. The Cyclohaler ® was then attached to Cheng 1 and the 
capsules actuated. 
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Figure 2.4 Example of dry powder inhaler (Cyclohaler®) connected with the cyclone spacer (Cheng 
1) 
 
2.3.8.4. Recovery of deposited salbutamol sulphate from the impactor 
In order to collect the drug, the Cyclohaler® and the capsules were washed 
with 20 ml of mobile phase and transferred into a volumetric flask. The bottom of the 
cyclone, the mouthpiece and the throat were each washed with 50 ml of mobile 
phase; whilst the upper section of the cyclone was washed with 10 ml. For collecting 
the drug from the pre-separator 100 ml of mobile phase was used for washing and 
dissolution of deposited drug. The volumetric flasks were sonicated using a sonicator 
(Kerry, Germany) for 2 min. When only the Cyclohaler® was employed, 10 ml of 
mobile phase was added to the first 5 stages, whilst 5 ml of solvent was used for the 
last 3 stages. All the stages were set on a laboratory rocker (Stirling Mixer, Sandrest 
Ltd, UK) and rocked for 2 min in order for the solvent to wash the entire surface. 
When the Cyclohaler® was employed with the cyclone, 5 ml of mobile phase was 
added to each stage. The concentration of the drug from each stage was determined 
by HPLC assay at 272 nm according to Section 2.3.3. After performing the 
experiments, each stage and the NGI were thoroughly cleaned with Millipore water 
and the coating was removed with acetone before rinsing with methanol. 
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2.3.9. Aerosolization studies using laser diffraction technique 
Aerosolization was assessed by laser diffraction particle size analysis using the 
Sympatec Inhaler module (Inhaler Helos/KF, Sympatec Limited, Bury, UK) at 30, 45, 
and 60 Lmin-1 for the Cyclohaler® device in the absence and presence of the Cheng 
1. A carrier free DPI (Pulmicort/Turbuhaler®) was also tested at 2 and 4 kPa in the 
absence and presence of the cyclone-spacer. The lens used to detect the aerosol 
cloud was a R3 lens (0.5-175 µm). The measurement was set to trigger when the 
optical concentration was between 0.1 and 0.2 % for 5 sec duration (time base 1 
ms).  
 
2.3.10. Monodisperse aerosol study using Cheng 1 
In order to estimate the cut off diameter of the Cheng 1, a VOAG (Vibrating 
Orifice Aerosol Generator, model 3450) was used. A solution of uranine (15%) and 
oleic acid (85%) was dissolved in isopropanol (IPA). In order to calculate the 
required solute concentration to generate a suitably sized aerosol (uranine and oleic 
acid) equation (2.6) was used: 
 
(𝐶 + 𝐼) = (
𝐷𝑝
𝐷𝑑
)3                                                 (2.6) 
 
Where “C” is solute concentration, “I” is the impurity of the solvent, “Dp” is the final 
size of monodisperse aerosol to be generated (µm) and “Dd” is the diameter of the 
primary droplets (µm). When monodisperse aerosol was created with particle size 
(Dp) of 2 and 3 µm, the Dd was 40 µm, the solution feed through the orifice was set to 
speed rate 0.139 ml min-1 (flow rate of the solution to create the aerosol) and the 
vibration frequency for the orifice (20 µm) was set between 40-80 kHz (typically 
69.13 kHz). In order to calculate the frequency needed the equation (2.7) was used: 
 
𝑓 =
6𝑄 (𝐶+𝐼)
𝜋𝐷𝑝
3                                                       (2.7) 
 
To perform the experiment, the cyclone-spacer was placed facing the VOAG outlet. 
The outlet of the Cheng 1 was connected to an impinger (conical flask) to collect any 
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aerosol particles exiting the spacer. Airflow through the iminger and Cheng 1 in 
series was achieved with a vacuum pump. The flow rates used were 30, 45 and 60 
Lmin-1 to represent the aerosolisation studies. The flow rates were measured with a 
flow meter across the Cheng 1 prior the study. 20 ml of solution was used to clean 
the instrument and stabilise the jet. The dilution air to carry the air and particles into 
Cheng 1 was set to 30 L min-1 as it was the optimum air flow to avoid particle loss 
inside the VOAG tube. The duration of each measurement was 10 min. To collect 
the fluorescein aerosol, 50 ml of NaOH 0.1 M was used as washing solution [161] for 
the cyclone-spacer and the same volume to clean the conical flask impinger. To 
calculate the Cheng 1 efficiency Equation (2.8) was used: 
 
% 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑢𝑟𝑎𝑛𝑖𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑝𝑎𝑐𝑒𝑟 (𝜇𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑢𝑟𝑎𝑛𝑖𝑛𝑒 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 (spacer+impinger)(𝜇𝑔)
𝑥100      (2.8) 
 
2.3.11. Data analysis of impaction experiment 
The % recovery was calculated, for full mass balance, as the total recovered 
drug (μg) on each stage and the device as a % of the total known mass of the drug 
actuated (i.e. the dose content). The recovered dose (RD) was calculated as the 
sum of the dose (μg) in each stage of the NGI and device or device and spacer. The 
emitted dose (ED) was calculated as the sum of the total dose recovered from NGI 
(or NGI and spacer) following actuation of the device. The spacer-emitted dose 
(sED) was calculated as the sum of the total dose recovered from the NGI only, 
when the spacer was used. The % retention of the cyclone was calculated as the 
mass of drug deposited in the spacer as a percentage of the ED. The % induction 
port/pre-separator (IP/PS) deposition was calculated as the mass of drug recovered 
on the IP/PS stage as a percentage of the ED or the sED. The % fine particle 
fraction below 5 μm (FPF 5μm) was calculated following interpolation of the 
cumulative particle size distribution of the dose deposited on the NGI stages as a 
percentage of the ED (i.e. ex device) or the sED (i.e. ex cyclone). The mass median 
aerodynamic diameter values (MMAD) were determined by interpolation of the 
cumulative particle size distribution of the dose deposited on the impactor stages. 
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2.3.12. Statistical analysis 
Statistical analysis was performed in Minitab (version 15) using one-way 
ANOVA and post-hoc Tukey’s test (multiple comparisons) or Student’s two-tailed t-
test for pair-wise comparisons, both at 95 % confidence intervals. 
 
2.4. Results 
 
2.4.1. Data analysis of high performance liquid chromatography assays 
 
2.4.1.1. Assay linearity, precision and reproducibility 
Linear regression analysis performed on raw data collected for three calibration 
series calibration is reported in Figure 2.5 for the SS. 
 
Figure 2.5. Linear regression analysis of peak area of salbutamol sulphate as a function of 
concentration (pooled raw data points of n=9 at each concentration level). 
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Regression results are reported in Table 2.2 .  
Table 2.2. Regression results for peak area response plotted as a function of concentration for 
salbutamol sulphate (SS). 
Day Intercept 
Standard 
deviation of 
the intercept 
Slope 
Standard 
deviation of 
the slope 
Correlation 
coefficient 
(R2) 
1 -0.701 0.593 15.050 0.023 0.999 
2 -0.493 0.856 15.105 0.032 0.999 
3 -1.036 0.478 15.564 0.019 0.999 
Pooled -0.706 1.319 15.237 0.051 0.999 
 
Intra-day variability of SS indicated good repeatability for SS between calibration 
range 1-50 µg/ml (Table 2.3). 
Table 2.3. Intra-day variability of concentration range for salbutamol sulphate (n=3). 
 % RSD 
 Concentrations (µg ml-1) 
 50 25  10  5  1  
Day 1 0.10 0.08 0.04 0.15 0.74 
Day 2 0.22 0.84 0.20 1.12 4.38 
Day 3 0.30 0.59 0.26 0.45 2.79 
 
Inter-day variability (Table 2.4) showed that at the lowest concentration for SS the 
reproducibility of the method was low. 
 
Table 2.4. Table of data from inter-day variability (riproducibility of the relative standard deviation, 
RSD) for salbutamol sulphate (SS) (n=9). 
Concentration 
(µg ml-1) 
RSD (%) 
50 1.49 
25 2.17 
10 1.34 
5 0.67 
1 3.29 
 
 
2.4.1.2. Limits of detection (LOD) and limits of quantification (LOQ) 
The sensitivity of the method used for SS was indicated by an LOD that was 
0.26 µg ml-1 and LOQ that was 0.87 µg ml-1. As the values are relatively low, the 
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method is suitably sensitive at low concentrations and lower than the lowest 
calibration standard. 
 
2.4.1.3. Accuracy determination 
The recoveries of SS alone and when lactose was added were 99.14 ± 2.33 % 
and 99.89 ± 2.44% respectively showing a high accuracy as the range was between 
95 and 105 %. A two-tailed unpaired t-test revealed no significant difference when 
lactose was added (p value > 0.05) indicating that the carrier does not interfere with 
the detection of the drug.  
 
2.4.2. Spectrofluorimetric assay for fluorescein disodium salt 
Linear regression analysis performed on raw data collected for three calibration 
series is reported in Figure 2.6 for fluorescein disodium salt. 
 
Figure 2.6. Linear regression analysis of peak area of fluorescein disodium salt as a function of 
concentration (pooled raw data points of n=12 at each concentration level). 
 
Regression results are reported in Table 2.5. 
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Table 2.5. Intra-day variability of concentration range for fluorescein disodium salt (n=3). 
Day Intercept 
Standard 
deviation of 
the intercept 
Slope 
Standard 
deviation of 
the slope 
Correlation 
coefficient 
(R2) 
1 15.362 1.219 2391.679 11.945 0.999 
2 14.650 1.273 2287.190 12.469 0.999 
3 16.446 1.718 2263.492 16.830 0.999 
Pooled 15.486 1.325 2314.120 12.985 0.998 
 
Intra-day variability indicated good repeatability for the fluorescein disodium salt 
between calibration range 0.2-0.01 µg ml-1 (equivalent of 0.5-0.25 µM, Table 2.6) 
and inter-day variability (Table 2.7) are shown below. Intra-day variability showed 
poor repeatability at the lowest concentration, whereas poor reproducibility was seen 
at 0.02 and 0.01 µg ml-1. 
Table 2.6. Intra-day variability of concentration range for fluorescein disodium salt (n=3). 
 % RSD 
Day 0.2 (µg ml-1) 0.1 (µg ml-1) 0.04(µg ml-1) 0.02 (µg ml-1) 0.01 (µg ml-1) 
1 0.341 0.704 0.612 1.837 2.945 
2 0.718 0.359 0.559 1.207 1.986 
3 0.566 0.548 3.499 3.957 9.018 
 
Table 2.7. Table of data from inter-day variability (riproducibility of the relative standard deviation, 
RSD) for fluorescein disodium salt (n=3). 
Concentration 
(µg ml-1) 
RSD (%) 
0.2 2.179 
0.1 3.331 
0.04 4.967 
0.02 8.480 
0.01 11.616 
 
The sensitivity of the method used was indicated by an LOD and LOQ that were 
0.0017 and 0.0057 µg ml-1, respectively. 
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2.4.3. Dose content assay 
2.4.3.1. Dose content for mixture of salbutamol sulphate and lactose recovered 
from Ventolin/Accuhaler™ 200 µg/dose 
The dose content of the mixture of SS and lactose formulation collected from 
the Ventolin/Accuhaler™ was 15.12 ± 0.49 µgmg-1 (mean ± SD, n=6). The label 
claim was 200 µg/dose of SS. The mean of the six standards prepared from the  
mixture of SS and lactose determined using HPLC (Section 2.3.3) was 191.68 ± 7.50 
µg/dose that corresponds to 95.84 ± 3.74 % (mean ± SD, n=6). The RSD was 3.91 
%. 
2.4.4. Resistance of Cheng 1 
The cyclone-spacer posed high resistance to air flow (0.08 kPa1/2L-1min) as 
shown from the slope of the line in Figure 2.7. 
 
Figure 2.7. Linear relationship between pressure drop and flow rate across the Cheng 1 and 
Cyclohaler® in series (pooled raw data of n=3, at each data point. R
2
 = 0.9891). 
 
2.4.5. Impaction studies 
2.4.5.1. Aerodynamic deposition assessment using next generation impactor 
for Cyclohaler® 
The emission of SS from the Ventolin/Accuhaler™ formulation using a 
Cyclohaler® was assessed between 30-100 Lmin-1 with the highest flow rate 
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corresponding to 4 kPa. The % drug recovery was adequate at all the flow rates 
ranging from 79.44 ± 2.90 % to 81.45 ± 3.14 %, according to the British 
Pharmacopoeia [147]. The drug retention in the Cyclohaler® did not change when 
the flow rate was increased (25.98 ± 8.07 % and 28.69 ± 10.69 % of recovered dose 
at 30 and 75 Lmin-1 respectively, p value > 0.05, One way ANOVA). However, at 4 
KPa, fewer drug particles were captured in the device (14.95 ± 3.00 %, p value < 
0.05, One way ANOVA, Figure 2.8). 
 
Figure 2.8. Recovered dose of salbutamol sulphate emitted from the Cyclohaler® at 30 Lmin
-1
 (black 
bar), 45 Lmin
-1
 (dark grey bar), 60 Lmin
-1
 (grey bar), 75 Lmin
-1
 (light grey bar) and 100 Lmin
-1
 (white 
bar) (mean ± SD, n=4). 
When the Cyclohaler® was assessed alone, increasing the flow rates led to a 
decrease in the throat deposition (ANOVA, p< 0.05, Table 2.8). The same trend was 
seen in the mass median aerodynamic diameter (MMAD), that was almost halved at 
4 kPa compared to 30 Lmin-1. This led to a two-fold increase of the fine particle 
fraction (FPF) below 5 µm (i.e. the respirable fraction the patient would inhale) at the 
highest flow rate (p value< 0.05, Table 2.8). The FPF5µm from the Cyclohaler® 
increased from 20.83 ± 3.00% to 40.82 ± 2.53% when the flow rates were increased 
(ANOVA, p value < 0.05). The same trend was seen also for the fine particle dose 
(FPD) per actuation. An almost 100% increase in the FPD was seen at 100 L min-1 
(e.g. 54.47 ± 5.02 µg/act) compared to 27.21 ± 4.33 µg/act at 30 L min-1 (Table 2.8).  
D
ev
ic
e
Th
ro
at
P
re
-s
ep
st
ag
e 
1
st
ag
e 
2
st
ag
e 
3
st
ag
e 
4
st
ag
e 
5
st
ag
e 
6
st
ag
e 
7
st
ag
e 
8
0
10
20
30
40
50
60
70
80
90
100
%
 R
e
c
o
v
e
re
d
 d
o
s
e
 
Stages
 30 Lmin
-1
 45 Lmin
-1
 60 Lmin
-1
 75 Lmin
-1
 4 kPa (=100 Lmin
-1
)
78 
 
 
 
 
 
Table 2.8. Aerosolisation metrics for salbutamol sulphate from a carrier based blend using the Cyclohaler® between 30 and 100 L min
-1
 (mean ± SD, n ≥ 4) 
(IP/PS – induction port/pre-separator deposition, MMAD - mass median aerodynamic diameter, FPF5µm (ED) - fine particle fraction < 5 μm of the emitted dose, 
FPD - fine particle dose). 
Device 
Flow rate 
(Lmin-1) 
IP/PS deposition 
(% ED) 
MMAD 
(µm) 
% FPF5µm 
(ED) 
FPD (µg/act) 
Cyclohaler® 
30 70.22 ± 3.23 3.07 ± 0.26 20.83 ± 3.00 27.21 ± 4.33 
45 66.34 ± 3.38 2.49 ± 0.22 27.86 ± 3.50 32.67 ± 2.37 
60 61.74 ± 3.02 1.98 ± 0.09 33.84 ± 2.90 39.55 ± 3.58 
75 75.51 ± 16.70 2.07 ± 0.22 35.76 ± 1.51 38.76 ± 7.87 
100 (=4kPa) 52.75 ± 1.98 1.90 ± 0.06 40.82 ± 2.53 54.47 ± 5.02 
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2.4.5.2. Aerodynamic deposition assessment using the next generation 
impactor for Cheng 1 
Impaction studies were performed using the Cheng 1 in series with the 
Cyclohaler® at the same conditions as when the Cyclohaler® was employed alone. 
However, when the Cheng 1 was added 75 Lmin-1 and 4 kPa (corresponding to 100 
Lmin-1) were not achievable due to the high resistance of the spacer. Altering the 
flow rate did not significantly alter the % deposited within the Cyclohaler® device 
(18.02 ± 4.50 % to 21.51 ± 3.70 % at 30 and 60 Lmin-1, respectively p value > 0.05, 
one way ANOVA) when the Cheng 1 was employed. The deposition within the 
Cheng 1 was high, although it did decrease with increasing flow rate (from 81.68 ± 
6.88 % to 55.90 ± 10.64 %, at 30 and 60 Lmin-1, p value < 0.05, Figure 2.9). 
 
Figure 2.9. Recovered dose of salbutamol sulphate emitted from the Cyclohaler® in combination with 
the Cheng 1 at 30 Lmin
-1
 (black bar), 45 Lmin
-1
 (dark grey bar) and 60 Lmin
-1
 (mean ± SD, n=4). 
When the Cheng 1 was employed a dramatically decreased induction port/pre-
separator (IP/PS) deposition was seen (p<0.05, Table 2.9) compared to when the 
Cyclohaler® was assessed alone. The extent of IP/PS deposition was unaffected by 
the change in the flow rate (p > 0.05) due (in part) to the variability between replicate 
analyses. When the Cheng 1 was added in series with the Cyclohaler®, the results 
indicate that the presence of the cyclone did not change the FPD of the emitted dose 
at 45 and 60 Lmin-1 (Table 2.9).  
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Table 2.9. Aerosolisation metrics for salbutamol sulphate from a carrier based blend using the Cyclohaler® in presence of the Cheng 1 at 30, 45 and 60 L 
min
-1
 (mean ± SD, n ≥ 4) (IP/PS – induction port/pre-separator deposition, MMAD - mass median aerodynamic diameter, FPF5µm (ED) - fine particle fraction < 
5 μm of the emitted dose, FPD - fine particle dose). 
Device 
Flow rate 
(L min
-1
) 
MMAD(µm) IP/PS deposition (% ED) % FPF5µm(ED) FPD (µg/act) 
Cyclohaler® 
+ Cheng 1 
  
Expressed as % of dose 
emitted from DPI (%ED) 
Expressed as % of dose 
emitted from Cheng I (%sED) 
Expressed as % of dose 
emitted from DPI (%ED) 
Expressed as % of dose 
emitted from Cheng I (%sED) 
Expressed as  dose emitted 
from DPI 
30 0.90 ± 0.06 2.45 ± 1.18 14.82 ± 7.80 14.48 ± 5.84 82.75 ± 7.34 18.41 ± 6.63 
45 0.76 ± 0.04 2.32 ± 2.77 6.95 ± 7.91 26.44 ± 4.34 92.24 ± 7.74 29.51 ± 3.45 
60 0.76 ± 0.14 9.56 ± 6.50 22.27 ± 9.96 33.42 ± 5.86 77.0 ± 10.07 39.44 ± 7.67 
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The FPF5µm of SS was expressed as the percentage of the emitted dose (ED) 
of the drug when escaping either the Cyclohaler® (%ED) or the cyclone spacer 
(%sED). No statistical difference was observed in the FPF5μm (% ED, Table 2.9) 
between 45 and 60 Lmin-1 (26.44 ± 4.34% and 33.42 ± 5.86 %, respectively) and 
when the Cyclohaler® was used alone at the same flow rate (Table 2.8). At low flow 
rate, however, both FPD and FPF5µm (%ED) of SS emitted decreased compared to 
the Cyclohaler® when used alone: FPD of 27.21 ± 4.33 µg/dose for SS when emitted 
for Cyclohaler® and FPD of 18.41 ± 6.63 µg/dose when Cheng 1 was in place 
(p<0.05). When the FPF5μm (%sED) was considered, an improved specificity of the 
particle delivery was seen compared to the emitted dose from the Cyclohaler® 
(Table 2.9, p < 0.05). The FPF5µm (%sED) did not change significantly upon 
increasing the flow rate (p>0.05). However, a high variability was seen in the FPF5μm 
at the highest flow rate (77.0 ± 10.07%). However, the metric FPD should be 
considered for comapring the dose as it would be respirable for the patient. When 
the Cheng 1 was employed the FPD increased with the flow rates with a similar trend 
of the FPD calculated to when the Cyclohaler® was employed alone. Almost double 
the amount of FPD was seen at 60 L min-1 compared to 30 L min-1 (39.44 ± 7.67 
µg/act vs.18.41 ± 6.63 µg/act, respectively, Table 2.9). The median aerodynamic 
diameter (MMAD) values (Table 2.9) were ~3 times smaller with the Cheng 1 in 
place than for the Cyclohaler® alone (ANOVA, post-hoc Tukey’s test, p < 0.05). The 
MMADs were, however, unchanged upon altering the flow rate with the cyclone in 
place (ANOVA, p > 0.05). 
 
2.4.6. Aerosolization studies using laser diffraction analysis 
2.4.6.1. Aerosolization studies for Cyclohaler® 
The aerosol size distribution was tested using laser diffraction analysis. When 
the Cyclohaler® was tested alone, consistency was seen between flow rates (Figure 
2.10). However, 100 L min-1 could not be tested due to the low power of the pump. 
The carrier-based formulation showed the presence of large agglomerates escaping 
with fine particles from the DPI (e.g. the volume median diameter (Dv50) was 
between 40.04 ± 4.03 µm and 50.12 ± 6.97 µm at 30 and 75 L min-1, respectively). 
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Figure 2.10. Representative particle size distributions of salbutamol sulphate from the Cyclohaler® at 
30 Lmin
-1
 (●), 45 Lmin
-1
 (▲).60 Lmin
-1
 (■) and 75 Lmin
-1
 (▼). 
 
2.4.6.2. Aerosolization studies using laser diffraction technique for Cheng 1 
In order to understand the lower FPF5μm and FPD and the variability in IP/PS 
deposition with the cyclone at 60 Lmin-1, laser diffraction analysis (LDA) on the 
emitted aerosol cloud was performed for the Cheng 1. LDA also displayed the 
potential of the cyclone to retain both large agglomerates of micronized drug and the 
carrier particles. The volume median diameter (Dv50) of the aerosol cloud released 
from the cyclone at 30 Lmin-1 was 1.03 ± 0.01 μm which was of the same order of 
magnitude as the MMAD and substantially lower than when the cyclone was absent 
(40.04 ± 4.03 μm). The same trend was seen at 45 and 60 Lmin-1 when the Dv50 
was 1.18 ± 0.03 μm and 0.96 μm respectively. Only one value is reported for the 
highest flow rate because of the variability from actuation to actuation. In fact, 
variability was observed in the particle size distributions of the aerosol emitted from 
the cyclone (an example of two size distribution measurements at 60 Lmin-1 are 
presented in Figure 2.11). 
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Figure 2.11. Representative particle size distributions of salbutamol sulphate from Cheng 1 at 30 
Lmin
-1
 (○), 45 Lmin
-1
 (Δ) and 60 Lmin
-1
 (□). At 60 Lmin
-1
 some agglomerates have been detected 
emitted from the Cheng 1 (x) causing a bi-modal distribution. 
 
The bi-modal PSD indicated that some fine material is emitted at 60 Lmin-1 as well 
as at the other flow rates. However, at the highest flow rate, a plateau size is 
reached suggesting for particle size of 3 µm (e.g. no particles are delivered between 
3 and 20 µm). Additionally, at 30 µm, some agglomerates and/or carrier particles 
escaped the cyclone which would have resulted in IP/PS deposition (observed in 
Figure 2.9). However, the latter observations of agglomerate emission displayed 
variability from actuation to actuation.  
 
2.4.6.3. Aerosolization studies using laser diffraction technique for 
Pulmicort/Turbuhaler® with Cheng 1 
The Pulmicort/Turbuhaler® device, which does not contain lactose 
monohydrate as a carrier in the formulation, was tested with and without Cheng 1. In 
Figure 2.12 the cumulative distribution of budesonide (Bud) particles emitted from 
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the Turbuhaler® shows that the formulation is composed of micronized particles 
without the presence of the carrier (e.g. Dv50 = 5.84 ± 0.31 at 2 kPa). Therefore, 
when the DPI was tested in presence of the spacer, it was difficult to obtain particle 
size distributions consistent with the Cyclohaler®, especially at 4 kPa where only one 
measurement was obtained (Dv50 = 0.97 µm) suggesting that the Cheng 1 worked 
only with carrier based formulations. Insufficient optical concentration of particles 
was achieved, which indicated poor emission of drug from the Turbuhaler into the 
Cyclone, or excessive drug retention by the Cyclone. 
 
Figure 2.12. Representative particle size distributions of Bud from the Pulmicort/Turbuhaler® at 2 (■) 
and 4 kPa (●) and from the Cheng 1 at 2 (□) and at 4 kPa (○) (mean ± SD, n≥2). 
 
2.4.7. Monodisperse aerosol study using the Cheng 1 
The Cheng 1 showed 100% efficiency in collecting the monodisperse aerosol 
particles of fluorescein (particle sizes of 2 and 3 µm) between 30-60 L min-1. The 
cyclone retained between 14.45 ± 4.32 µg and 17.12 ± 7.12 µg at 30 and 60 L min-1 
respectively with orifice diameter of 20 µm and particle size of 3 µm. However, when 
the particle size was 2 µm (with orifice diameter of 20 µm), the cyclone retained 0.59 
± 0.41 µg and 1.68 ± 0.62 µg at 30 and 60 L min-1, respectively.  The concentration 
of fluorescein aerosol was too low in the conical flask to be detected by 
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spectrofluorimetric assay. This was probably due to the very low cut off diameter of 
the spacer and the unavailability of a lower diameter orifice for monodisperse aerosol 
testing of the Cyclone. 
 
2.5. Discussion 
Whilst DPIs have been accepted to treat asthma and COPD, the lung 
deposition and throat impaction is still very variable and dependent on the patient 
inhalation strength [152, 154].  Many studies have been conducted to improve the 
device design for a better pulmonary delivery [79, 93]. However, the variability of the 
patient’s inhalation flow still affects the amount of emitted fine particles and their 
size. Therefore, the aim of the current work was to manufacture and characterise a 
cyclone spacer with reverse flow cyclone technology for use with DPIs. 
 
The main outcome was to assess the ability of a cyclone spacer (Cheng 1) to 
decrease throat deposition using a wide range of flow rates (30-60 L min-1). The 
Cyclohaler® was used as a trial DPI to emit the SS formulation recovered from the 
Venolin/Accuhaler™. A HPLC assay was validated for detection of SS, which is a 
hydrophilic weak base and β2 agonist and therefore, used as a bronchodilator for 
treatment of asthma and COPD. SS has two pKa values from the amino group and 
from the phenol group (9.3 and 10.3, respectively). Therefore, the ionization of SS 
varies with the pH. The mobile phase used was an 80:20 (v/v) mixture of 0.6% (w/v) 
aqueous ammonium acetate: methanol and the pH was adjusted to 4.5 with HCl 1M 
to ionize the drug completely. The stationary phase was a C18 column with particle 
size of 3 μm to increase the surface area and therefore to improve interaction with 
the stationary phase. The HPLC method in this study was validated with regards to 
the linearity, LOD, LOQ, accuracy and precision. The calibration curves generated 
for quantification of SS showed a good linearity (R2=0.999) and high sensitivity at low 
concentrations. The reproducibility of the SS assay was acceptable. The accuracy 
studies performed on drug alone and with lactose confirmed that the carrier did not 
interfere with the detection of the drug (% accuracy between 99.14 ± 2.33 and 99.89 
± 2.44 %, respectively). Therefore, the blend mixture of SS and lactose collected 
from a marketed product Accuhaler™ could be used for cascade impactor analysis 
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for studying the variance in deposition and FPF of emitted particles with Cheng 1 in 
place. SS was studied as a pilot drug for this current project for a better comparison 
with a previous study that used a reverse cyclone technology DPI to deliver the 
same drug (i.e. the Conix™[162]).  
The Cyclohaler® was chosen for this project as it is a single-unit dose inhaler 
that consists in a capsule to be pierced prior the dose delivery and replaced after 
each actuation. Upon inhalation, collisions between drug, the grid and the capsule 
occur and, due to increasing air velocity, turbulence increases [163, 164]. Together 
with the type of formulation, the design of the DPI affects the deagglomeration of the 
blend. The main features of the Cyclohaler® are air inlet size, the presence of the 
capsule and the grid [95, 164-166]. The latter has been the subject of many studies 
to improve the Cyclohaler® design (or Aerolizer®, which has a very similar shape to 
the Cyclohaler®) as it does affect the deagglomeration of the particles from the 
carrier.  
 
When breathing through the Cyclohaler®, cyclonic turbulent flow predominates, 
leading to collision between particle-particle and particle-device wall. This would 
enhance deagglomeration of the emitted dose and, therefore, the FPF [95, 163]. 
However, the presence of the grid straightens the flow and helps the particle-
mouthpiece or particle-particle interactions. Some studies indicated that the 
dispersion of the aerosol cloud inside the inhaler is also due to the movement of the 
capsule leading to a greater number of particle-wall collisions than otherwise would 
not be detected if the capsule was absent [153]. Increasing the flow, the turbulence 
and the dispersion of agglomerates increase, leading, however, to increased 
retention inside the device [167]. This would lead to a dependency on the delivered 
dose with such inhaler. The design of the DPI improves the deagglomeration of the 
emitted particles upon increasing the flow rate [166]. However, changing the design 
of the DPI will change the resistance to the airflow and the device resistance is the 
key element of evaluating how comfortable and easy it is for a patient to breathe 
through his/her inhaler [81, 125]. The resistance of the Cyclohaler is 0.02 kPa0.5L-
1min [168]. In vitro studies have investigated how the emitted dose and particle size 
change with increases of the flow rate to confirm the findings of in vivo studies. 
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In the current study, the Cyclohaler® was tested alone using the impaction 
technique at different flow rates (30 - 100 Lmin-1). The flow rates tested were chosen 
based on flow rates achievable by patients through the device to aerosolize the drug 
particles [153]. It is reported that the aerosolization of the particles depends either on 
the design of the DPI or mainly on the inhalation strength of the patients [85, 153]. 
Also, the variability in patients’ inhalation profiles [77, 85, 169] lead to high variability 
in fine particle liberation from DPI formulations and devices [12, 125].A good % drug 
recovery from Cyclohaler® was seen between 30 - 100 Lmin-1. The % emission did 
not change when the flow rate increased for the Cyclohaler®, when used alone 
(74.02 ± 8.08% at 30 Lmin-1, 73.45 ± 3.36 at 45 Lmin-1, 74.44 ± 5.95 at 60 Lmin-1). 
This is in accordance with a study from Srichana et al. [153] where the drug 
deposition of SS (400 µg) was studied from different devices at 30, 60 and 90 Lmin-1 
in the twin-stage impinge (TSI). Also Taki et al. [170] showed a good delivered dose 
(>82.5% from the Aerolizer® for FP and SX at 60 Lmin-1 with the NGI). The 
deposition of a combined formulation of the two drugs was studied. Although using a 
different active pharmaceutical ingredient (API)-lactose blend, the % of deposition of 
the drug on the throat and pre-separator (IP/PS deposition) agrees with the current 
study, i.e. ~60%. 
 
Srichana et al [153] showed an increased FPF with the flow rate for a wide 
range of DPIs. The Cyclohaler® showed an increased FPF of approximately 10 % 
from 30 to 90 L min-1. A previous study [163] showed that increasing the airflow in 
the Aerolizer®, the turbulence inside the DPI increased significantly as well as the 
number and intensity of particle-device collisions. This did increase the overall 
potential of deagglomeration of the mannitol powder used. Increases were seen 
especially between 30 and 75 L min-1, although after this flow rate, increasing the 
flow rate was not significant. This is in accordance (except at 100 Lmin-1) with the 
results of the current project where the FPF of the emitted SS from the Cyclohaler® 
were not significantly different between 60 and 75 L min-1 (p value>0.05,  
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Table 2.8). It was previously suggested [163] that the flow rate where any 
change in the dispersion system is not significant is 65 L min-1. Our study is in 
accordance as no difference was seen in both the FPF or in the recovered dose in 
device and throat between 60 and 75 L min-1. However, a much reduced amount of 
particles retention in the device was seen at 100 L min-1 (Figure 2.8), whereas, 
Coates et al [163] showed no difference above 60 L min-1, although they used 
micronized mannitol. They also showed a great reduction in recovered dose in the 
device between 30 and 60 L min-1 (50% to 5.1%, respectively) which is not shown in 
the current project. This is presumably due to the different powder used in the two 
studies. Increasing the air flow leads also to a reduced MMAD [149]. In the current 
study at the highest flow rates the MMAD of SS was halved when the Cyclohaler® 
was employed alone (Table 2.8). 
 
Previous studies showed that the cyclone technology helped to retain large 
agglomerates and enhance the liberation of fine particles from DPIs.  The Conix™ 
DPI, developed by Cambridge Consultants Ltd. [156] and licensed by 3M Drug 
Delivery Systems (3M Ltd.), was demonstrated to deliver an higher % of fine 
particles of SS and a better fine particle distribution than the Accuhaler™ [162]. At 4 
kPa using the ACI the % of delivered dose of the SS from the Conix™ was 25 % in 
stage 4 and 5. The Accuhaler™ showed only 10 and 5 % of delivered dose on stage 
4 and 5, respectively. Also, the MMAD of SS emitted from the Conix™ was halved 
(0.97 μm) compared to the MMAD from the Accuhaler™ (1.99μm). Additionally, the 
% FPF of the emitted dose was double that from the Accuhaler™ (~ 90 and ~ 40 %, 
respectively) [91]. Another DPI with a cyclone separator system, the AirMax™ 
showed a significant improvement of FPF of budesonide or salbutamol compared to 
the Turbuhaler® and more consistent dose delivered regardless the flow rates used 
[93]. Although cyclone technology inhalers showed efficiency in delivering a higher 
respirable fraction compared to more common DPIs, they do only provide the 
delivery of a specific formulation-device product [91-93, 146]. The idea of spacer for 
DPIs (as seen already for MDIs [171]) has been suggested and investigated. A 
spacer decreases aerosol velocity and particle size in order to prevent the 
oropharyngeal deposition of the biggest particles and to ensure smaller particles 
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reach the patient’s airways [172]. The fine particle mass should be unchanged when 
a spacer is employed, and extra-thoracic deposition should be reduced [172]. The 
combination of spacer and DPI was previously suggested to reduce potential 
oropharyngeal deposition [173, 174]. However the authors failed to perform a full 
particle side distribution study. Thus, it is crucial to understand the impact of cyclone 
spacers on drug release and potential lung delivery. 
 
Based on the cyclone separation technology applied to DPI development, CFD 
studies have been conducted towards miniaturization of reverse airflow cyclone-
spacer prototypes (e.g. Cheng 1) [159] to classify particles based on size and 
enhance powder de-agglomeration at different flow rates. CFD revealed near-wall 
velocity and integral scale strain rates with enhanced aerodynamic separation and 
impaction forces. Therefore, the Cheng 1 (intended as a spacer for DPIs) was 
manufactured and assessed with the Cyclohaler®. The cyclone-spacer functions 
using reverse airflow cyclone technology theory. A vortex occurs when the airflow is 
drawn through the outlet and the centrifugal forces within the conical section (Figure 
2.1) help the removal of fine particles from the coarse carrier that is retained within 
the conical section. The SS formulation was delivered using the Cyclohaler® instead 
of placing the powder in the conical section of the spacer because there was the 
need to create an aerosol cloud prior to entering the conical section of the cyclone 
spacer [95, 175]. CFD studies [159], also, suggested that impaction on the cyclone 
wall due to centrifugal forces occurs when vacuum is applied to the outlet of the 
cyclone and therefore, the velocity of the emitted particles from the Cyclohaler® 
would increase the particle-particle and particle-walls collisions inside the Cheng 1. 
Finally, due to the design of the Cheng 1, placing the powder inside the spacer was 
not trivial, and counter-productive to the concept of a generic spacer. 
 
Initial experiments in the current study focussed on assessing the resistance of 
the cyclone spacer. The aim was to achieve 75 Lmin-1 and 100 Lmin-1 (= 4 kPa) 
through the spacer as already achieved for the Cyclohaler® alone. However, the 
resistance of the Cheng 1 was excessive (0.0805 kPa1/2 /L min-1) and therefore, the 
latter flow rates could not be reached. However, the study was carried out at three 
significant flow rates (30, 45 and 60 Lmin-1) to investigate the flow rate dependence 
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of the emitted dose of a lactose/SS mixture using Cyclohaler® in series with the 
Cheng 1 spacer. Although the % recovery of the SS was within pharmacopoeial 
limits when the Cheng 1 was used, a high retention of the dose was seen within the 
spacer (e.g. 81.68 ± 6.88 % at 30 Lmin-1). This is a common feature widely seen 
when spacers are employed with MDIs [143, 176]. Positively, spacer retention 
typically reduces the oropharyngeal deposition observed when the spacer is not 
employed. In the current study a much-reduced IP/PS deposition of SS was detected 
when the Cheng 1 was employed regardless of the flow rate (Table 2.9). 
Approximately a 3-fold decrease in the induction port/pre-separator deposition was 
seen with the Cheng 1 in place at 60 L min-1, compared to the Cyclohaler® alone. 
This occurred principally because the cone section of the cyclone collected the non-
inhalable fraction; i.e. dae> 10 μm [43]. The same trend was seen in a previous study 
[173] where  terbutaline sulphate was emitted from the Turbuhaler® at 70 L min-1 
with an add-on spacer chamber. The authors showed high retention in the spacer as 
well (approximately 25 % of the recovered dose of the drug). A filter collected 55.5 ± 
3.3% of the emitted particles as being respirable and the remaining 20 % deposited 
in the throat [173]. Drug delivery efficiency was improved to 47% compared to 38.0 ± 
2.4% delivery when the spacer was not used. Ehtezazi et al [174] confirmed that 
retention in the spacer reduced oropharyngeal deposition. When SS was emitted 
from the Clickhaler® with a long add-on spacer, 40.18 ± 6.94 % deposited in the 
oropharyngeal model compared to 70.86 ± 14.87 % without the spacer. The same 
trend has long been confirmed for MDIs with spacer chambers, showing that 
approximately 75 % of salbutamol emitted from the Ventolin™ with add-on spacer 
was collected inside the spacer [176]. In the current study, significant difference (p < 
0.05) was observed in the IP/PS deposition when the flow rate was increased for the 
Cyclohaler® (70.22 ± 3.23 % - 75.51 ± 16.70% between 30 and 75 Lmin-1, 
respectively). However, employing the cyclone significantly decreased the drug 
deposition in the throat and pre-separator due to both high retention in the cyclone 
and the liberation of only the finest particles that were likely to deposit in stages with 
a cut-off < 5 µm (i.e. the respirable fraction) [40, 44, 45].  
 
High retention in the spacer indicates that in the presence of the cyclone 
increased less throat deposition may occur (Table 2.9). However, the respirable 
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dose expressed as FPD was unchanged when the spacer was used, except at low 
flow rate (i.e. 30 Lmin-1, p<0.05).  This suggests that at low flow rate, lower 
deaggregation forces occur inside the spacer and a lower respirable dose is emitted 
compared to when the DPI is used alone. This might lead to the high retention seen 
in the spacer [173] and potentially to an additional inhalation to be required for each 
actuation to achieve a consistent FPD between DPI alone and the DPI with the 
cyclone (i.e. uninhaled drug remains in the cyclone and may be inhaled more than 
once). The same trend of consistent FPF (%ED) was seen when Cyclohaler and 
spacer were compared (except for 30 Lmin-1: 20.83 ± 3.00 % (30 Lmin-1), 27.86 ± 
3.50 % (45 Lmin-1) or 33.84 ± 2.90 % (60 Lmin-1) of the ED from the Cyclohaler® 
was potentially respirable vs. 14.48 ± 5.84 % (30 Lmin-1), 26.44 ± 4.34 % (45 Lmin-1) 
or 33.42 ± 5.86 % (60 Lmin-1) when the Cheng 1 was in place. In this study a great 
increase in the % FPF5µm (%sED) has been shown with the Cheng 1 in place. The 
corresponding FPF5µm from the spacer (%sED) were between 82.75 ± 7.34 % and 
77.00 ± 10.07 % at 30 and 60 Lmin-1, respectively. However, it has to be kept in mind 
that FPF5µm (%sED) was calculated without considering the high retention of the 
particles in the conical section of the spacer. This great amount of powder that is not 
considered in the calculation would effectively increases the numerical value of the 
FPF5µm (%sED). It was promising to observe that the FPF5µm of the emitted particle 
from the Cheng 1 (%sED, and %ED Table 2.9) and the FPD was unaffected by the 
alteration of the flow rate at 45 and 60 Lmin-1 with the cyclone in place because 
similar findings have not been revealed in previous studies using DPI spacers [173, 
174, 177]. The only authors to suggested similar finding were Zeng et al [93] where 
they showed that the delivered dose of salbutamol emitted from the Airmax™ was 
within 85-115 % of the label claim at flow rates between 30-90 L min-1. However, 
both FPD and FPF5µm of the emitted particle at the lowest flow rate from the 
Cyclohaler® with the Cheng 1 in place were affected by increasing the flow rate 
(Table 2.9). At 30 L min-1 both parameters were half those at 60 L min-1. At lower 
flow rate the velocity of particle is diminished and therefore, more retention in the 
spacer was seen. This arises from the lower turbulence collision forces in the inner 
walls of the spacer than when the flow rate is 60 Lmin-1. The force was not enough to 
lift the particles towards the outlet or to separate the micronized drug from the 
carrier, which is heavier and, therefore, deposits at the bottom of the conical section. 
Large particles (e.g. lactose carrier) have higher collision forces than micronized 
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particles. Hence the conical section of the Cheng 1 enhances deagglomeration of 
the former. Moreover, smaller particles, although emitted from the inhaler, would not 
impact on the cyclone wall with the same energy as the big agglomerates as their 
inertia is lower.  
 
In addition the MMAD values (Table 2.9) with Cheng 1 in place were ~3 times 
smaller than for the Cyclohaler® itself (Table 2.8, ANOVA, post-hoc Tukey’s test, p < 
0.05) and this can potentially improve the specificity of lung deposition. Moreover, as 
the Cheng 1 is a classifier chamber that classifies the particle based on the size, the 
MMAD was unaltered upon increasing the flow rate (p value > 0.05). In fact, SS was 
emitted from the circular outlet of Cheng 1 that helped the consistency in the particle 
size. Thus the cyclone served to reduce potential oropharyngeal deposition (i.e. IP/ 
PS deposition) whilst limiting particle output to the respirable range, owing to the 
aerodynamic fractionation of the cyclone. This represents a major advantage 
compared to the use of the DPIs alone, where changes in MMAD are commonly 
observed due to differences in inspiratory parameters between patients [12, 81]. 
 
The cut off diameter of the spacer depends not only on the geometry and 
design of the outlet, but also on the air velocity pulled through it. Vortex instability 
occurring in the Cheng 1 might explain the variability in both IP/PS deposition and 
FPF at the highest flow rates (Table 2.9). Vortex instability was previously detected 
by CFD [159] and confirmed by LDA in the current work (Figure 2.11). The Cheng 1 
showed a much reduced Dv50 (volume median diameter of 50 % of the particles 
population) when used compared to the Cyclohaler® by itself (1.03 ± 0.01 and 40.04 
± 4.03 µm, respectively at 30 Lmin-1). However, at 60 L min-1, a bi-model particle size 
distribution was observed confirming the escape of agglomerates or carrier lactose 
from the spacer, showing only 50 % of the volume distribution being below 3 µm. 
The prototype cyclone has shown the potential to be used as a classifier and spacer 
for DPI. However, when the Pulmicort/Turbuhaler™ was assessed, the LDA 
displayed micronized particles emitted from the device and the Cheng 1 decreased 
the Dv50 only at low pressure (2 kPa), failing to have reproducible data at the 
highest (4 kPa) (Figure 2.12). This confirms the theory that the cyclone spacer 
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worked only with carrier based DPI. A carrier-free formulation would be composed of 
only micronized material. The cyclone spacer appeared to classify the particles 
based on the size with retention of coarse carrier. If the formulation studied with the 
Cheng 1 was carrier-free, micronized particles would aerolize with a cohesive 
behavior, and due to their low momentum, they would not collide into the spacer’s 
walls as seen for large particles. The cyclone technology operates with the presence 
of a coarse carrier for liberation of micronized drug. However, the LDA should not be 
used to evaluate the PSD alone [178]. The difference between laser diffraction and 
impaction techniques is that LDA provides information of the geometric particle size, 
whereas impaction gives information on the aerodynamic particle size and, therefore, 
a prediction of how particles will deposit in the lungs based on their aerodynamic 
size.  
 
2.6. Conclusion 
This study has shown the potential of a prototype cyclone spacer to be used 
with the Cyclohaler® to decrease predicted oropharyngeal deposition and to 
increase the respirable particle fraction of SS/carrier formulation. There was a high 
retention of non-respirable drug within the Cheng 1, a feature common to spacers. 
The MMAD of the emitted aerosol was shown to be determined by the low cut-off 
diameter (<5 μm) of the cyclone itself that also increased the respirable fraction (e.g. 
FPF5µm). The Cheng 1, however, showed a high resistance leading to the inability to 
achieve flow rates above 60 L min-1. Nevertheless, the mitigation of the flow rate 
dependence of the emitted dose and MMAD was a promising finding. However, the 
resistance of the spacer was too high and remanufacture will be necessary. 
Suggestions have been proposed to change the orifice diameter and shape from a 
cylindrical to a more oval shape to decrease the resistance. Moreover, increasing the 
cut off diameter from 2 to 5 µm would improve the liberation of fine particles and 
probably a more consistent delivery of the dose. Further study is required to focus on 
such a more suitable cyclone spacer prototype (Cheng 2) with a higher cut off and 
lower resistance than Cheng 1. 
  
94 
 
 
 
 
 
 
 
 
 
 
 
3 Chapter 3: Optimization of a reverse airflow cyclone-
spacer for pulmonary delivery 
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3.1 Optimization of a reverse airflow cyclone-spacer for pulmonary delivery 
 
3.1.1. The high variability of oropharyngeal and lung deposition from dry powder 
inhalers 
Lung deposition from DPIs can be calculated from two variables: variability of the 
delivered dose and variability in the throat deposition. Higher throat deposition leads 
to lower lung deposition [179]. Many studies have focused on both oropharyngeal 
and lung deposition of the delivered dose emitted from DPIs either in vitro or in vivo. 
Many have suggested that on increasing the flow rates the particle size decreases 
leading to an increase peripheral lung deposition as smaller particles would be able 
to reach the small airways. Many others have also suggested there is a high 
variability between patients and devices used as represented in Table 3.1. 
Table 3.1.Table of variability in oropharyngeal and lung deposition from dry powder inhalers at 
different flow rates. The sign “-“indicates not data were available for the specific parameter. 
Authors Inhalers 
Flow rates 
(Lmin-1) 
Oropharyngeal 
Deposition (%) 
Lung 
deposition (%) 
Thorsson et 
al[180] 
Diskus - - 13% 
 Turbuhaler - - 36% 
Newman et al[181] Turbuhaler 60 21.4 % 54.8 - 80.0% 
 ASTA Medica  45-90 19.9-32.1% 12.1-37.4% 
Borgstrom et al[78] Turbuhaler 35 66.6% 14% 
Newman et al[79] Genuair® DPI 80 61.9 % 34.0% 
Newman et al[155] MAGhaler 30-60 78.7%-72.5% 26.4% 
 Novolizer - - 35.7% 
 Pulvinal - - 14.8% 
 Spinhaler - - 18.5% 
Gibbons et al[182] Handihaler - 68% 18% 
 Respira DPI - - 46% 
 
3.1.2. In vitro simulation with mouth-throat models 
Although in vivo study of throat and lung deposition of radiolabelled APIs could 
give a true estimate of the delivery performance of an inhaler, it requires ethical 
approval and it is time consuming. Therefore, many studies have focused on 
reproducing mouth-throat models to mimic oropharyngeal deposition of aerosols 
[183-186]. However it must be kept in mind that a human throat cast may show a 
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higher collection of the emitted particles compared to the standard throat used in 
impaction studies [187]. 
 
  Zhou et al [185] and Zhang et al [186] showed that in vitro deposition with an 
idealized throat manufactured using computed tomography (CT) scanning of a 
human throat had a good correlation with in vivo deposition data. Using an idealized 
throat, the mouth-throat deposition of aerosol emitted from the Turbuhaler® was 67.8 
± 2.2 %, which showed a good correlation with in vivo values of 65.8 ± 10.1% [185]. 
Other studies have tested the mouth-throat cast at different flow rates (e.g. 15-90 
Lmin-1) with different nozzle exit diameters to represent marketed DPI [188, 189], 
suggesting that deposition in the mouth-throat cast of a monodisperse aerosol (e.g.  
5 µm) emitted at low flow rates (e.g. 32 Lmin-1) varied from 1.45% to 94.1 % when 
decreasing the diameter of the orifice inlet [188]. However, the deposition of the 
smallest particle (2 µm diameter) was unaffected by changes in mouthpiece diameter 
at all inspiratory flow rates [189]. This may be because 2 µm particles have lower 
inertia. Slower air velocity could result in a reduction in particle inertial values, 
decreasing the possibility of impaction of particles in the posterior oropharynx where 
the air stream changes its direction suddenly. Therefore, throat deposition would be 
high depending on the device design and on the flow rate used. 
 
3.1.3. Improvement of in vitro drug delivery: the concept of a spacer for dry powder 
inhalers 
Many studies have reported the in vitro variability on the particle size, fine 
particle fraction and fine particle dose with increasing the flow rates [149, 153-155]. 
Also, high throat deposition occurs in patients. Spacers for DPIs have been 
proposed in the last 20 years to decrease throat deposition of the emitted particles, 
as used for MDIs already [173, 174]. An example is shown in Figure 3.1. 
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Figure 3.1. Diagram of a spacer used with inhaler devices for in vitro aerosolisation studies [174]. 
 
Although the reduction of the throat deposition was a promising finding, Matida 
et al. and Ehtezazi et al. [173, 174] did not perform a full particle size distribution with 
the spacers, which inhibits the potential to predict the aerosol deposition, which can 
be achieved with cascade impaction. They also showed that the spacers remained 
susceptible to the inter-patient flow rate-derived variability in fine particle 
characteristics (e.g. particle size and fine particle dose) from the DPI itself. However, 
Everard et al [177], showed an unchanged respirable fraction with an aerodynamic 
size below 6.8 µm emitted from the Turbuhaler with a spacer-chamber at 60 Lmin-1, 
suggesting the spacer would not affect the lung deposition. Therefore, there is still 
potential for a spacer for dry powder inhalers although some consideration needs to 
be made regarding their design constraints. 
 
3.1.4. Considerations regarding spacers with DPIs 
The concept of the spacer is successful for MDIs because, broadly, the type of 
the formulation (except for the APIs) and design of the MDI device is identical 
between inhalers. Therefore, the aim of the spacer was mainly to reduce the throat 
deposition of the emitted aerosol [80, 190]. When a spacer is suggested for DPIs, 
two main things need to be taken into consideration: the design of the DPIs and the 
type of formulation. The design of the DPI affects the powder deagglomeration 
(together with the patient’s inhalation strength) and the size of the internal diameter 
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of the device mouthpiece might affect the turbulence to air flow through each device 
[84]. This is important as turbulent flow would increase the deagglomeration of the 
emitted dose [95]. Additionally, Al-Sowair et al. [81] showed that the higher is the 
internal resistance of a DPI, the lower is the flow rate generated for a given pressure 
drop. This means that a patient would breathe fast across a low resistance device 
such as the Aerolizer, but for longer when a higher resistance device is used. 
Therefore, introducing a spacer to an already high resistance inhaler can increase 
the resistance of the DPI and the adherence of the patients to the therapy as they 
struggle to breathe through a high resistance device. As DPIs have a wide range of 
resistances to the air, manufacturing a generic spacer might be difficult to account 
for all the design of the inhalers.  
 
3.1.5. Overview on commercial DPIs 
It has been previously mentioned, many DPIs are available in the market [66]. 
The DPIs that will be studied in this chapter are Accuhaler™, Easyhaler™ and 
Cyclohaler® due to their different design and different formulations. Accuhaler™ is a 
multidose inhaler, Easyhaler™ is a reservoir inhaler and Cyclohaler® is a single 
dose inhaler. The different design would lead to different plume geometry between 
inhalers. If a spacer is used, this might affect the outcome of the emitted particles. 
For example, when using an Aerolizer (similar design to a Cyclohaler®), upon 
inhalation the velocity of the particles increases and more collision occurs between 
the drug and the grid which creates more energetic turbulence [95]. Thereby 
enhancing the FPF [95]. Turbulence is the major controlling factor on particle 
deagglomeration, and studies showed that inside the Aerolizer, turbulent flow 
(cyclonic flow) is predominant but approaches a maximum at 65 L min-1 [95]. By 
comparison, the Accuhaler device presents a cross-shape grid compared to the 
Cyclohaler®. This would affect the FPF, reducing the powder-grid impactions, and 
therefore the deagglomeration potential with increasing grid voidage [95]. This leads 
to an increased impaction in the mouthpiece and induction port stage for the 
Accuhaler™ [95, 166]. Another device that shows turbulent flow is the Easyhaler™. 
As a result, the FPF and the lung deposition ratio of drug particles are enhanced 
[86]. Both Easyhaler™ and Accuhaler™ show consistency in the delivered dose 
observed between the different flow rates [89, 152] However, dissimilarity was 
99 
 
observed with the Turbuhaler, which is subject to inconsistency in the delivered dose 
depending on the inhalation flow [191]. 
 
3.1.6. Cyclone technology applied for different formulations 
Harrison et al [146] and Needham et al [91] studied SX/FP formulation and SS  
formulation emitted from the Conix™, respectively, as well as from the Accuhaler. 
Nine asthmatics were involved in the study comparing Accuhaler and the Conix 
[146]. They were prescribed with 100 µg/dose of FP and 50 µg/dose and SX, emitted 
from the Accuhaler and Conix. The study showed that FP was absorbed faster when 
emitted from the Conix in the first 2.5 h. In vitro studies showed that the Conix 
delivered a larger fraction of small particles than the Accuhaler for FP, with a lower 
MMAD [146]. This would explain a faster absorption in vivo because greater amount 
of small particles would reach the peripheral airways and pass through to the blood 
vessels. The same trend was seen for SX with a prolonged absorption from the 
Accuhaler (Diskus). 
 
The formulations of SS and SX/FP emitted from the Conix showed a different 
IP/PS deposition although the cyclone technology was applied to both inhalers. 
Interestingly the combination of two drugs showed a higher IP/PS deposition (e.g. 
SX deposition was 76 % of the delivered dose) [146] than when only a single API 
was emitted from the Conix (e.g. SS deposition was 13% of the delivered dose) [91]. 
This may have been due to cohesive behaviour of SX when blended with coarse 
carrier that leads to less efficient deagglomeration processes than SS during 
emission from the device [98, 113]. 
 
Although in Chapter 2 neither cyclone-spacer retention nor IP/PS deposition 
was affected by the flow rate, the only API tested was SS/lactose. The Conix study, 
therefore, suggests that drug formulation/product type needs to be taken in 
consideration when applying new technology to DPIs, as they might not lead to an 
unaltered delivery of the dose. Therefore the aim of this chapter was to test the 
potential of a cyclone-spacer as a generic platform for a range of marketed DPI, with 
different device design and formulations. 
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3.2 Aim 
A high resistance prototype spacer decreased the throat deposition of emitted 
aerosol particles and had potential to mitigate the flow rate dependency of the 
delivered dose and particle size of a carrier-based formulation. Moreover, it was able 
to capture the large particle size carriers (e.g. coarse lactose) emitted from the 
Cyclohaler®. The aim of the current chapter was to assess the potential of a low 
resistance cyclone-spacer to improve in vitro delivery of a range of commercial 
carrier based DPIs. 
The objectives of the current work were: 
- To manufacture a lower resistance cyclone-spacer than the Cheng 1 (i.e. 
Cheng 2) 
- To test the resistance of the Cheng 2 in series with Cyclohaler®, Easyhaler 
and Accuhaler 
- To assess Cheng 2 with carrier-based marketed inhalers to represent 
products regarded as a cohesive blend, an adhesive blend and a combination 
bronchodilator and corticosteroid formulation  
 
3.3 Materials and methods 
3.3.1 Materials 
Micronized fluticasone propionate (FP) was purchased from Sicor de Mexico 
(Toluca, Mexico) and micronized budesonide (Bud, batch number U0015/1V040) 
was supplied from LGM Pharma (Boca Raton, USA). Salmeterol xinafoate (SX) was 
purchased from Vamsi Labs Ltd (Solapur, India). The DPIs tested were an 
Easyhaler/Budesonide™ 400μg/dose and Easyhaler /SS™ 200 µg/dose (purchased 
from Orion Pharma, Newbury, UK), a Seretide/Accuhaler™ 50 µg/500 µg/dose and 
Ventolin/Accuhaler™ 200 µg/dose (purchased from Allen & Hanburys, Uxbridge, 
Middlesex, UK). A Cyclohaler® device (obtained from AAH Hospital Supplies, 
Coventry, UK). Size 4 hard gelatine capsules were obtained from Meadow 
Laboratories Ltd. (Romford, UK). The cyclone spacer was manufactured in-house 
(University of Cambridge, UK) from a Perspex blocks (Engineering & Design Plastics 
Ltd, Cambridge, UK); the exit duct was cut and polished from stock brass tubing 
(Engineering Department Storeroom, University of Cambridge, UK) The flow meter 
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(model number DFM2), next generation impactor (NGI) and a model HCP5 vacuum 
pump were all purchased from Copley Scientific Ltd (Nottingham, UK).  
 
3.3.2 Cyclone manufacture 
A miniature reverse-flow cyclone (Cheng 2) was optimised from previous studies 
using empirical models [157] to have a theoretical particle cut-off diameter below 5 
μm for flow rates between 30 and 120 Lmin-1. The Cheng 2 was machined from 
Perspex with an oblong inlet orifice of 10.1 x 6 mm to facilitate relatively high inlet 
velocities with acceptable pressure drops. For dimensional accuracy, easy sample 
collection and interchangability, the Cheng 2 was manufactured in three separate 
sections as per Cheng 1 (Figure 3.2). 
 
 
 
 
 
 
 
 
 
Figure 3.2. Dimensions of simulated cyclone geometries (units in mm) 
  
 Cheng 2 
D 21 
De 5.9 
a1 10.1 
b1 6 
H 56.4 
H 23.5 
S 23.5 
B 7.1 
102 
 
3.3.3 High performance liquid chromatographic assay validation of active 
pharmaceutical ingredients 
Three micronized active pharmaceutical ingredients (APIs) were tested using 
high performance liquid chromatographic (HPLC) assay: salmeterol xinafoate (SX), 
budesonide (Bud), fluticasone propionate (FP). A stock solution of each API was 
prepared by weighing accurately approximately 0.0025 g of the drug with an 
analytical balance (Mettler Toledo, UK), transferring it into a 50 ml volumetric flask 
and bringing the solution to volume with the appropriate mobile phase (Table 3.3). 
The stock solution was used in order to prepare a calibration series by pipetting the 
volumes shown in Table 3.3 and the set of calibration standards were run using 
HPLC (Agilent 1050 Series, Agilent Technologies UK Ltd., Edinburgh, UK) with a 
Luna 3 μm C18 column (150 mm x 4.6 mm x 3 μm) at 1 ml min-1 (the high 
performance liquid chromatographic conditions are reported in Table 3.3). 
 
Table 3.2. Volume of stock solution (ml) required to prepare a calibration series in the concentration 
range of 0.05-50 µg ml
-1
. 
Theoretical 
concentration 
(µgml-1) 
Volume of stock 
solution 
(ml) 
Final 
volume 
(ml) 
25 10 20 
10 5 25 
5 1 10 
2 1 25 
1 1 50 
0.5 1 (from 1 µgml-1) 10 
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Table 3.3. High performance liquid chromatographic (HPLC) conditions for salmeterol xinafoate (SX), fluticasone propionate (FP), and budesonide (Bud). 
Active 
pharmaceutical 
ingredients 
Mobile phase 
Column 
temperature 
(°C) 
Injection 
volume 
(µl) 
Detector 
Wavelength 
(nm) 
Calibration range 
SX 
75:25 (v/v) mixture of methanol: 0.6% (w/v) 
aqueous ammonium acetate. 
40 50 228 0.5-50 µgml-1 
FP 
75:25 (v/v) mixture of methanol: 0.6% (w/v) 
aqueous ammonium acetate 
40 50 240 0.5-50 µgml-1 
Bud 
75:25 (v/v) mixture of methanol: 0.6% (w/v) 
aqueous ammonium acetate. 
40 50 240 0.5-50 µgml-1 
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3.3.4 Data analysis of high performance liquid chromatography assays 
3.3.4.1 Linearity assay precision and reproducibility 
The linear regression analysis was performed according to Chapter 2, Section 
2.3.4.1. 
 
3.3.4.2 Limits of detection (LOD) and limits of quantification (LOQ) 
The LOD and LOQ were calculated according to Chapter 2, Section 2.3.4.2 
 
3.3.4.3 Accuracy determination 
Two sets of five standard solutions were prepared; the first set were prepared 
with 0.002 g of the API dissolved into 20 ml of mobile phase and making a 1:10 
dilution in order to obtain 10 µg/ml solution. The second set was prepared with 0.002 
g of the API (FP, BUD or SX) and 0.048 g of lactose monohydrate dissolved into 50 
ml of mobile phase and 1:4 dilutions were performed to obtain the same 
concentration to above. The peak area response of the standards when analyzed by 
HPLC according to the assay in Section 3.3.3 (Table 3.3) was determined. The 
amount of the API recovered was calculated using the calibration curve and the 
percentage recovery of the drug was calculated using the equation (3.1). 
 
% recovery = 
𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔𝑚𝑙−1)
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎l 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔𝑚𝑙−1)
   (3.1) 
 
 
3.3.5 Dose content assay of emitted dose 
The dose uniformity sampling apparatus (DUSA, Copley Scientific Ltd., Nottingham, 
UK) with a glass microfiber filter (Whatman, GE Healthcare Ltd., Buckinghamshire, 
UK) was used for the dose content determination (n=5). The pressure drop was set 
(2 and 4 kPa to represent values achievable by patients across the DPIs in series 
with the spacer Cheng 2). Then, the respective flow rate at the cyclone entrance was 
measured with a flow meter (Copley Scientific Ltd., Nottingham, UK). In Table 3.4 
the flow rates at the spacer inlet corresponding to 2 and 4 kPa are reported for all the 
105 
 
DPIs tested. The drugs were collected from the DUSA and the filter with the 
appropriate mobile phase (Section 3.3.3). The concentrations were determined by 
HPLC assay (Section 3.3.3).  
 
Table 3.4. Pressure drops and measured flow rates at the spacer inlet for dry powder inhalers tested 
at 2 and 4 kPa with the Cheng 2 (SS= salbutamol sulphate, SX= salmeterol xinafoate, FP = 
fluticasone propionate, Bud = budesonide). Pressure drop the flow rates generates through the DPI 
alone 
Dry powder inhalers Drug 
Pressure 
drop (kPa) 
Flow rates 
(L min-1) 
Seretide/Accuhaler™ SX, FP 
2 34 
4 50 
Cyclohaler® SS 
2 37 
4 51 
Easyhaler™ BUD 
2 31 
4 43 
 
3.3.6 Resistance of Cheng 2 
The resistance of Cheng 2 was measured across the spacer and Cyclohaler®, 
Accuhaler™ and Easyhaler™, in series using a dose uniformity sampling apparatus 
(DUSA, Copley Scientific Ltd., Nottingham, UK). The DUSA was connected to a 
critical flow controller TPK (Copley Scientific Ltd., Nottingham, UK) to adjust the flow 
rate. Once the flow rate was set through the DUSA, the Cheng 2 with the inhaler was 
attached to the DUSA to record the pressure drop of the respective series device-
spacer combinations. The range of flow rates tested was between 15-60 L min-1. The 
pressure drops obtained were then plotted against the corresponding flow rates and 
the resistance calculated by interpolation. 
 
3.3.7 Impaction studies using next generation impactor 
Each DPI was tested at 2 and 4 kPa with and without Cheng 2 according to 
Sections 3.3.5. Prior to performing the measurements with the NGI, the desired flow 
rate was adjusted with a flow meter. Prior to measurement, 15 ml of mobile phase 
was added in the central cup of the pre-separator. When the Cyclohaler® was 
assessed alone, six Size 4 hard gelatine capsules were used.  When the Cheng 2 
was employed as spacer device, 12 capsules were actuated at 2 kPa and eight 
capsules at 4 kPa. When the Accuhaler™ and Easyhaler™ were used alone, six 
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actuations were counted at both pressure drops. When the cyclone was employed, 
12 actuations were counted at 2 kPa and eight at 4 kPa for both the devices. In order 
to recover the drugs, the DPIs were washed with 20 ml of mobile phase. The bottom 
of the cyclone, the mouthpiece and the USP throat were each washed with 50 ml of 
mobile phase; whilst the upper section of the cyclone was washed with 10 ml. For 
collecting the drugs from the pre-separator 100 ml of mobile phase was used. The 
volumetric flasks were sonicated (Kerry, Germany) for 2 min. When only the DPIs 
were employed, 10 ml of mobile phase was added to the first 5 stages, whilst 5 ml of 
solvent was used for the last 3 stages. All the stages were set on a laboratory rocker 
(Stirling Mixer, Sandrest Ltd, UK) and rocked for 2 min in order to allow the solvent to 
clean the entire surface. When the cyclone was used, 5 ml of mobile phase was 
added to all the stages. The concentrations of the drugs from each stage were 
determined by HPLC assay as described in Section 3.3.3. After performing the 
experiments, each stage and the NGI were thoroughly cleaned with Millipore water 
and the silicone coating was removed with acetone before rinsing with methanol. 
 
3.3.8 Aerosolization studies using laser diffraction technique 
Aerosolization was assessed by laser diffraction particle size analysis using the 
Sympatec Inhaler module (Inhaler Helos/KF, Sympatec Limited, Bury, UK) at 2 and 4 
kPa for all the DPIs with and without Cheng 2. The lens used to detect the aerosol 
cloud was an R3 lens (0.5-175 µm). The measurement was set to trigger when the 
optical concentration was between 1.0 and 1.1 % for 5 sec duration (time base 1 ms) 
to avoid reading of dust particles. The formulation was then recovered from each DPI 
and particle size tested with the Sympatec Rodos module to determine the DV50 for 
carrier particle size and the % of population with size < 5 µm. The trigger conditions 
were identical to when the inhaler module was used. 
 
3.3.9 Statistical analysis 
Statistical analysis was performed in Minitab (version 15) using one-way 
ANOVA and post-hoc Tukey’s test (multiple comparisons) or Student’s two-tailed t-
test for pair-wise comparisons, both at 95 % confidence intervals. Data analysis was 
performed according to Chapter 2, Section 2.3.11. 
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3.4 Results 
3.4.1 Resistance of the Cheng 2 
The DPIs and the cyclone-spacer Cheng 2 on their own posed a wide range of 
resistances (slope of the curves in Figure 3.3). The Cheng 2 alone had 0.037 kPa1/2 
/L min-1 resistance, the Accuhaler had 0.032 kPa1/2 /L min-1, the Easyhaler, 0.054 
kPa1/2 /L min-1, and the Cyclohaler 0.024 kPa1/2 /L min-1. 
 
Figure 3.3. Linear relationship between pressure drop and flow rate across the inhalers alone 
(Easyhaler- black, Accuhaler – blue and Cyclohaler-pink) and Cheng 2 alone (red line). 
 
However, when the resistance of Cheng 2 was tested together with the 
inhalers, it offered a more usable resistance (0.04 kPa1/2 /L min-1) than Cheng 1 
resistance (0.08 kPa1/2 /L min-1) as showed from the slope of the curve in Figure 3.4, 
and was additionally consistant between devices. 
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Figure 3.4. Linear relationship between pressure drop and flow rate across the Cheng 2 and 
Cyclohaler® as a whole device (black line), Cheng 2 and Accuhaler (blue line) and Cheng 2 and 
Easyhaler (red line). 
 
3.4.2 Data analysis of high performance liquid chromatography assays 
3.4.2.1 Assay Linearity precision and reproducibility 
Linear regression analysis performed for peak area response as a function of 
drug concentration for three calibration series is reported in Figure 3.5 for all APIs 
used. 
 
Figure 3.5. Linear regression analysis for budesonide (black), fluticasone propionate (red), and 
salmeterol xinafoate (blue) as a function of concentration (pooled raw data points of n=9, for each 
concentration level). 
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In Table 3.5 pooled linearity data of regression results are reported. 
 
Table 3.5. Regression results for peak area response plotted as a function of concentration for 
fluticasone propionate (FP), budesonide (Bud), and salmeterol xinafoate (SX). 
Day Drug Intercept 
Standard 
deviation of 
the intercept 
Slope 
Standard 
deviation of 
the slope 
Correlation 
coefficient 
(R2) 
1  5.982 2.537 108.514 0.206 0.999 
2 FP -1.124 1.929 107.743 0.083 0.999 
3  0.346 4.210 107.122 0.177 0.999 
Pooled  4.013 2.280 107.440 0.109 0.999 
1  -7.832 3.857 95.175 0.170 0.999 
2 Bud -0.016 2.451 96.394 0.104 0.999 
3  -5.403 2.891 96.310 0.119 0.999 
Pooled  -4.816 3.209 96.000 0.137 0.999 
1  -2.890 2.648 37.414 0.102 0.999 
2 SX 0.829 1.566 37.696 0.064 0.999 
3  3.151 1.034 37.138 0.041 0.999 
Pooled  1.350 1.361 37.388 0.056 0.999 
 
Intra-day variability indicated good repeatability for all the APIs within the calibration 
range 0.5-50 µg/ml (Table 3.6). 
Table 3.6. Intra-day variability for peak area response plotted as a function of concentration for 
fluticasone propionate (FP), budesonide (Bud), and salmeterol xinafoate (SX). 
  %RSD 
  Concentrations (µg ml-1) 
  50 25 10 5 1 0.5 
SX 
Day 1 0.01 0.03 0.11 0.14 1.49 0.63 
Day 2 0.05 0.38 0.64 0.19 0.57 2.25 
Day 3 0.26 0.24 1.10 0.10 0.41 5.37 
FP 
Day 1 N/A 0.32 0.69 0.95 3.04 4.26 
Day 2 0.21 0.16 0.59 0.33 1.08 3.09 
Day 3 0.81 0.18 0.30 0.48 1.85 4.08 
BUD 
Day 1 0.03 0.01 0.19 0.11 0.28 0.68 
Day 2 0.22 0.14 0.01 0.05 0.06 0.20 
Day 3 0.07 0.09 0.02 0.08 0.06 0.24 
 
Inter-day variability (Table 3.7) showed that at the lowest concentration for all the 
drugs the reproducibility of the methods were low. 
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Table 3.7. Table of data from inter-day variability (reproducibility of the relative standard deviation, 
RSD) for fluticasone propionate (FP), budesonide (Bud), and salmeterol xinafoate (SX) assays (n=3). 
 %RSD 
 Concentration (µg ml-1) 
 50 25 10 5 1 0.5 
SX 0.75 0.68 2.24 1.21 3.28 9.29 
FP 0.65 0.74 0.87 1.95 2.69 6.14 
BUD 0.68 0.63 2.13 1.10 2.46 3.02 
 
 
3.4.2.2 Limits of detection (LOD) and limits of quantification (LOQ) 
The sensitivity of the method used for the FP was indicated by an LOD that was 
0.06 µg ml-1 and LOQ that was 0.21 µg ml-1. As the values are relatively low, the 
method was suitably sensitive at low concentrations. The same was indicated for 
Bud (LOD = 0.10 µg ml-1 and LOQ = 0.33 µg ml-1), and for SX (LOD =0.11 µg ml-1 
and LOQ =0.36 µg ml-1). 
 
3.4.2.3 Accuracy determination 
The recoveries of FP alone and when lactose was added were 99.64 ± 2.57 % 
and 98.65 ± 1.86 % respectively showing a high accuracy as the range was between 
95 and 105 %. A two-tailed unpaired t-test revealed no significant difference when 
lactose was added (p value < 0.05) as the carrier does not interfere with the 
detection of the drug. The same performance resulted for Bud, and SX. The % 
recoveries of the drugs were between 100.48 ± 2.19 % for Bud, and 100.30 ± 5.26 
for SX. 
 
3.4.3 Dose content assay of the emitted dose 
The dose contents of the DPIs are reported in Table 3.8. The label claims were: 
Easyhaler/Budesonide™ 400μg/dose, Easyhaler/SS™ 200μg/dose, 
Seretide/Accuhaler™ 50 µg/500 µg/dose, Ventolin/Accuhaler™ 200 µg/dose. 
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Table 3.8. Emitted dose content of dry powder inhalers tested at flow rates corresponding to 2 and 4 
kPa when the inhalers where tested with the Cheng 2 in series (SS = salbutamol sulphate, SX = 
salmeterol xinafoate, FP = fluticasone propionate, Bud = budesonide) (mean ± SD, n=5). 
Dry powder inhalers Drug 
Flow rate 
(Lmin
-1
) 
Dose content 
(µg/dose) 
Ventolin/Accuhaler™ SS 
34 192.59 ± 8.53 
50 186.57 ±6.24 
Seretide/Accuhaler™ 
SX 
34 
50 
70.37 ± 18.99 
60.08 ± 9.71 
FP 
34 
50 
491.75 ± 127.29 
350.64 ± 24.59 
Easyhaler™ Bud 
32 238.15 ± 15.16 
44 276.98 ±24.89 
Easyhaler™ SS 
32 191.92 ± 6.98 
44 199.59 ± 6.82 
The dose emitted of SS for Ventolin/Accuhaler is in accordance with values 
reported in Chapter 2. Regarding Seretide/Accuhaler, the label claim is 50 µg of 
salmeterol base which is equivalent to 72.5 µg salmeterol xinafoate. FP however 
showed a much lower emitted dose compared to the label claim at the highest flow 
rate. The Accuhaler showed variable dose content values at different flow rates. 
Therefore, the flow did affect the emitted dose from the device when the spacer was 
used. 
3.4.4 Impaction studies using next generation impactor 
The DPIs were tested at the flow rates corresponding to at 2 and 4 kPa in the 
presence and absence of the spacer (Table 3.4). The Easyhaler/SS™ did not emit 
enough drug to be recovered from the impactor body of the NGI when the Cheng 2 
was in place at both pressure drops. On the other hand, the Ventolin/Accuhaler™ 
emitted enough drug into the NGI body only at 4 kPa with the Cheng 2 for recovery 
above 75% as per the Pharmacopoeial limits [147]. At the lowest pressure drop SS 
did not leave the inhaler suggesting the Cheng 2 created lower collision forces 
between particle-spacer walls than Cheng 1. For all the other inhalers (i.e. 
Seretide/Accuhaler™, Cyclohaler® and Easyhaler/Bud™) the percentage recovery 
for all the APIs with and without the Cheng 2 was within pharmacopoeial limits 
(Table 3.9). The Cheng 2 showed high retention of non-respirable drug as observed 
for Cheng 1 (Chapter 2, Section 2.4.5.2) although no change was detected when the 
flow rate increased (p >0.05,Table 3.9).   
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Table 3.9. Dose recovery (%), emission (% of RD) from the device (or Device - Cheng 2), retention within the Cheng 2 (%RD) and % induction port/pre-
separator (%ED, IP/PS) deposition for salbutamol sulphate (SS), budesonide (Bud), salmeterol xinafoate (SX) and fluticasone propionate (FP) emitted from 
the Cyclohaler®, Easyhaler™ and Accuhaler™, with and without Cheng 2, respectively at 2 and 4 kPa (mean ±SD>4). 
Device 
Pressure 
drop(kPa) 
Drug % RD 
% Emission 
Ex device (% 
RD) 
% Retention in the 
cyclone (% ED) 
IP/PS deposition 
(% ED) 
IP/PS deposition 
(% sED) 
Cyclohaler® 
2 
SS 
85.68 ± 1.20 81.45 ± 3.14 N/A 67.28 ± 2.09 N/A 
Cheng 2-Cyclohaler® 82.29 ± 3.98 11.61 ± 3.03 87.61 ± 2.96 N/A 
15.87 ± 6.76 
Easyhaler™ 
BUD 
97.07 ± 3.78 97.62 ± 0.56 N/A 62.01 ± 2.52 N/A 
Cheng 2-Easyhaler™ 105.48 ± 3.69 24.51 ± 1.68 75.23 ± 1.70 N/A 15.65 ± 1.39 
Accuhaler™ 
SX 
88.94 ± 9.10 98.65 ± 0.27 N/A 78.27 ± 0.54 N/A 
Cheng 2-Accuhaler™ 89.56 ± 10.58 19.33 ± 0.46 80.48 ± 0.56 N/A 38.70 ± 4.56 
Accuhaler™ 
FP 
90.99 ± 7.92 98.84 ± 0.49 N/A 78.21 ± 1.87 N/A 
Cheng 2-Accuhaler™ 82.39 ± 4.43 18.13 ± 1.09 82.01 ± 1.18 N/A 
35.03 ± 1.45 
Cyclohaler® 
4 
SS 
82.14 ± 2.19 78.59 ± 1.69 N/A 64.44 ± 2.49 N/A 
Cheng 2-Cyclohaler® 79.66 ± 4.43 11.36 ± 0.93 85.69 ± 1.11 N/A 
18.44 ± 2.79 
Easyhaler™ 
BUD 
104.61 ± 5.70 97.91 ± 0.56 N/A 63.18 ± 3.72 N/A 
Cheng 2-Easyhaler™ 104.50 ± 4.66 24.28 ± 2.41 75.12 ± 2.94 N/A 
15.19 ± 1.74 
Accuhaler™ 
SX 
97.73 ± 2.96 99.05 ± 0.15 N/A 76.93 ± 2.39 N/A 
Cheng 2-Accuhaler™ 101.25 ± 13.56 16.16 ± 2.99 83.05 ± 3.67 N/A 36.01 ± 9.77 
Accuhaler™ 
FP 
115.61 ± 7.16 99.27 ± 0.19 N/A 75.53 ± 3.50 
N/A 
Cheng 2-Accuhaler™ 102.68 ± 12.07 13.85 ± 2.01 85.70 ± 2.28 N/A 29.63 ± 5.85 
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The high retention in the spacer decreased the deposition of the particles in the 
induction port/pre-separator stages (Table 3.9) when the Cheng 2 was employed for 
all the DPIs tested. Interestingly the reduction of throat deposition with the cyclone-
spacer in place was constant upon increasing the flow rate with the exception of 
FP/Accuhaler (p<0.05, Table 3.9). In the case of Cyclohaler/SS® and 
Easyhaler/Budesonide™, increasing the flow rate did not alter the IP/PS deposition 
(p > 0.05) both with and without the cyclone in place (e.g. for 
Easyhaler/Budesonide™ IP/PS deposition with Cheng 2 was 15.65 ± 1.39 % and 
15.19 ± 1.74 % at 2 and 4 kPa, respectively). The decrease in the IP/PS deposition 
was due to the high retention of the emitted dose within the spacer. However, lower 
retention within the Cheng 2 cyclone was seen for Bud compared to SS (Table 3.9, 
p< 0.05). When the SX and FP were tested from the Seretide/Accuhaler™, even with 
the cyclone, the IP/PS deposition was double that of the other formulations at both 
flow rates (p<0.05, Table 3.9). The aerodynamic particle size distributions shown in 
Figure 3.6 for SS (A), BUD (B) and Figure 3.7 for SX and FP confirmed the reduction 
of IP/PS deposition (see arrows on  Figure 3.6, A). The distribution shows the 
cyclone improved the % of particles with size < 5 µm (dashed line). Figure 3.6 and 
Figure 3.7 show an unconventional representation of the cumulative undersize 
distribution. The calculation was based following the method of Thiel et al [192] and 
Mitchell et al. [44]. Typically the aerosol PSD is normalized for the impactor sizeable 
fraction only. However, such a conventional representation does not demonstrate the 
extent of the IP/PS deposition, which is visible in Figure 3.6 and Figure 3.7 in the 
distributions calculated as % ED (solid line plot). 
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Figure 3.6. Cumulative aerodynamic undersize (%) of SS of emitted dose from Cyclohaler® at 2 kPa 
(▲) and 4 kPa(●) and from Cyclone (A) and of BUD emitted from Easyhaler™ and from Cyclone (B) 
at 2 kPa (Δ) and 4 kPa(○) (mean ± SD; n = 4). 
 
 
Figure 3.7. Cumulative aerodynamic undersize (%) of SX of emitted dose from Accuhaler™ at 2 kPa 
(▲) and 4 kPa(●) and from Cyclone (A) and of FP emitted from Accuhaler™ and from Cyclone (B) at 
2 kPa (Δ) and 4 kPa(○) (mean ± SD; n = 4). 
 
The FPD is the dose respirable by the patients below a particular size range 
(e.g. 5 µm). Similar trends to that reported for Cheng 1 of decreased MMAD and 
unchanged FPD values (Section 2.4.6.3) were observed for Cheng 2 compared to 
the devices alone.   
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Table 3.10. Mass median aerodynamic diameter (MMAD), fine particle fraction < 5 µm (FPF5µm), and fine particle dose < 5 µm (FPD5µm); of salbutamol 
sulphate (SS), budesonide (Bud), salmeterol xinafoate (SX) and fluticasone propionate (FP) emitted from the DPIs and from the DPIs through the Cheng 2 
cyclone, (mean ± SX, n ≥ 4). 
Device 
Pressure 
drop(kPa) 
Drug FPF5µm (%ED) FPF5µm (%sED) FPD5µm (µm/dose) MMAD (µm) 
Cyclohaler® 
2 
SS 
24.92 ± 1.61 N/A 31.64 ± 2.70 3.00 ± 0.12 
Cheng 2-Cyclohaler® 12.90 ± 4.43 83.62 ± 6.88 15.13 ± 4.78 1.24 ± 0.10 
Easyhaler™ 
BUD 
20.41 ± 2.56 N/A 45.87 ± 3.72 4.72 ± 0.34 
Cheng 2-Easyhaler™ 19.44 ± 0.96 78.58 ± 1.69 48.37 ± 3.66 1.78 ± 0.05 
Accuhaler™ 
SX 
12.12 ± 0.47  N/A 7.49 ± 0.89 4.35 ± 0.36 
Cheng 2-Accuhaler™ 11.04 ± 0.83 56.81 ± 4.21 6.90 ± 0.69 1.54 ± 0.10 
Accuhaler™ 
FP 
12.25 ± 1.58 N/A 54.19 ± 8.42 4.48 ± 0.21 
Cheng 2-Accuhaler™ 11.26 ± 0.68 61.79 ± 1.51 45.43 ± 4.42 1.63 ± 0.14 
Cyclohaler® 
4 
SS 
25.29 ± 6.95 N/A 36.14 ± 5.04 2.65 ± 0.13 
Cheng 2-Cyclohaler® 11.39 ± 0.64 79.66 ± 2.79 13.77 ± 1.67 1.05 ± 0.05 
Easyhaler™ 
BUD 
23.47 ± 2.65 N/A 66.73 ± 9.78 3.91 ± 0.24 
Cheng 2-Easyhaler™ 20.05 ± 2.02 81.63 ± 1.48 57.32 ± 5.78 1.45 ± 0.02 
Accuhaler™ 
SX 
14.38 ± 1.33 N/A 8.36 ± 0.81 3.67 ± 0.34 
Cheng 2-Accuhaler™ 9.71 ± 1.03 60.26 ± 9.18 5.84 ± 1.12 1.17 ± 0.08 
Accuhaler™ 
FP 
15.96 ± 2.44 N/A 64.21 ± 11.07 3.70 ± 0.07 
Cheng 2-Accuhaler™ 9.54 ± 1.46 68.70 ± 5.83 34.57 ± 8.67 1.20 ± 0.06 
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All the inhalers exhibited flow-rate dependence of the % FPF5μm (%ED) when 
employed alone (Table 3.10). Easyhaler/Budesonide was the only product where the 
change in flow rate altered the FPF5μm (sED) (p<0.05) when the cyclone was 
employed. The FPF5μm (%sED, fine particle fraction “ex-spacer”) differed significantly 
between the products at both flow rates (SX Accuhaler™ < FP Accuhaler™ < Bud 
Easyhaler™ = SS Cyclohaler®, p<0.05). This was similar to the behaviour of the 
devices when tested without the cyclone (i.e. comparing FPF5μm %ED). When the 
cyclone was employed the fine particle dose (<5 μm, FPD) was unaffected by a 
change in flow rate (p>0.05), with the exception of the Easyhaler/Budesonide™ (p 
<0.05). However, with the exception of SX, the FPDs of all inhaled drugs were 
significantly lower (p <0.05) when Cheng 2 was employed (Table 3.10). By way of 
example, the FPD of SS combined with Cheng 2 (15.13 ± 4.78 μg and 13.77±1.67 
μg at 2 and 4 kPa, respectively) was lower than from the Cyclohaler® alone (31.64 ± 
2.70 μg and 36.14 ± 5.04 μg at 2 and 4 kPa, respectively). This was in accordance 
with data from Cheng 1, Section 2.4.5 that showed that the FPDs at 30 Lmin-1 
decreased compared to the Cyclohaler alone (e.g. 27.21 ± 4.33 µg/dose ex DPI and 
18.41± 6.63 µ/dose ex Cheng 1). However, at 60 Lmin-1 an equivalent FPD of SS 
was seen with Cheng 1 in place (39.55 ± 3.58 µg/dose ex DPI and 39.44 ± 7.67 
µg/dose ex Cheng 1). 
 
When the DPIs were tested alone, the MMADs decreased when the flow rate 
was increased (Table 3.10, p <0.05).The aerosols which would be inhaled by the 
patient (sED) possessed lower MMADs when emitted from the cyclone than from the 
devices alone (Table 3.10, p <0.05). For example, the MMAD of SS was halved 
when the cyclone was employed (Cyclohaler®: 3.00 ± 0.12 μm and Cheng 2: 1.24 ± 
0.10 μm at 2 kPa). This showed the screening ability of Cheng 2; however unlike 
Cheng 1, the MMADs were lower for all formulations at the 4 kPa than 2 kPa flow 
rate with the cyclone in place (Table 3.10, p <0.05). The latter differences were not 
as large in magnitude as when the DPIs were tested without the spacer. 
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The size of the inlet of the cyclone was 6 mm x 10 mm with a cut-off size 
determined to be < 2 µm. Therefore, the spacer should classify the particles emitted 
from the devices. The fine particle ratio < 1.5 µm (FPR1.5) was defined as equation 
(3.2):  
𝐹𝑃𝑅1.5 =
𝐹𝑖𝑛𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 1.5𝜇𝑚 (𝐶ℎ𝑒𝑛𝑔 2)
𝐹𝑖𝑛𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 1.5𝜇𝑚 (𝐷𝑃𝐼)
   (3.2) 
 
It was calculated as a measure of classification of particles below the cut-off 
diameter per Equation 3.2. Whilst accepting the undesirability of modifying the 
MMAD by spacer use, with the Cyclohaler/SS®, the FPR1.5 was 1.73 ± 0.38 times 
higher at 2 kPa and 1.30 ± 0.18 at 4 kPa with the cyclone in place than without. For 
Accuhaler™/Cheng 2 the FPR1.5 of SX was twice that without the cyclone (2.29 ± 
0.31 and 1.98 ± 0.30 at 2 and 4 kPa, respectively) and of FP was 4.65 ± 0.12 and 
2.63 ± 0.21 times at 2 and 4 kPa, respectively. The greatest FPR1.5 was seen when 
the cyclone was tested for Bud emitted from the Easyhaler™ (6.70 ± 0.25 and 4.24 ± 
0.29 times greater than Bud/Easyhaler™ at 2 and 4 kPa, respectively). This means 
that particles underwent deagglomeration within the cyclone spacer, since the 
proportion of fines < 1.5 µm had increased. However, the FPD was still lower when 
the Cheng 2 was employed due to the bigger agglomerates (1.5 - 5 µm) that are 
likely to be retained inside the cyclone as the cut off of the spacer was relatively low. 
 
3.4.5 Aerosolization studies using laser diffraction technique 
Laser diffraction analysis was performed on the aerosol emitted from the DPIs 
in presence and absence of the Cheng 2 at 2 and 4 kPa. The Dv50 (volume diameter 
of 50 % of the particle population) was dramatically decreased when the cyclone was 
employed for all the DPIs (Table 3.11). 
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Table 3.11. Values of volume median diameter (DV50) of the active pharmaceutical ingredient (API) 
emitted from the dry powder inhalers with and without the Cheng 2 (mean ± SD, n=3) 
API Device DV50 (µm) 
Pressure drop  2 kPa 4 kPa 
SS Cyclohaler® 58.66 ± 3.42 61.56 ± 3.18 
Cheng 2-Cyclohaler® 1.29 ± 0.07 1.13 ± 0.02 
Bud Easyhaler™ 32.68 ± 2.09 31.14 ± 2.12 
Cheng 2-Easyhaler™ 1.88 ± 0.02 1.68 ± 0.05 
SX/FP Accuhaler™ 48.13 ± 2.03 46.01 ± 2.99 
Cheng 2-Accuhaler™ 1.73 ± 0.13 1.15 ± 0.12 
 
However, when the Accuhaler™ was tested, some agglomerates escaped the 
Cheng 2 as shown in Figure 3.8 (the arrows in the figure indicate a shift in PSD to 
larger sizes caused by the agglomerates). A similar behaviour was already seen with 
the higher resistance Cheng 1 with SS at 60 Lmin-1 (Chapter 2, Section 2.4.6.2). 
 
 
Figure 3.8. Representative particle size distributions of salmeterol xinafoate and fluticasone 
propionate from Seretide/Accuhaler™ at 2kPa (■) and 4 kPa (●) and from Cheng 2 at 2 kPa (□) and 4 
kPa (○). The arrows indicate the agglomerates emitted from the cyclone for salmeterol xinafoate and 
fluticasone propionate at 2kPa (□) and 4 kPa (○). 
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The formulations were recovered from each DPI and the Sympatec Rodos 
module where used to determine DV50 of the carrier particle at 4 Bar dispersing 
pressure. The formulation collected from the Ventolin (SS/carrier lactose) and 
Seretide (SX/FP/carrier lactose) showed almost identical particle size for DV50 
(63.46 ± 0.86 µm and 61.95 ± 0.46 µm, respectively, p>0.05). On the other hand, 
when formulation of SS + carrier lactose was recovered from the Easyhaler, the 
Dv50 was 52.06 ± 0.24 µm. Budesonide recovered from the Easyhaler showed the 
lowest Dv50 of all products (45.09 ± 0.36 µm, p<0.05). If the % of particle with size < 
5 µm was taken in consideration, budesonide showed the greatest proportion 
compared to the other formulations (21.73 ± 0.85 %) whilst SS/Easyhaler showed 
the lowest (10.97 ± 0.42 %).  
 
 
3.5 Discussion 
 
In Chapter 2 the prototype cyclone-spacer Cheng 1 was manufactured and 
assessed with the Cyclohaler® using the SS/lactose formulation recovered from 
Ventolin/Accuhaler™. The Cheng 1 cyclone was tested between 30 and 60 L min-1 
to evaluate its capacity to retain large agglomerates and particles. The reverse 
airflow cyclone technology is not new in the inhalation field to improve fine particle 
delivery [91-93]. However, previous applications of cyclones have been integrated 
into device platform to gain advantages of size selectivity and for improved 
deagglomeration. This was mirrored for a generic spacer approach in Chapter 2 
when the Cyclohaler® delivered a constant FPD through the Cheng 1 (Chapter 2, 
Section 2.4.5.2, Table 2.9) at high flow rates. The spacer also reduced the MMAD, 
that also remained unchanged regardless of the flow rate tested. However, the 
spacer seemed to be incompatible with carrier-free formulations. When assessed 
with Turbuhaler® using LDA, the spacer did not show a similar trend to the 
SS/lactose formulation emitted from the Cyclohaler® (Section 2.4.6.3, Figure 2.12). 
The finding suggested that the spacer might only work with carrier-based 
formulations. Moreover, the prototype showed a high resistance to the air when 
tested there making difficult to reach flow rates above 60 L min-1. 
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The aims of the current study were to manufacture a second prototype spacer 
(Cheng 2) with the same reverse airflow cyclone technology, but with lower flow rate 
resistance and different orifice design to allow a higher cut off diameter (target 5 µm) 
than Cheng 1. This was done to confirm whether a new manufactured spacer could 
still mitigate the dependence of the respirable dose and of the aerodynamic diameter 
on the inhalation flow rate. The Cheng 2 was then tested with a wide range of 
commercial carrier-based DPIs with different types of formulations. The 
Cyclohaler/SS® was tested again to confirm the capability of the Cheng 2 function to 
still retain agglomerates and it was used as a control device due to its assessment 
with Cheng 1. Easyhaler/SS™ 200 µg/dose and Ventolin/Accuhaler 200 µg/dose 
were also tested. However, the latter products did not release sufficient dose when 
tested with Cheng 2 for analysis suggesting, perhaps, the Cheng 2 might be 
ineffective with these products. This might be because Cheng 2 showed lower 
impaction forces and lower integral strain rate measurements by the inlet and at the 
vortex cone base than Cheng 1 which would promote fine particle detachment from 
carrier particles under impaction and turbulent shear forces [193]. 
 
Seretide/Accuhaler™ (SX and FP) and Easyhaler/Bud™ were also tested, 
together with Cyclohaler/SS® at 2 and 4 kPa to represent low and high pressure 
drops achievable by patients and to represent different formulations. SS was 
considered as an adhesively balanced blend when added to lactose [194], Bud as a 
cohesively balanced blend [195], and SX/FP was considered as a combination of 
anti-inflammatory and bronchodilator [196]. HPLC assays were validated with 
regards to the linearity, LOD, LOQ, accuracy and precision for Bud, SX and FP. The 
three drugs are highly lipophilic, therefore a 75:25 (v/v) mixture of methanol: 0.6% 
(w/v) aqueous ammonium acetate was used. Budesonide and fluticasone propionate 
are corticosteroids and they are used in asthma to treat inflammation in the lungs. 
Salmeterol xinafoate, on the other hand, is a bronchodilator for treatment of asthma 
and COPD. The stationary phase used for the APIs was a C18 column with particle 
size of 3 μm. The calibration curves generated for quantification of the APIs showed 
a good linearity (R2 = 0.999) and high sensitivity at low concentrations with a 
coefficient of variance at 0.5 µg/ml above 5%, regarding the inter-day variability (e.g. 
SX = 9.29%, FP = 6.14%). Therefore, for SX and FP the method was not as robust 
as for BUD and SS and the reproducibility had to be tested for each run. 
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Spacers for DPIs have been suggested over the last 10 years [173, 174]. Such 
spacers showed a reduced deposition of emitted particles in the induction port stage 
when used with the Turbuhaler®. However, the authors suggested that the optimum 
length of the spacer should be used for low resistance devices [173]. Commercial 
DPIs have a small outlet that increases the turbulence upon inhalation. Therefore it 
has been suggested that spacer should have a greater outlet than the orifice of the 
DPI to decrease aerosol deposition in the mouth [188]. Moreover, the outlet of the 
spacer should have low resistance to reduce turbulence and, therefore, to reduce 
diffusion of respirable aerosol that otherwise will move toward the walls of the 
spacer. In the previous chapter, Cheng 1 showed a high resistance to the airflow due 
to the 4.1 x 4.1 mm circular shape of the orifice with cut-off diameter between 0.46 – 
0.90 µm between 30-120 L min-1 (Chapter 2, Section 2.3.2). The modified Cheng 2 
cyclone was manufactured with a 10.1 x 6 mm oval shape to decrease the 
resistance and achieve a cut-off diameter between 1.19 – 1.55 µm. In accordance 
with previous studies on the orifice of the inhalers [188], the Cheng 1 showed a 
greater tangential wall velocity than Cheng 2 at equivalent flow rates, indicating high 
impaction forces for Cheng 1 [159] and, therefore, impaction and deagglomeration 
forces would be higher for emitted masses passing through the Cheng 1. In addition, 
Cheng 1 produced higher integral strain rate measurements by the inlet and at the 
vortex cone base which would promote fine particle detachment from carrier particles 
under impaction and turbulent shear forces, which could explain the enhanced FPF 
and FPD for Cheng 1 at the highest flow rate, compared to Cheng 2 [193].  
In Chapter 2, Cheng 1 showed high resistance to airflow (0.08 kPa1/2 min L-1) 
due to the circular inlet orifice (4.1 mm diameter). Therefore, the Cheng 2 was 
manufactured and it showed a lower resistance then Cheng 1 (0.04 kPa1/2 min L-1) 
that was also within the range of DPIs (Turbuhaler®, 0.03 kPa1/2 min L-1 and 
Handihaler®, 0.05 kPa1/2 min L-1) acceptable to patients with obstructive lung 
disease [125, 168]. This was an improvement over Cheng 1 as patients with lung 
disease should be able to achieve a reasonable flow rate through the prototype. 
 
Although studies have been shown that spacers can reduce the velocity of the 
emitted aerosol and, therefore, mouth and throat deposition, electrostatic charges 
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are common problems in the aerosol delivery especially for plastic spacers. The 
interactions between particles and spacer walls lead to acquisition of charges due to 
the stress in the electrical double layer. The increment of charge would alter the 
output of the aerosol, therefore, leading to a variable lung deposition, especially in 
the alveoli [197]. Moreover, this can lead to high retention of the aerosol inside the 
spacer [198, 199].  Wildhaber el at [198] showed that the charge in the Volumatic® 
spacer plays a major role in the delivery of salbutamol from pMDI at 60 Lmin-1. They 
compared patients’ old spacers with new ones and discovered that the delivery of 
particles with size < 6.8 µm into the multistage liquid impinge (MSLI) from a new 
spacer was lower than when the spacer was previously used (30 ± 3 % of the 
delivered dose vs. 37 ± 4 %, respectively), due to high electrostatic charges in the 
inner surface. The authors tested the spacer also after treatment with detergent to 
decrease static charge in the spacer, concluding that ionic detergent coating 
significantly improved the delivery of salbutamol < 6.8 µm. Kwok et al [200] also 
showed that detergent coated spacer for MDI decreased the deposition of the 
aerosol inside the chamber. In addition, DPIs shows electrostatic charges too. The 
material used to manufacture DPIs (mainly plastic) and the type of formulation lead 
to accumulation of electrostatic charges within the device, which affect the output of 
the delivered dose [201]. Therefore, when adding a plastic spacer to a DPI, the 
electrostatic charge effect would be enhanced, although in the current study, this 
was not controlled. It is important to note that this may account for the retention of 
drug in the spacers. 
 
The previous chapter confirmed the ability of the Cheng 1 to retain the coarse 
carrier with an SS formulation; however, it was not tested with different formulations 
due to the high resistance of the spacer. Therefore, the Cheng 2 was tested with 
Seretide/Accuhaler™ that contains a combination of salmeterol xinafoate (SX) and 
fluticasone propionate (FP), Easyhaler/Budesonide™ and Cyclohaler® with 
SS/lactose blend recovered from the Ventolin/Accuhaler™ to assess the functionality 
of the prototype with a wide range of marketed inhalers. The % recovered doses for 
all the DPIs were within the pharmacopoeial limits with and without the spacer. When 
the Cheng 2 was employed the % emission into the impactor of the particles from the 
inhalers dramatically decreased as seen already for the Cheng 1. The % emission 
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calculated for the emitted dose of Bud from Easyhaler™ was 97.62 ± 0.56% at 2 kPa 
but dropped to 24.51 ± 1.68% with the cyclone in place. When the aerosolization of 
SX from Accuhaler™ was assessed, the % emission at 2 kPa was 98.65 ± 0.27% 
but 19.33 ± 0.46% with the Cheng 2. The same trend was seen for FP and SS from 
the Accuhaler™ and Cyclohaler® respectively. The reduced emission was due to the 
high retention within the spacer (almost 80% of the emitted drug was retained within 
the cyclone for all the formulations) due to the low cut off (< 2 µm) and possibly to 
the electrostatic charges of the emitted particles and the spacer walls, although a full 
study was not performed. The highest retention was seen for the Accuhaler™ 
formulation compared with Cyclohaler® and Easyhaler/Bud™. The high retention of 
the drug within the spacer was also shown for SS when using the Conix™ [91]. The 
author showed that almost 80 % of SS was recovered from the conical section. 
 
By capturing the drug particles inside the spacer, throat deposition is reduced, 
which in clinical use serves to reduce oropharyngeal deposition [174]. Because of 
the high retention in the cyclone, the IP/PS deposition was reduced four-fold when 
the spacer was employed. However, the formulations showed different behaviours 
even with the cyclone in place. Interestingly, when the formulation containing SX and 
FP was tested, the IP/PS deposition was twice that of the Bud or SS emitted from 
Easyhaler™ and Cyclohaler®, respectively (e.g. 18.44 ± 2.79 % for SS, 15.19 ± 1.74 
% for Bud, 36.01 ± 9.77 % for SX and 29.63 ± 5.85 % for FP at 4 kPa). Harrison et al 
[146] and Needham et al [91] studied an SX/FP formulation and an SS formulation 
emitted from the Conix™, respectively. The difference in the SS and SX IP/PS 
deposition that has been shown in the current project is in accordance with the 
Conix™ study. This was probably due to the combination of SX and FP. Their 
cohesive behaviour when blended with coarse carrier might lead to less efficient 
deagglomeration process than SS when emitted from a device, due to the strongly 
cohesive interaction forces  [202] that would present large sized agglomerates, when 
drug particles redistribute in the interstitial spaces of the carrier in agglomerated form 
[203]. However, we need to keep in mind that the aerosolization studies were 
performed with an ACI for Conix/SS™ [91] and NGI for Conix/SX/FP™ [146], 
therefore the particle distribution in the impactor would be different. SS deposition in 
the throat was 13% (of the delivered dose) [91], whilst SX deposition was 76 % 
[146]. Although the label claim for the Conix™ and the DPIs studied in the current 
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project were different, the same trend of higher % throat deposition for SX than SS 
could be seen. As reported in Chapter 2, Section 2.4.5.2, neither cyclone retention 
nor IP/PS deposition was affected by the flow rate for SS formulation, nor for any of 
the drug-device formulations tested in the current study. Although the extent of IP/PS 
deposition and cyclone retention did depend on the drug formulation/product type 
(Table 3.9), the potential for flow-rate independence of oropharyngeal drug 
deposition for a specific formulation was a promising finding towards overcoming 
inter-patient variability in DPI deposition profiles. 
 
The traditional view of spacer use with MDIs is that extra-thoracic deposition is 
reduced but that the fine particle deposition is unchanged when a spacer is 
employed [172]. The target with a DPI is therefore similar. While the cyclone was 
designed to emit a similar fine particle dose to the Cheng 1 for SS to improve in vitro 
drug delivery (Chapter 2) that was only accieved at 45 and 60 Lmin-1, the current 
study showed that there was enhanced deagglomeration of Bud from the 
Easyhaler™ compared to SS from Cyclohaler® and SX and FP from Accuhaler™ 
(e.g. FPR1.5 of 4.24 ± 0.29 times greater for Bud vs. 1.30 ± 0.18 for SS at 4 kPa with 
the cyclone in place than without). This means that particles underwent 
deagglomeration within the cyclone spacer, since the proportion of fines < 1.5 µm 
had increased. Nevertheless, the cyclone delivered a lower fine particle dose of the 
“inhalable” aerosol compared to when DPIs were tested alone only for SS and FP. 
This was attributed to the high fraction of the dose (>80 %) depositing in the cyclone. 
However, the cyclone managed to remove the non-sizeable fraction; i.e. dae > 10 μm 
[43] which has potential for high oropharyngeal deposition (e.g. IP/PS deposition 
>40%  without cyclone in place). When the fine particle fraction was calculated as 
the % spacer-emitted dose, higher FPF (%sED) were seen for the formualtions 
compared to when the cyclone was not used. The results were in accordance with 
the Conix™ DPI [91], where almost 85 % FPF was detected for SS, whilst only 35 % 
was shown for the Accuhaler™. Although the FPF (%ED) of SS was approximately 
halved by the use of the cyclone (p <0.05), with the exception of SX and FP at the 
highest flow rate (4 kPa, slightly lower, p <0.05), there were no significant differences 
in the FPF (%ED) for Bud, SX or FP when the cyclone was added to the DPI product 
(Table 3.10). The latter findings were also reflected in the fine particle dose (FPD) 
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values (Table 3.10). As well as the comparability (excluding SS) to the DPI results, it 
was important to note that using the cyclone minimized (or removed) the magnitude 
of change in FPD and FPF (%ED), caused by increasing the flow rates. Differences 
in the FPF (% ED) when the cyclone was used indicate pharmaceutical non-
equivalence.  
 
It is also appropriate to compare the FPF as a %sED  (i.e. the dose exiting the 
spacer) and examine its similarity when the cyclone is used (%sED) because this 
indicates the fraction which would be inhaled by the patient. The cyclone was 
designed to emit a similar FPF5μm (%sED) from all products. There were clear 
differences in the FPF (% sED) values observed in this study. The highest FPF was 
seen for SS and Bud (almost 80 % of the dose exiting from the spacer). A decrease 
in the FPF (%sED) was observed for the Accuhaler™ emission. The lower FPF was 
attributed to the higher IP/PS deposition of SX and FP even with the spacer in place 
(FPF was ~60 % of the emitted dose). Moreover, a much lower FPF (%sED) for SX 
was seen compared to SS emitted from the Conix™ (13 % vs. 85%, respectively). 
This was a consequence of the different % IP/PS deposition previously described for 
the two drugs. It was notable that the FPF (%sED) for SS from Cheng 2 was 
markedly lower than from Cheng 1, attributable to the higher retention of SS in 
Cheng 2 compared to Cheng 1 (Chapter 2, Section 2.4.5.2). The lower FPFs for 
Cheng 2 than Cheng 1 may be attributed to the different orifice geometry due to the 
narrower cyclone inlet of the latter [193]. 
 
It must be borne in mind that the factors governing deposition within induction 
ports appear to be drug specific [204]. However, it appeared from the current study 
that the functioning of the reverse-flow cyclone as a spacer may depend on the 
deagglomeration state of the drug particles entering the cyclone. For example, laser 
diffraction studies (Figure 3.8) of the Seretide/Accuhaler™ formulation revealed the 
emission of some agglomerates that escaped the cyclone similar to the 
Ventolin/Accuhaler. CFD studies highlighted the potential for vortex instability within 
the conical region of the spacer which would enable the escape of agglomerates 
[158, 159]. 
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The design of the DPI helps the deagglomeration of the formulation, but the 
characterization of aerosol and plume geometry is also an important tool to study 
aerosol dispersion and it has been used widely to evaluate the performances of the 
valve and the actuator for MDIs [205]. Although FDA (Food and Drug Administration) 
introduced a CMC (Chemistry, Manufacturing and Controls) Guidance in 1998 for 
MDIs and DPIs, the study of spray pattern and plume geometry was only applied for 
MDI aerosols [150]. The guidance did not specify the need of this particular study for 
DPIs and there is also poor research on this particular field. However, Oxford Lasers 
[206] presented a study on the plume geometry and pattern of SV003 Lactose 
emitted from the Easyhaler, using FDA guidance. They showed that the plume 
degree was 15.89 ± 1.42 degrees with a mean plume length of 16.11 ± 0.92 cm. The 
plume width at 6 cm from the inhaler was 2.15 ± 0.28 cm. They also compared the 
spray pattern at 3 and 6 cm from the Easyhaler, showing that the pattern is more 
consistent at 6 cm [206]. Therefore, the plume geometry is important to consider 
when the aerosol enters the spacer as wide plume geometry would impact on the 
spacer walls, potentially leading to an enhanced deagglomeration. 
 
The Easyhaler™ is designed to maximize the particle separation by changing 
the dimensions of the airflow path [207] with a cylindrical outlet with length of 3.28 
cm. The mouthpiece of the Easyhaler is designed to re-disperse the micronized 
particles from the carrier. The dosing of the Easyhaler is based on the gravitational 
flowability of the powder which is dosed accordingly to the volume of the metering 
cavity. Easyhaler contained fine particles of lactose as an additive to improve 
flowability of the powder. The lactose used is large enough to avoid deposition in the 
lower part of the lungs to reduce irritation of the airways [208]. The Cyclohaler® 
shows a cylindrical outlet length of 4.80 cm, whilst the Accuhaler™ has a mouth 
shape outlet only approximately 0.80 cm. The entire design of the DPIs is very 
different between each other. The Cyclohaler® is a single dose inhaler consisting of 
a capsule that spins and the formulation is deagglomerated with the help of a grid 
[209]. The Accuhaler™ is a multi-unit dose inhaler contains a blister with multiple 
doses and due to the short outlet the formulation might not have sufficient 
opportunity to deagglomerate before reaching the patient’s lung. Moreover, the 
mouth shape orifice with a cross shape grid might increase the dispersion of the 
particles in the air instead of leading the emitted dose through a cylindrical pathway 
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like in the Cyclohaler® and Easyhaler™, increasing therefore the impaction in the 
mouth and throat. More than 10 % difference was seen in the throat deposition 
between SS or Bud and SX or FP when emitted from Cyclohaler®, Easyhaler™ and 
Accuhaler™, respectively at 2 and 4 kPa. The literature [89] highlights that dose 
emission from an Easyhaler™ is constant regardless the flow. This is in agreement 
with the data showed in this study where the FPF of Bud from the Easyhaler™ alone 
was 20.41 ± 2.56 at 2 kPa and 23.47 ± 2.65 at 4 kPa. Therefore, spacers for DPIs 
might only be suitable for certain inhalers, such as the ones that do not show 
consistency of the emitted dose when changing the flow rates. For example, 
differences between the SS fine particle emission of Cheng 1 and Cheng 2 spacers 
was seen as well as the reduction of FPD for FP but not SX when the flow rate 
through the Seretide/Accuhaler™ was increased. There is potential that the cyclone 
does not solely behave as a classifier, but that deagglomeration also takes place 
within the cyclone vortices. Drug which adheres strongly to the carrier is more 
difficult to aerosolize than drug which forms agglomerates on the carrier surface 
[109]. Bud, which typically forms agglomerates with lactose, would be more easily 
removed at equivalent flow rates from the carrier surface than SS (which typically 
adheres to the surface), thereby leading to higher Bud FPF values. Collisions 
between particles and the cyclone wall or other particles in the cyclonic flow aids 
powder dispersal [146], particularly collisions with particles of large mass such as 
carrier lactose. Upon increasing the flow rate, sufficient force is provided to break up 
drug agglomerates further, but also aid removal of surface-adhered drug from the 
carrier. 
 
The lower FPF when Accuhaler™ was tested was in accordance with Taki et al 
[170] who tested the aerosolization of SX and FP through the Accuhaler™ and 
through the Aerolizer® at 60 L min-1 with the NGI. The Accuhaler™ showed a much 
reduced FPF, higher MMAD values and higher IP/PS deposition compared to the 
Aerolizer®. In the current study, the FPF of SX and FP emitted from the Accuhaler™ 
were lower than the FPF of SS emitted from the Cyclohaler® (Table 3.10). In the 
current project, the decreased FPF from the Accuhaler™ could be explained by the 
higher IP/PS deposition compared to SS from Cyclohaler®. However, when the 
Ventolin/Accuhaler was tested to assess the SS distribution with Cheng 2, the 
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spacer did not perform as expected compared when it was used with the Cyclohaler 
to emit SS formulation recovered from the Ventolin/Accuhaler. Although the dose of 
the formulation was the same for both inhalers (label claim: 200 µg/dose of SS), the 
design of the DPI used (Accuhaler vs. Cyclohaler) played a major role on the 
emission of the dose into the spacer (Figure 3.8).  
 
When FPD (fine particle dose) was assessed, Bud had an equivalent FPD with 
and without Cheng 2, unlike for the SS formulations (Table 3.10). The lower FPD for 
Bud when the cyclone was compared with Cyclohaler®/SS could be due to the 
higher affinity of SS to the lactose than Bud which would decrease the release of 
adhered SS particles from the carrier during passage through the spacer. Bud shows 
a cohesive behaviour with lactose compared to the more adhesive interaction of SS 
with the carrier [109, 194]. Begat et al [109], using SEM (scanning electron 
microscopy), showed that SS was equally distributed over the lactose surface, 
whereas, Bud was unevenly spread creating agglomerates on the carrier surface. 
However, the authors showed that for the same DPI the Bud delivery released a 
greater quantity of fine respirable particles than SS. This is probably due to the 
adhesive balance of SS with lactose, which decreases the degree of respirable 
particle dispersion leading to high emission yet poor fine particle fraction. On the 
other hand, Bud creates large agglomerates with greater aerodynamic drag forces 
than smaller agglomerates (e.g. SS). When the dose is emitted from the device into 
the spacer, the large agglomerates of Bud would collide better with the spacer’s 
walls or outlet, enhancing the dispersion efficiency and creating greater percentage 
of fine respirable particles. The SX and FP showed a similar behaviour to the Bud. 
However, the extent of deagglomeration appeared lower. 
 
The mass median aerodynamic diameter (MMAD) is one determinant 
(alongside inhalation parameters) of the potential deposition site of an inhaled 
aerosol. It would be expected that the MMADs for the aerosols emitted from the 
spacers would be limited by the effective cut-off diameters of the cyclone itself[158, 
159] because the cyclone should act as a classifier, releasing only particles smaller 
than the cut-off size. Although different values were seen when DPIs were tested 
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alone (Table 3.10) as expected [170], when Cheng 2 was employed similar values of 
MMADs were seen for the formulations (Table 3.10), in keeping with other studies 
with reverse flow cyclone [91, 146]. Similar observations of reduction in the MMAD 
when Cheng 1 was used (Chapter 2, Section 2.4.5.2), were seen with Cheng 2 for all 
drugs studied. Indeed the MMADs were roughly equivalent to the calculated cut-off 
diameters of the cyclones (Cheng 1 ~0.9 μm, Cheng 2 ~2 μm). It appeared that both 
Cheng 1 and 2 functioned effectively as classifiers, a finding confirmed by laser 
diffraction analysis (Chapter 2), albeit with an indication of intra-cyclone 
deagglomeration occurring. 
 
The MMAD was low because off the cut off size of Cheng 2. The FPR1.5 
calculates the extent of classification of particles below the cut-off diameter of the 
spacer and quantifies their deagglomeration. Bud showed the greatest 
deagglomeration as its FPR1.5 with the Cheng 2 in place was 6.70 ± 0.25 and 4.24 ± 
0.29 times greater than Bud/Easyhaler alone at 2 and 4 kPa, respectively. The same 
trend was seen for FP (4.65 ± 0.12 and 2.63 ± 0.21 times at 2 and 4 kPa, 
respectively). On the other hand, SS and SX showed the lowest FPR1.5 at both 
pressure drops (e.g. 1.73 ± 0.38 times higher at 2 kPa for SS). An FPR1.5 > 1.0 
indicates not solely classification but also deagglomeration occurring. The 
deagglomeration depended on the physico-chemistry of the particles, and the 
geometry of the conical section of the cyclone. This was confirmed by the variable 
IP/PS deposition seen from the NGI studies for SX/FP emitted from the Accuhaler™ 
with Cheng 2 in place (twice that of SS and Bud) and by the particle size distribution 
from the LDA. The variable deposition in the throat was confirmed by the laser 
diffraction studies, where some agglomerates escaped the cyclone, probably due to 
vortex instability within the spacer [210]. When aerosolized with the Cheng 2, 
agglomerates of FP and SX shifted the Dv50 to greater values (Figure 3.8). 
However, Cheng 2 exhibited lower impaction forces than Cheng 1, with decreased 
ability to improve the deagglomeration of low quantities of micronized material that 
are less likely to be detached from the coarse carrier. Therefore, the low % of 
micronized material recovered from the formulation of the Easyhaler/SS may have 
arisen due to difficulties in escaping the Cheng 2, revealing undetectable recovered 
dose in the cascade impactor. Moreover, the highest % of fine material from the 
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budesonide formulation might explain the highest FPF seen in the aerosolization 
study (Table 3.10) when using the spacer. 
 
3.6 Conclusion 
This chapter has explored the potential of the Cheng 2 spacer to be used with a 
wide range of DPIs to both decrease throat deposition and MMAD. Despite the high 
retention of the carrier within the spacer, attributed to the low cut-off diameter of the 
cyclone (< 2 μm), high FPF were seen for SS and budesonide emitted from 
Cyclohaler® and Easyhaler™, respectively. However, unchanged FPDs were only 
detected for Bud and SX when the cyclone was used. The IP/PS deposition was 
dramatically decreased with the cyclone in place. However, the formulation and the 
physico-chemistry of the APIs need to be considered for further studies, as they 
affected the deagglomeration within the spacer. When the Accuhaler™ was 
assessed, SX and FP showed a higher deposition in the throat and pre-separator 
stages than SS and Bud. This led to a much reduced FPF for SX and FP compared 
to SS and Bud. In the next Chapter, the Cheng 2 will be assessed with in-house 
manufactured “control” blends with different formulation behaviour (cohesive and 
adhesive) and with different grades of lactose to explore the physicochemical 
relationship further. 
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4 Chapter 4: Investigating deagglomeration mechanisms 
of inhaled formulations within a reverse airflow cyclone-
spacer 
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4.1. Investigating deagglomeration mechanisms of inhaled formulations within a 
reverse airflow cyclone-spacer 
 
4.1.1. Morphology of cohesive micronized particles 
In the market, carrier free DPIs are available along with formulations containing 
different types of sugars such as mannitol, coarse lactose monohydrate, fine 
particles of lactose monohydrate, and combinations of coarse and fine lactose 
monohydrate. The absence of the coarse particle affects the formulations that 
contain only agglomerates [106, 211]. Budesonide (Bud), for example, is more 
cohesive the salbutamol sulphate (SS), showing bigger agglomerates under the 
SEM (scanning electron microscope) [212]. It has been suggested [212-214] that FP, 
like SX (salmeterol xinafoate) and Bud shows greater agglomeration forces then SS. 
However, the formation of agglomerates of micronized APIs leads to an increased 
entrainment of the drug particles, but poor blend flowability. Therefore, lactose or 
other sugars are usually present in the formulation acting as carrier particles to 
enhance flowability upon aerosoliation [103, 215]. 
 
4.1.2. Distribution of cohesive micronized particles on the carrier surface 
Micronized material (e.g. FP (fluticasone propionate)) shows high cohesive 
behaviour forming big agglomerates, especially when carrier is added (DV50 40.15 ± 
6.02 at 90 Lmin-1) [202]. The authors [202] mixed coarse and fine lactose with the 
most cohesive batch of FP and the formulation generated a lower fine particle 
fraction then when the coarse carrier was not used. The authors [202] suggested 
that it was due to the presence of very large agglomerates of FP in the mixtures. In 
Chapter 3, the Cheng 2 spacer was tested with commercial carrier based 
formulations, showing that the deagglomeration behaviour of the particles within the 
spacer was affected by the type of formulation. It was suggested that this arose due 
to physico-chemical properties of micronized material when blended with coarse 
carrier. This would overcome the high energy between agglomerates, leading to the 
re-arrangement of the API on the surface of the carrier. The way of re-distribution of 
the API on the carrier particles differs from drug to drug (e.g. batch to batch 
variability of the same drug), and depends on how great is the cohesive force 
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between agglomerates [216]. Although all micronized particles are cohesive, when 
coarse carrier such as lactose is added to the formulation, the micronized material 
starts to redistribute on the lactose surface exhibiting very different behaviour [99, 
109, 202]. For example, SS, which has been widely investigated [108, 109, 217], 
presents a rectangular or a plate-like shape when analysed under the SEM [217]. 
Other studies [108, 109] suggested that SS exhibits an adhesively balanced 
behaviour when added to coarse lactose and redistributes evenly on the lactose 
surface, with lower adhesive energy to the carrier with respect to other particles 
[109]. This is probably due to the relative balance of cohesive and adhesive 
interparticulate forces in binary (and ternary) formulations with carriers. SS showed 
also a lower cohesive energy compared to Bud, with SX also reported to exhibit a 
balance in favour of cohesion when added to lactose [104, 109, 194]. The interaction 
between lactose and drug molecules has to be strong enough to prevent 
segregation. However, upon aerosolization, the drug must be easily detached to 
allow lung deposition. 
 
4.1.3. Effect of carrier and fine particles on aerosolization of the inhaled formulation 
The design of the inhaler and the inhalation strength of the patients affect drug 
dispersion. In addition the forces of interaction within the powder formulation play a 
role in the aerosolization. Studies have demonstrated that the strong adhesion 
between API and coarse carrier, decreased the drug dispersion [99, 110]. 
Enhancement of the dispersion process (e.g. aerosol fraction of fine particles) and 
modification of inter-particulate forces within the powder formulation by the presence 
of ternary agent has been suggested [111, 112].  Adi et al. [99] showed that adding 
fine lactose improved the dispersion process of SX from the coarse carrier, because 
the interaction between the fine lactose and the SX produced mixed agglomerates. It 
may be the decreased drug/carrier adhesion energy or the easier break up of mixed 
agglomerates with low carrier adhesion that enhances dispersion efficiency. 
 
It has been suggested that the addition of fine lactose would increase the 
respirable fraction [101], whilst the presence of coarse lactose improves the 
flowability of the formulation. However, Behara et al [113] showed that the presence 
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of coarse carrier is not necessary. The aerosolization was improved by increasing 
two-fold the concentration of fine lactose to SS (from 1:4 to 1:8). They suggested 
that increasing the concentration of fine lactose reduced the agglomerate strength 
between SS and fine lactose. SEM images indicate more diffuse agglomerates when 
SS-fine lactose (1:8) were analysed compared to SS-fine lactose (1:1) that showed a 
more agglomerated structural characteristics [113]. A comparison between SS and 
budesonide (adhesively and cohesively balanced particles, respectively), showed 
that FPF was greater when a cohesively balanced blend (Bud) was emitted from the 
Rotahaler (26.3 ± 6.2 %) than when SS was used (12.6 ± 1.2 %) [109]. However, the 
addition of fine particles does not always enhance the FPD (fine particle dose) as 
shown by Jones et al [203]. 
 
4.1.4. Empirical model for the study of deagglomeration mechanisms 
The adhesion forces between drug and carrier consist mainly of inter-
particulate forces such as van der Waals forces, electrostatic charges, and capillary 
interactions and influence aerosol dispersion from dry powder inhalers (DPIs) [40]. 
Studies have investigated the interaction between individual particles using atomic 
force microscopy (AFM) [218, 219]. However, the technique does not quantify the 
cohesion force of a powder bed as it only measures the interaction between one 
drug or excipient particle and the probe of the AFM. Laser diffraction techniques 
have been used for dry and liquid dispersion systems to study powder 
deagglomeration [220]. Airflow and pressure drop titration experiments have been 
performed [213, 220] to assess the change in particle size when a fine powder bed is 
subjected to an increasing pressure drop and empirical models have been proposed 
for micronized particles with or without the common carrier coarse lactose [213, 220, 
221].  
When only micronized APIs are present in the formulation alone or in presence 
of fine lactose, studies have suggested that the liberation of fine particles < 6 µm 
shows a sigmoidal trend with increasing airflow rate and a three-parameter sigmoidal 
equation has been used [220] as shown in equation (4.1): 
𝑦 =
𝑎
1+𝑒−(𝑥−𝑥0)/𝑏
     (4.1) 
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With ‘a’ = maximum extent of deagglomeration, ‘x0’ = flow rate required to achieve 
50% deagglomeration and ‘b’ = change in the deagglomeration with the flow rate. 
However, the problem occurs when the coarse lactose is added to the formulation. 
Higher flow rates are required to deaggregate the mixture fully than if the lactose 
carrier was not present. Therefore, more energy is required to fully aerosolize 
micronized APIs away from the surface of the carrier. An equation similar to the 
Langmuir adsorption isotherm was proposed with the name of Powder Aerosol 
Deaggregation Equation (PADE, equation 4.2) [221]: 
𝐹𝑃𝐹
𝐹𝑃𝐹𝑚𝑎𝑥
=
𝑘𝑑𝜏𝑠
1+𝑘𝑑𝜏𝑠
     (4.2) 
With FPFmax= FPF at maximum shear stress, 𝜏𝑠=shear stress, kd = deagglomeration 
constant. However, the latter equation implies that a cascade impactor should be 
used for the experiments affecting the deagglomeration of the particles. Moreover, 
Behara et al. [220] used the Rotohaler for the experiments, allowing the design of the 
DPI to affect the deagglomeration. 
 
Adding a fine ternary agent to the formulation could be an important 
consideration for guiding formulation design, and may affect formulation suitability for 
the cyclone spacer. The spacer showed variable behaviour with different design of 
the DPIs and different formulations as shown by the PSD (particle size distribution) 
of SS and SX emitted from the Cyclohaler® and Seretide/Accuhaler® in Chapter 3. 
Perhaps, Cheng 2 only works with a particular device such as the Cyclohaler and the 
difference in the deagglomeration mechanism seen in Chapter 3 would not be 
present if the formulation was emitted from the same inhaler into the spacer, despite 
testing different APIs (active pharmaceutical ingredients). Studies [213, 220, 222]  
have been performed on the deagglomeration mechanism of micronized particles. 
Although these studies suggested a rapid methodology using laser diffraction, the 
models proposed to explain the deagglomeration process did not show any 
parameter with a physical meaning. This would be helpful to predict deagglomeration 
mechanisms of novel formulation and, particularly for the current study, to 
understand the impact of formulation design prior entering the cyclone-spacer. 
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4.2. Aims  
Chapter 3 showed different behaviour for SS and SX formulations when emitted from 
the spacer. The Cheng 2 was still able to retain large agglomerates for carrier based 
commercial DPIs, however, the SS formulation showed a much reduced IP/PS 
deposition than the SX formulation when the spacer was used. The aim of the 
current chapter was to characterise and assess SS and SX in formulation with 
different grades of lactose in order to understand the deagglomeration behaviour of 
the API when emitted from the Cyclohaler® and its importance on performance of 
the spacer. This was done to assess whether the deagglomeration within the spacer 
was affected by the design of the device only or by the physico-chemical and blend 
properties of the formulation.  
 
The objectives of the current work were: 
- To prepare in-house manufactured blends of particles reported in the 
literature to be cohesively or adhesively balanced particles (SX and SS, 
respectively) with different grades of lactose carrier (fine lactose, coarse 
lactose and combination of both). 
- To assess blend aerosolization with  and without Cheng 2 using only the 
Cyclohaler®  
- To characterize the blend morphology and particle distribution after 
aerosolization with scanning electron microscopy (SEM) 
- To study the deagglomeration process of cohesively and adhesively balanced 
blends using an iterative empirical model 
 
 
4.3. Materials and methods 
 
4.3.1. Materials 
Micronized salbutamol sulphate (SS, batch number B027798) was obtained from 
GlaxoSmithKline Research and Development (Ware, UK). Salmeterol xinafoate (SX) 
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was purchased from Vamsi Labs Ltd (Solapur, India).  Lactose monohydrate, 
chromatography grade methanol, hydrochloric acid solution (HCl) 5M, sodium 
hydroxide and n-Hexane were purchased from FisherScientific (Loughborough, UK). 
Fine lactose (LH300) was a gift from Friesland Foods (The Netherlands). Hipersolv® 
grade ammonium acetate was purchased from Lab3 Ltd (Northampton, UK). A Luna 
3 μm C18 column (150 mm x 4.6 mm x 3 μm) was obtained from Phenomenex 
(Macclesfield, UK). Silicone oil - Dow Corning Corporation 200® fluid was obtained 
from Sigma-Aldrich (Gillingham, UK). A Cyclohaler® device was obtained from AAH 
Hospital Supplies (Coventry, UK). Size 4 hard gelatine capsules were obtained from 
Meadow Laboratories Ltd. (Romford, UK). Cyclone spacer (Cheng 2) was 
manufactured in-house (University of Cambridge, UK) from a Perspex block 
(Engineering & Design Plastics Ltd, Cambridge, UK. The flow meter (model number 
DMF2), next generation impactor (NGI) and a model HCP5 vacuum pump were all 
purchased from Copley Scientific Ltd (Nottingham, UK). Adhesive carbon tabs and 
aluminium pin stubs were purchased from Agar Scientific Ltd (UK). 
 
4.3.2. Preparation of API-blends 
 
4.3.2.1. Lactose monohydrate sieving 
Lactose monohydrate (Fisher Scientific, UK) was sieved to separate the 63-90 
µm particle fractions. The lactose powder was placed on the 90 µm sieve which was 
above the 63 µm sieve and the mechanical sieve shaker (model - AS 200 digit, 
Retsch, Germany) was operated for 5 min at 100 amplitudes. The fraction of lactose 
between the sieves was collected to prepare the blends. 
 
4.3.2.2. Particle size analysis 
Salbutamol sulphate (SS), fine lactose (FL) salmeterol xinafoate (SX) and 
coarse lactose (CL) were tested for the homogeneity of the particle size using the 
laser diffraction technique. The Sympatec Rodos module (Inhaler Helos/KF, 
Sympatec Limited, Bury, UK) with Aspiros feeder was used. The speed of the feeder 
was set at 25 mm/sec. The pressure drops used were 2 and 4 bar in order to have a 
titration of the size and the duration of the measurements was 5 sec. The optimum 
concentration of the powder to be detected was in the range of 1.0 and 1.1 %. 
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4.3.2.3. Blend preparation 
A total of 3 g of blends were prepared. The drug was sandwiched with coarse 
lactose (CL) in equal volumes. When the FL was used, it was first blended with the 
drug and the pre-mixture sandwiched with coarse lactose. Glass vials were used for 
the blending and vortexed (Vortex Genie 2, model G – 560E, Scientific Industries 
LTD, New York) for 2 min. The blending was carried out in a Turbula mixer (Turbula 
2583, type +2C, Glen Mills, Clifton) for 40 min. In Error! Reference source not found. 
eights of the components and ratios are reported for all the blends. 
 
Table 4.1. Blend preparation with ratios (API= active pharmaceutical ingredient, CL=coarse lactose, 
FL=fine lactose, SX=salmeterol xinafoate, SS= salbutamol sulphate) 
Blend 
Ratio 
(w/w) 
Drug 
Mass 
(g) 
API:CL 1:67.5 
SS or SX 0.044 
CL 2.970 
API:FL:CL 1:4:63.5 
SS or SX 0.044 
FL 0.176 
CL 2.794 
API:FL 1:4 
SS or SX 0.600 
FL 2.400 
 
 
4.3.2.4. Dose content of the blends 
Five samples of each blend were prepared by accurately weighing ~0.0125 g of 
each blend with dissolution into 20 ml of the respective mobile phase (Chapter 2, 
Section 2.3.3 and Chapter 3, Section 3.3.3). The concentration of the drugs was 
detected by HPLC assay (Chapter 2, Section 2.3.3 and Chapter 3, Section 3.3.3) and 
the dose content calculated using Equation (4.3) in order to identify the amount of 
drug per dose (µg/dose, where the capsule fill weight was ~0.0125 g): 
 
Dose content =  
mass of drug (µg)
mass of blend (mg)
    (4.3) 
 
4.3.3. Impaction studies using Next Generation Impactor 
Each blend was tested using the Cyclohaler® at 2 and 4 kPa with and without 
Cheng 2 according to Section 3.3.5. Prior to performing the measurements with the 
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NGI, the desired flow rate was adjusted with a flow meter. Prior the measurement, 
15 ml of mobile phase was added in the central cup of the pre-separator. When the 
Cyclohaler® was assessed alone with blends with either CL or FL:CL, six Size 4 
hard gelatin capsules were used.  When the Cheng 2 was employed as spacer 
device, 12 capsules were actuated at 2 kPa and eight capsules at 4 kPa. When the 
drug:FL ratio was assessed with the Cyclohaler®, two capsules were actuated at 
both pressure drops and four when the Cheng 2 was employed. In order to collect 
the drugs, the DPIs were washed with 20 ml of mobile phase. The bottom of the 
cyclone was washed with 100 ml of mobile phase and the mouthpiece and the USP 
throat with 25 ml each; whilst the upper section of the cyclone was washed with 10 
ml. For collecting the drugs from the pre-separator 100 ml of mobile phase was 
used. The volumetric flasks were sonicated (Kerry, Germany) for 2 min. When only 
the Cyclohaler® was employed, 10 ml of mobile phase were added at the first 5 
stages, whilst 5 ml of solvent was used for the last 3 stages. All the stages were set 
on a laboratory rocker (Stirling Mixer, Sandrest Ltd, UK) and rocked for 2 min in 
order for the solvent to clean the entire surface. When the cyclone was used, 5 ml of 
mobile phase was added to all the stages. The concentrations of the drugs from 
each stage were determined by HPLC assay as described in Chapter 2, Section 
2.3.3 and Chapter 3, Section 3.3.3. After performing the experiments, each stage 
and the NGI were thoroughly cleaned with Millipore water and the coating was 
removed with acetone before rinsing with methanol. 
 
4.3.4. Particle size analysis 
4.3.4.1. Laser diffraction analysis with Inhaler Module 
Aerosolization was also assessed by laser diffraction particle size analysis 
using the Sympatec Inhaler module as described in Chapter 3 Section, 3.3.8. 
 
4.3.4.2. Dry dispersion laser diffraction analysis with Rodos 
The particle size distribution (PSD) of the blends was tested by laser diffraction 
using the Sympatec Rodos module (Sympatec Limited, UK) with Aspiros feeder. The 
lens used to detect the aerosol cloud was a R3 lens (0.5-175 µm). The speed of the 
feeder was set at 25 mm/sec and the duration of the measurement was 5 sec with 
optical concentration between 0.1-1.1 %. The pressure drop was set between 0.1 to 
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5 Bar in order to titrate the dispersion pressure. The PSD vas collected every 0.1 Bar 
when tested from 0.1-1 Bar and every 1 Bar when tested from 1-5 Bar. 
 
4.3.4.3. Liquid dispersion laser diffraction analysis with Malvern Mastersizer 
To measure the ‘true’ fully dispersed particle size, the blends were suspended 
in 0.5% Span 80 in cyclohexane (for SX blends, SX, FL, CL) and 1% Span 80 (for 
SS blends and SS). Malvern Mastersizer X (Malvern Instruments Ltd, UK) was used 
[213] with 100 mm focal length lenses (0.5-180 µm) and MS7 magnetically stirred 
cell. Prior to measurement, the solvents were saturated with the appropriate particles 
and sonicated for 30 min followed by overnight stirring. For the measurements, 
approximately 1 mg of powder was added to 2 ml filtered dispersant (0.2 µm 
cellulose acetate syringe filter, Sartorius Stedim Biotech., UK) and sonicated 
(Sonicleaner, DAWE, Ultrasonics Ltd, USA) for 1 min for SS, FL and CL and 5 min 
for SX. The stirring was set at 3 for all the powders with sweeps of 2500 for SX and 
3500 for the other powders. A background reading was taken and the suspension 
was added to the sample cell until the obscuration was 10–30%. Following 
equilibration (60 s for SX and 30 s for the others), ten individual measurements were 
taken for n = 3 samples. From the instruments, Dv10, Dv50, and Dv90 (corresponding 
to the cumulative percentage particle undersize values for 10%, 50% and 90% of the 
particles by volume), and the % volume < 5 µm were used for analysis. 
 
4.3.5. Particle morphology 
 
4.3.5.1. Preparation of the powder 
Powder samples were transferred to adhesive carbon tabs, mounted onto 
aluminium pin stubs (Agar Scientific Ltd, England). 
 
4.3.5.2. Collection of the powder from the impactor 
Each blend was tested using the Cyclohaler® at 4 kPa with and without Cheng 
2. Prior to performing the measurements with the NGI, the desired flow rate was 
adjusted with a flow meter. To collect the drug from the USP throat, a glass coverslip 
(diameter 12 mm, Scientific Laboratory Supplies, Nottingham, UK) was attached with 
a double side adhesive tape in the 90° angle. Glass coverslips of 22 mm diameter 
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were used for the pre-separator (placed in the middle of the collection cup), and 
stage 3 and 5 of the NGI (to represent the respirable fraction size range). The 
powder was then transferred to an adhesive carbon tab. When the Cyclohaler® was 
assessed alone with blends with either CL or FL:CL, six Size 4 hard gelatine 
capsules were used.  The powder was collected from the capsules and transferred to 
an adhesive carbon tab. When the Cheng 2 was employed as spacer device, eight 
capsules were actuated. When the drug:FL ratio was assessed with the Cyclohaler®, 
two capsules were counted and 4 when the Cheng 2 was employed. The powder 
was collected from the bottom of the cyclone and transferred to an adhesive carbon 
tab. 
 
4.3.5.3. Particle morphology using the scanning electron microscopy 
To assess blend interactions, scanning electron microscopy (SEM, Jeol Carry 
Scope JCM 5700, Welwyn Garden City, UK) was performed. Samples were sputter 
coated with gold under argon for 4 min to achieve a thickness of approx. 30 mm 
using an Emitec SC 7620 coater (Quorum Technologies Limited, West Sussex, 
England). To view the particle morphology, the SEM operated at 15 kV in low 
vacuum mode and a working distance of 13 mm. 
 
4.3.6. Statistical analysis 
Statistical analysis was performed in Minitab (version 15) using one-way 
ANOVA and post-hoc Tukey’s test (multiple comparisons) or Student’s two-tailed t-
test for pair-wise comparisons, both at 95 % confidence intervals. Non-linear 
regression analysis of the powder dispersion data was performed using OriginPro 
(ver. 8) and MatLab software (ver. R2013a). Data analysis from aerosolization 
studies has been done according to Chapter 2, Section 2.3.11. 
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4.4. Results 
 
4.4.1. Preparation of API-blends 
 
4.4.1.1. Particle size analysis 
Due to the high variability of IP/PS deposition with the Seretide/Accuhaler™ 
formulation and the different deagglomeration behaviour compared to 
Cyclohaler/SS® when the Cheng 2 (Chapter 3) was employed, a deeper 
investigation was carried out. Two different APIs were taken into consideration: 
adhesively- and cohesively-balanced blend (SS and SX, respectively according to 
literature search) with lactose. The two drug were blended with different grades of 
lactose (FL, CL or combination of both) in order to understand the deagglomeration 
process that might occur within the cyclone. Both the APIs and the FL were 
micronized as detected by the laser diffraction Figure 4.1). However, the coarse 
lactose showed a small shoulder in the fine particle size range due to the presence 
of fine lactose already present in the coarse carrier formulation (Figure 4.2). 
 
Figure 4.1. Representative particle size distributions for salbutamol sulphate (●), salmeterol xinafoate 
(●) and micronized lactose (●). 
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Figure 4.2. Representative particle size distribution for coarse lactose (●). 
 
The DV50 at 4 kPa were: 1.65 ± 0.01 µm for SS, 2.14 ± 0.01 µm for SX, 2.72 ± 0.04 
µm for LH300, 65.78 ± 0.44 µm for coarse lactose. 
 
4.4.1.2. Dose content of the blends 
In Table 4.2 the dose content for each blend is shown with the coefficient of 
variance expressed as percentage (%CV). The %CV for all particles, with the 
exception of SS:FL and SX:FL:CL was acceptable. For the latter blends, replicates 
were made (n≥5) in order to understand the variance.  
 
Table 4.2. Dose content for all blends with coefficient of variance (CV) (mean ± SD, n ≥ 5). (SS= 
salbutamol sulphate, CL=coarse lactose, FL= fine lactose, SX=salmeterol xinafoate). 
Blends Ratio 
Dose content 
(µg/mg) 
% CV (n>5) 
SS:CL 1:67.5 14.41 ± 0.16 1.31 
SS:FL:CL 1:4:63.5 15.41 ± 0.28 1.35 
SS:FL 1:4 212.32 ± 12.60 5.94 
SX:CL 1:67.5 14.42 ± 0.05 0.32 
SX:FL:CL 1:4:63.5 14.93 ± 0.79 5.32 
SX:FL 1:4 197.43 ± 6.25 3.17 
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4.4.2. Impaction studies using next generation impactor 
Aerosolization studies were performed on the blends with and without Cheng 2 
and emitted from the Cyclohaler®. The pressure drops used were 2 and 4 kPa as 
per Chapter 3. The % recovery of all the blends was adequate and within the limits of 
75 and 125 % as recommended by the British Pharmacopoeia (e.g. 91.52 ± 2.20% 
for SS:FL:CL at 2kPa using the Cyclohaler® and 78.92 ± 4.63% for SX:CL at 4 kPa 
with the cyclone added at the Cyclohaler®). As seen already in Chapter 3, the 
retention of the drug within the cyclone was high especially for the blend with fine 
lactose only (e.g. 95.76 ± 0.67 % and 96.83 ± 0.34 % for SS and SX). Cohesively-
balanced formulations (SX) demonstrated higher emission from the Cheng 2 than 
adhesively-balanced blends (SS) especially for drug:FL:CL blends at 4 kPa: 2.54 ± 
0.47% for SS:FL, 10.25 ± 3.85% for SS:CL and 22.86 ± 4.30 % for SS:FL:CL vs. 
1.71 ± 0.36 % for SX:FL, 16.30 ± 3.25 % for SX:CL and 30.64 ± 10.44 for SX:FL:CL 
(p<0.05).  
 
When the Accuhaler™ was previously assessed a high IP/PS deposition was 
still seen when the cyclone was employed (Chapter 3, Section 3.4.4). The 
comparison between SS and SX blends confirmed the finding (Table 4.3). IP/PS 
deposition for the cohesively-balanced SX formulation was almost double that of 
adhesively-balanced SS blends when only coarse lactose was used as carrier with 
Cheng 2 was in place (Table 4.3). However, when FL was added to the formulation, 
a similar IP/PS deposition was seen for both SS and SX blends.  
 
Table 4.3. Induction port/pre-separator (IP/PS) deposition of all the blends emitted from the Cheng 2 
at 2 and 4 kPa (mean ± SD, n > 3). (ED = emitted dose). 
Blends Ratio 
Pressure 
drop (kPa) 
IP/PS 
deposition 
(% ED) 
Pressure 
drop 
(kPa) 
IP/PS 
deposition 
(% ED) 
SS:CL 1:67.5 
2 
32.52 ± 9.24 
4 
29.65 ± 4.82 
SS:FL:CL 1:4:63.5 24.24 ± 16.45 15.53 ± 2.25 
SS:FL 1:4 0.00 ± 0.00 0.00 ± 0.00 
SX:CL 1:67.5 46.56 ± 13.51 58.71 ± 8.30 
SX:FL:CL 1:4:63.5 24.53 ± 2.90 21.74 ± 1.66 
SX:FL 1:4 0.00 ± 0.00 0.00 ± 0.00 
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The greater IP/PS deposition for SX blends led to a decreased fine particle 
fraction compared to SS blends. The aerodynamic PSD at 2 kPa (Figure 4.3, A) 
showed that the blends with coarse lactose containing SS released a higher 
respirable fraction of the particles < 5 µm compared to the blends containing SX 
regardless of the device used to deliver the dose (e.g. Cheng 2 vs. Cyclohaler). 
Moreover, as reported in Figure 4.3, B an increased % of the FPF was seen for both 
API when FL was added at the formulation (Figure 4.3, B). The same trend was 
observed at 4 kPa (Figure 4.4, A-B). The difference in the FPF for both materials 
when either the Cheng 2 or the Cyclohaler was used decreased when fine lactose 
was employed in the formulation. 
 
 
Figure 4.3. Particle size distribution expressed as cumulative % undersize (%) of the emitted dose of 
SS:CL (■-Cyclohaler, ■-Cheng 2), SX:CL (▲-Cyclohaler, ▲-Cheng 2), (A) and of SS:FL:CL (■-
Cyclohaler, ■-Cheng 2), SX:FL:CL (▲-Cyclohaler,▲-Cheng 2), (B) at 2 kPa (mean ± SD; n > 3). 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
10
20
30
40
50
60
70
80
90
100
C
u
m
u
la
ti
v
e
 %
 u
n
d
e
rs
iz
e
Cut-off diameter (m)
A B
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
10
20
30
40
50
60
70
80
90
100
C
u
m
u
la
ti
v
e
 %
 u
n
d
e
rs
iz
e
Cut-off diameter (m)
146 
 
 
Figure 4.4. Particle size distribution expressed as cumulative % undersize (%) of the emitted dose of 
SS:CL (■-Cyclohaler, ■-Cheng 2), SX:CL (▲-Cyclohaler,▲-Cheng 2), (A) and of SS:FL:CL (■-
Cyclohaler, ■-Cheng 2), SX:FL:CL (▲-Cyclohaler,▲-Cheng 2), SX (B) at 4kPa (mean ± SD; n > 3). 
 
If the values of the fine particle fraction are analysed, SS blends showed a 
higher FPF than SX (p<0.05). However, the FPF is a metric of a proportion of the 
particles below a certain size (e.g. 5 µm) and does not provide a clear explanation on 
the PSD like the Figure 4.3 and Figure 4.4. When the highest flow rates are taken 
into account, a higher FPF was seen only for SX:FL, whilst the remaining blends for 
SS show an improvement compared to the other SX blends in the FPF. The ratios of 
fine particles with size < 1.5 μm are more important to consider as they might explain 
the propensity and extent of deagglomeration of the blend within the cyclone. The 
FPRs < 1.5 μm (FPR1.5) were calculated as a measure of quantifying emission of 
particles below the cut-off diameter of the cyclone (i.e. 2 μm) according to Equation 
(3.2) (Table 4.4). 
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Table 4.4. Fine particle fraction (FPF) below 5 µ, and fine particle ratios (FPR) below 1.5 µm of SX 
and SS blends emitted from the Cheng 2 with different grade of lactose 
Blends Ratio 
Pressure 
Drop (kPa) 
FPF5µm 
Ex-Cheng 2 
(% sED) 
FPR1.5µm 
(ED) 
SS:CL 1:67.5 
2 
65.53 ± 8.99 1.45 ± 0.31 
SS:FL:CL 1:4:63.5 72.68 ± 16.83 2.01 ± 0.52 
SS:FL 1:4 85.39 ± 0.99 1.03 ± 0.27 
SS:CL 1:67.5 
4 
70.14 ± 5.15 1.97 ± 0.22 
SS:FL:CL 1:4:63.5 81.83 ± 4.11 2.18 ± 0.18 
SS:FL 1:4 86.45 ± 3.02 0.43 ± 0.32 
SX:CL 1:67.5 
2 
45.83 ± 5.03 2.34 ± 0.61 
SX:FL:CL 1:4:63.5 71.76 ± 2.80 2.82 ± 0.24 
SX:FL 1:4 94.54 ± 1.01 0.87 ± 0.27 
SX:CL 1:67.5 
4 
43.06 ± 6.88 1.67 ± 0.49 
SX:FL:CL 1:4:63.5 76.66 ± 1.35 3.44 ± 0.34 
SX:FL 1:4 91.27 ± 12.28 0.37 ± 0.20 
  
Despite the higher IP/PS deposition, a cohesively-balanced blend with fine lactose 
added to coarse carrier improved deagglomeration within the cyclone. Also, blends 
with the carrier showed a higher FPF and FPR for both SS and SX compared to 
blends with only fine lactose. Therefore, blends should have CL present in the 
formulation to enhance deagglomeration in the cyclone. 
 
4.4.3. Particle size analysis 
 
4.4.3.1. Laser diffraction analysis with inhaler module 
The LDA was performed on the SS and SX blends with different grades of 
lactose. When the fine lactose was present in the blends, the % of particles emitted 
with a size < 5µm increased compared to the blends with only coarse lactose (Table 
4.5). 
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Table 4.5. Table of values for % of particles with size < µm emitted from the blends when Cyclohaler® 
and Cheng 2 were used (mean ± SD, n=3). 
Cyclohaler Ratio 
Pressure 
drop (kPa) 
% < 5µm DV50 (µm) 
SS:CL 1:67.5 
2 
4.64 ± 1.20 63.31 ± 1.57 
SS:FL:CL 1:4:63.5 12.6 ± 2.00 60.11 ± 0.37 
SS:FL 1:4 52.90 ± 3.07 4.74 ± 0.28 
SX:CL 1:67.5 4.31 ± 0.91 67.94 ± 4.17 
SX:FL:CL 1:4:63.5 17.05 ± 0.42 53.29 ± 1.55 
SX:FL 1:4 52.76 ± 3.62 4.76 ± 0.33 
SS:CL 1:67.5 
4 
5.39 ± 0.56 64.86 ± 1.71 
SS:FL:CL 1:4:63.5 22.51 ± 1.57 50.20 ± 1.12 
SS:FL 1:4 68.76 ± 3.24 3.59 ± 1.14 
SX:CL 1:67.5 5.79 ± 1.84 66.61 ± 2.40 
SX:FL:CL 1:4:63.5 15.37 ± 0.65 55.36 ± 1.13 
SX:FL 1:4 61.66 ± 2.26 3.95 ± 0.21 
Cyclone Ratio 
Pressure 
drop (kPa) 
% < 5µm DV50 (µm) 
SS:CL 1:67.5 
2 
98.65 ± 2.33 1.96 ± 0.04 
SS:FL:CL 1:4:63.5 100.00 ± 0.0 1.81 ± 0.12 
SS:FL 1:4 100.00 ± 0.0 1.64 ± 0.12 
SX:CL 1:67.5 100.00 ± 0.0 1.83 ± 0.04 
SX:FL:CL 1:4:63.5 100.00 ± 0.0 1.50 ± 0.12 
SX:FL 1:4 100.00 ± 0.0 2.05 ± 0.01 
SS:CL 1:67.5 
4 
100.00 ± 0.0 1.65 ± 0.36 
SS:FL:CL 1:4:63.5 100.00 ± 0.0 1.19 ± 0.04 
SS:FL 1:4 100.00 ± 0.0 1.26 ± 0.03 
SX:CL 1:67.5 100.00 ± 0.0 1.26 ± 0.08 
SX:FL:CL 1:4:63.5 100.00 ± 0.0 1.26 ± 0.04 
SX:FL 1:4 100.00 ± 0.0 1.49 ± 0.04 
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When the cyclone was employed an improved deagglomeration occurred at the 
highest flow rate. The LDA confirmed that the blends that contained fine lactose 
released the finest aerosol compared to other blends (p<0.05) (Table 4.5). However, 
a change in size with the Cheng 2 in place was seen between the blends. The 
blends with CL showed a greater Dv50 at 2kPa (p<0.05, Table 4.5). The Dv50 for the 
blends with carrier when emitted from the Cyclohaler at 2 and 4 kPa were 
unchanged regardless the formulation (e.g. Dv50 for SS:FL:CL was 50.20 ±1.12 µm 
at 4 kPa, whilst the Dv50 for SX:FL:CL was 55.36 ± 1.13 µm at 4 kPa). On the other 
hand, when CL was absent from the formulation and only FL was used, the Dv50 of 
the blends emitted from the Cyclohaler was 3.59 ± 1.14 µm and 3.95 ± 0.21 µm at 4 
kPa for SS:FL and SX:FL, respectively. 
 
4.4.3.2. Dry dispersion laser diffraction analysis 
SX and FL showed a bi-modal distribution at 0.5 bar, indicating a fraction of 
poorly dispersed agglomerates (Figure 4.5, A and B) due to the low force applied to 
deaggregate the mixture. However, SS showed the same behavior also at 1 bar 
(Figure 4.5, C), indicating a poorer deagglomeration response of the agglomerates 
compared to the previous FL particles. 
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Figure 4.5. Density distribution of size of salmeterol xinafoate (A), fine lactose LH300 (B) and 
salbutamol sulphate (C) between 0.5 and 5 Bar. 
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When FL was added to SX or SS, the same trend of bi-modal distribution was 
observed at 0.5 Bar (Figure 4.6, A and B). However, SS:FL showed a much bigger 
shoulder in the 100 µm range than SX:FL (Figure 4.6, A) at low pressure, due to the 
more strongly cohesive forces of the agglomerates detected for SS alone compared 
to SX. However, the addition of FL enhanced deagglomeration of SS as at 1 Bar, as 
a monomodal distribution is detected (Figure 4.6, A) compared to when SS was 
tested alone at 1 Bar.  
 
 
Figure 4.6. Density distribution of size of salbutamol sulphate: fine lactose blends (A) and salmeterol 
xinafoate: fine lactose blend (B) between 0.5 and 5 Bar. 
Particle size (µm)
D
en
si
ty
 d
is
tr
ib
u
ti
o
n
0.5 Bar
1 Bar
2 Bar
3 Bar
4 Bar
5 Bar
A
Particle size (µm)
D
en
si
ty
 d
is
tr
ib
u
ti
o
n
0.5 Bar
1 Bar
2 Bar
3 Bar
4 Bar
5 Bar
B
152 
 
 
A larger particle size mode (seen already for the blends of micronized particles) 
was observed for the blends with either CL or FL:CL (Figure 4.7, A). However, when 
FL was added to the formulation API:CL, a shift towards the respirable range was 
seen due to a greater amount of fine particles present in the mixture (Figure 4.7, B). 
 
 
Figure 4.7. Density distribution of size of salbutamol sulphate: coarse lactose blend (A) and 
salmeterol xinafoate: fine lactose: coarse lactose blend (B) between 0.5 and 5 Bar. 
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The bimodal distribution of certain blends was attributed to the presence of 
coarse carrier in the formulation that, when pressure was applied led to a release of 
easily dispersible agglomerates (fine particles) and a poorly dispersible fraction of 
large cohesive agglomerates. At high pressures there was an increase in the release 
of fine particles, corresponding to the increased FPF as seen in the cascade 
impaction study (Table 4.4). Upon increasing the pressure, the Dv50 decreased 
(Figure 4.8, A). For formulations with fine particles only, a plateau particle size was 
reached suggesting that complete particle dispersion was achieved (Figure 4.8, B). 
 
 
Figure 4.8. Median particle size (A) and deagglomeration behaviour (B) as a function of pressure drop 
for micronized salmeterol xinafoate (SX, red), salbutamol sulphate (SS, black), fine lactose (FL, blue), 
salbutamol sulphate: fine lactose (SS:FL, green) and salmeterol xinafoate: fine lactose (SX:FL, pink) 
(mean ± SD, n=3). 
 
The descending part of the graph prior the plateau shows different 
deagglomeration behaviour between particles and formulations (e.g. SS vs. SX and 
FL in Figure 4.8, A). The difference, especially at low pressure drops, suggests 
variability in agglomerate size and strength as suggested from the density 
distributions of size in Figure 4.5. The degree of deagglomeration was calculated 
following Equation 4.4 [213] and plotted against the pressure drops (Figure 4.8, B). 
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DA =
Dv50 (μm,   fully dispersed)
Dv50(μm,   primary pressure )
    (4.4) 
 
Where DA is the degree of de-agglomeration. 
 
The % relative deagglomeration for micronized particles could also be 
calculated, instead, using the model proposed by Behara et al [220] in Equation 
(4.5). 
 
RD =
% volume<5μ𝑚 (dry dispersion)
% volume<5 μ𝑚 (𝑙𝑖𝑞𝑢𝑖𝑑 𝑑𝑖𝑠𝑝𝑒𝑟𝑠𝑖𝑜𝑛) 
∗ 100   (4.5) 
 Where RD is the relative deagglomeration. 
SX reached the maximum deagglomeration earlier than SS which, on the other 
hand, seemed to not reach a constant particle size at the highest pressure (Figure 
4.8, B). FL instead reached the plateau at lower pressure than the other APIs. When 
FL was added to both APIs, an increase in the degree of deagglomeration was seen 
at 2 Bar, which then decreased at 3 Bar (Figure 4.8, B). This was probably due to the 
instability of the formulation at high pressure drops. 
 
4.4.3.3. Liquid dispersion laser diffraction analysis 
The liquid dispersion laser diffraction was used to determine the fully dispersed 
particle size of the API and blends. The results confirmed the dry dispersion values 
as the Dv50 of the blends with the carrier were shifted to higher values than when 
the drugs were blended with fine lactose only (Table 4.6). On the other hand, the 
micronized API possessed a PSD within the micron size range (Table 4.6).  
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Table 4.6. Particle size distribution for pure material and blends of salbutamol sulphate (SS) and 
salmeterol xinafoate (SX) with lactose using liquid dispersion laser diffraction (mean ± SD, n=3) 
(FL=fine lactose, CL=coarse lactose). 
 
Materials Ratio Dv10 (µm) Dv50 (µm) Dv90 (µm) Volume%<5 µm 
SX n/a 0.90 ± 0.01 3.01 ± 0.05 7.40 ± 0.33 76.15 ± 1.22 
SS n/a 1.38 ± 0.03 3.63 ± 0.05 10.02 ± 0.40 66.15 ± 0.56 
LH300 n/a 1.51 ± 0.01 3.40 ± 0.07 6.76 ± 0.13 75.71 ± 1.25 
SS:CL 1:67.5 4.96 ± 3.11 53.42 ± 8.75 92.76 ± 2.83 13.36 ± 6.87 
SS:FL:CL 1:4:63.5 4.60 ±1.27 57.36 ± 4.07 95.24 ± 1.68 11.45 ± 2.74 
SS:FL 1:4 1.38 ± 0.04 3.60 ± 0.16 9.03 ±1.07 68.76 ± 2.69 
SX:CL 1:67.5 4.79 ± 3.65 56.05 ± 3.98 89.32 ± 11.57 12.50 ± 3.98 
SX:FL:CL 1:4:63.5 2.11 ± 0.43 43.35 ± 12.68 84.82 ± 8.61 22.87 ± 7.76 
SX:FL 1:4 1.23 ± 0.03 3.15 ± 0.06 6.73 ± 0.23 77.89 ± 0.82 
 
When the blends containing coarse lactose were analysed equation (4.5) was 
used to calculate % relative deagglomeration and plotted against the pressure drop 
(Figure 4.9). 
 
 
Figure 4.9. Bi-exponential distribution of the % relative deagglomeration for salbutamol sulphate and 
salmeterol xinafoate blended with coarse lactose (SS:CL black, SX:CL pink) and with fine lactose 
(SS:FL:CL blue, SX:FL:CL grey) (mean ± SD, n=3). 
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Unlike the micronized API and blends with FL only, the formulation containing 
both CL and FL or only CL did not show a plateau in the particle size. The graph 
shows a bi-exponential distribution with the first part showing an easily dispersed 
fraction and a second part showing a less easily dispersed fraction. The trend of the 
latter seemed to be the same for all the formulations. However, the first part of the 
curve shows difference in the deagglomeration behaviour of the blends. SS:CL 
seemed to have the steepest curve compared to the other API:CL blends. As 
expected, API:FL:CL blends, showed a steeper slope in the first fraction then API:CL 
blends (Figure 4.9).  
 
4.4.4. Empirical model 
The % relative deagglomeration for micronized particles and micronized 
formulations showed a mono-exponential trend when a pressure drop was applied to 
the agglomerates. The trend could be explained by the equation (4.6): 
 
))0/(1(
nxxemy       (4.6) 
The deagglomeration mechanism depends on the distribution of the APIs either 
alone or in combination with FL in formulation. The slope of the curve is the 
maximum gradient and represents how easily the deagglomeration process occurs 
before the drug reaches the plateau size. A plateau particle size was reached 
suggesting fully dispersed particles (Table 4.7; the positive asymptote or 'm' 
parameter).The deagglomeration behaviour can be described by the critical primary 
pressure at 95 % (CCP95, pressure where the degree of deagglomeration has 
reached 95 % of its final value) of the positive asymptote (m = maximal 
deagglomeration, Table 4.7). The deagglomeration response is described by ‘n’ 
(deagglomeration exponent) and ‘x0’, which reflect the agglomerate structure and 
deagglomeration mechanism. The maximum gradient of the fit (Table 4.7) defined 
the sensitivity of the deagglomeration response to increasing airflow. SX achieved 
full deagglomeration at lower pressures than SS (Table 4.7, Column CCP95), whilst 
SS reached the maximum deagglomeration process at higher pressure compared 
also to FL (Table 4.7, p<0.05), indicating that higher pressure was needed to 
deaggregate SS fully. However, the addition of FL to SS improved the 
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deagglomeration mechanism of the latter, as shown by an increased maximum 
gradient (Table 4.7, p<0.05) and increased the exponent two-fold, indicating easier 
deagglomeration due to an altered agglomerate structure. On the other hand, FL 
reduced the deagglomeration exponent of SX (Table 4.7, p<0.05). Due to the high 
variability in the repeats, an artificial error was added when normalizing the data. 
 
Table 4.7. Mono-exponential deagglomeration parameters for salbutamol sulphate (SS), salmeterol 
xinafoate (SX), fine lactose (FL) and SS-FL or SX-FL blends. 
Materials 
m 
(%) 
x0 
(bar) 
n 
Maximum 
Gradient 
(bar
-1
) 
CPP95 
(bar) 
R
2 
FL 101.99 ± 3.00  0.49 ± 0.02  2.65 ± 0.35  289.05 ± 32.08  0.74 ± 0.05  0.98274  
SX  101.18 ± 2.19  0.53 ± 0.03  2.03 ± 0.27  194.27 ± 9.67  0.90 ± 0.05  0.98606  
SS  99.89 ± 2.61  0.69 ± 0.04  1.53 ± 0.17  108.88 ± 5.06  1.25 ± 0.19  0.98587  
SS:FL  103.40 ± 5.40  0.61 ± 0.04  2.71 ± 0.71 230.20 ± 34.34  0.84 ± 0.08  0.93928  
SX:FL  99.40 ± 1.60  0.43 ± 0.01  1.68 ± 0.12  207.35 ± 6.1  0.82 ± 0.04  0.99360  
 
m= positive asymptote 
x0= pressure value in the x axis which takes a value of n ≥ 0 
n= deagglomeration exponent 
Maximum gradient= slope of the curve 
CPP95 = critical primary pressure where the degree of deagglomeration has reached the 95 % of its 
final value 
R
2
= value of the best fitted line 
 
When CL was added to the formulation, the plateau was not reached when the 
blends containing CL were analysed. Instead, the formulations showed a bi-
exponential trend (Figure 4.9), highlighting an easily dispersed fraction and a second 
poorly dispersible fraction of respirable particles. This response is described by 
Equation (4.7). 
)
)2/(
1)(100)(()
)1/(
1(
xx
eAwxxH
xx
eAy



   (4.7) 
 
'A' represents the amplitude of the easily dispersed fraction (i.e., extent of 
deagglomeration), whereas 100 - 'A' represents the deagglomeration extent of the 
poorly dispersed fraction; ‘xw’ is the pressure when the poorly dispersible fraction 
starts to deagglomerate; 'H' is the Heaviside-function (1 if x>xw, 0 if x<xw); x1 and x2 
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are pressure points when the deagglomeration response is at maximum for the 
easily and poorly dispersed fractions, respectively. With the exception of SX:CL, all 
blends exhibited an ‘xw’ value (Table 4.8). Greater deagglomeration responses for 
the easily dispersed fraction were seen for blends with FL:CL (e.g. 170.97 ± 12.74 
bar-1 for SX:FL:CL) than with CL (e.g. 71.64 ± 7.42 bar-1 for SX:CL).  The presence 
of ternary agent improved the liberation of the finest particles (higher 'A’ parameter, 
Table 4.8). The greatest ‘A’-value was observed for SS:FL:CL (Table 4.8). 
 
Table 4.8. Parameters from a bi-exponential equation for salbutamol sulphate (SS) blends (FL=fine 
lactose, CL=coarse lactose) and salmeterol xinafoate (SX) blends. 
Blends 
A 
(%) 
x1 
(bar) 
x2 
(bar) 
xw;yw 
(bar;%) 
R2 
SS:CL 37.6 ± 0.7 0.5 ± 0.0 11.2 ± 2.8 3.0 ± 0.3; 37.4 ± 0.8 0.81143 
SS:FL:CL 61.4 ± 2.6 0.6 ± 0.1 3.7± 1.0 2.0 ± 0.3; 59.8 ± 6.4 0.91714 
SX:CL 17.8 ± 2.8 0.3 ± 0.1 14.0 ± 1.0 0;0 0.88214 
SX:FL:CL 48.7± 1.8 0.3 ± 0.0 5.6 ± 1.4 1.9 ± 0.4; 48.6 ± 1.6 0.91714 
 
 
4.4.5. Particle morphology 
 
4.4.5.1. Micronized particle and blend morphology 
Microscopy was employed to examine blend structure. The micronized SS and 
SX showed a very similar elongated shape (Figure 4.10, left and right).  
 
 
Figure 4.10. Scanning electron microscopy images for salbutamol sulphate (left image) and 
salmeterol xinafoate (right image). 
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Alone, the drugs created agglomerates. However, when the coarse lactose was 
added, the distribution of SS and SX on its surface did not show any difference  
(Figure 4.11). 
 
 
Figure 4.11. Scanning electron microscopy images for salbutamol sulphate:coarse lactose(left image) 
and salmeterol xinafoate:coarse lactose (right image). 
 
However, when FL was added to SX:CL (Figure 4.12, left), clearly more 
agglomerates can be seen at the extremities of the surface of the carrier. 
Interestingly, when the fine lactose was added to SS:CL, “free” agglomerates of 
FL:SS were visible in the space between carrier particles (Figure 4.12, right). When 
energy is applied, these agglomerates would be dispersed more easily compared to 
those adhered to the surface of the carrier (e.g. in SX:FL:CL); leading to the higher 
% deagglomeration for the SS:FL:CL compared to SX:FL:CL (“A” parameter, Table 
4.8). However, the adhesive strength predicted (Table 4.8) of the CL-SS interactions 
in the agglomerates would require high pressure to achieve full deagglomeration 
(“x1” parameter in Table 4.8). 
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Figure 4.12. Scanning electron microscopy images for salbutamol sulphate blended with fine and 
coarse lactose (SS:FL:CL – left image) and salmeterol xinafoate blended with fine and coarse lactose 
(SX:FL:CL – right image) 
 
 
4.4.5.2. Agglomeration state of the deposited fraction 
SEM was carried out on particles emitted from both the Cyclohaler® and the 
Cyclohaler-Cheng 2 cyclone in series at 4 kPa into the impactor. The stages where 
the particles were collected were: capsule, 90° angle of USP throat, central cup of 
the pre-separator and stage 5, to represent the particle cut off size at 4 kPa. In 
Figure 4.13 the formulations emitted from the Cyclohaler® are reported. 
 
Figure 4.13. Scanning electron microscopy images for all the blends emitted using the Cyclohaler 
(capsule/stage). 
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Powder collected from the capsules showed the presence of fine particles when 
FL:CL blends were tested compared to API:CL blends. Some difference of the effect 
of the fine lactose when added to the formulation is seen on the SX:FL:CL blends 
when emitted from the Cyclohaler. Agglomerates can be seen on the extremities of 
the carrier. SX was assumed to be the cohesively-balanced particles when added to 
the lactose and FL helped the deagglomeration mechanism (Table 4.8). However, 
when FL was added to SS:CL blends, the particles typically regarded as adhesive 
did not behave similarly to SX. When the mixture of SS:FL:CL was collected form the 
capsule (Figure 4.13), some “free” agglomerates was seen in the surrounding space 
of the carrier than when the formulation SX:FL:CL was analysed (Figure 4.13). When 
SS:CL and SX:CL formulation were analysed, no difference was observed (Figure 
4.13) or when the Cheng 2 was employed (Figure 4.14). When Cheng 2 was used 
(Figure 4.14), the deposition in the capsules was unchanged in respect of the 
Cyclohaler alone. 
 
Figure 4.14. Scanning electron microscopy images for all the blends emitted using the 
Cyclohaler/Cheng 2 Cyclone in series (capsule/stage). 
A great amount of the blends was detected in the inlet of the Cheng 2 (Figure 
4.15). SX:FL:CL showed “free agglomerates” inside the conical section of spacer. In 
contrast to the SX:FL:CL collected from the Cheng 2, SS:FL:CL did not show “free” 
agglomerates (Figure 4.15). 
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SX:FL:CL
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Figure 4.15. Scanning electron microscopy images for all the blends emitted using the Cheng 2 (inlet 
of cyclone-spacer). 
 
As already described in Section 4.4.2, some agglomerates and carrier particles 
were detected in the IP/PS stage for all the blends when the Cyclohaler was used 
alone (Figure 4.16). For SS blends, drug was trapped in the asperities of the lactose. 
Therefore, the force was not sufficient enough to detach all SS from the high energy 
sites. 
 
SX:CL
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SX:FL:CL
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Figure 4.16. Scanning electron microscopy images for all the blends emitted using the Cyclohaler 
(IP/PS stage). 
Agglomerates that would have been retained inside the Cyclone (Figure 4.15) 
were seen in the IP/PS stage when Cyclohaler was used alone (Figure 4.16). Fewer 
coarse carrier particles were detected in the IP/PS stage when Cheng 2 was used 
Figure 4.17). 
 
Figure 4.17. Scanning electron microscopy images for all the blends emitted using the 
Cyclohaler/Cheng 2 (IP/PS stage). 
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In general, when the blends were emitted from the Cyclohaler® only, more 
powder was collected from the throat and pre-separator stage than when the Cheng 
2 was employed (e.g. Figure 4.16 and Figure 4.17). A higher magnification of the 
microscope in the pre-separator stage (Figure 4.16) showed agglomerates of SX 
with FL on the carrier surface. When Cheng 2 was used, some carrier particles were 
detected with clearly some SX still attached or in the surrounding space in the IP/PS 
stage (Figure 4.17). However, the vacuum of the sputter coating process fragmented 
one particle that was recovered from the throat stage (Figure 4.17).  
As expected, in stage 5 only micronized particles were collected (Figure 4.18). 
However, the presence of fine lactose in the blends enhanced the detachment of 
drug from the carrier surface resulting in higher deposition of the micronized mixture 
in stage 5 compared to when blends with CL only were assessed for both Cyclohaler 
and Cheng 2. This was previously reported in the impaction data (Table 4.4). 
 
Figure 4.18. Scanning electron microscopy images for all the blends emitted using the 
Cyclohaler (stage 5). 
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Figure 4.19. Scanning electron microscopy images for all the blends emitted using the Cyclohaler 
/Cheng 2 (stage 5). 
 
4.5. Discussion 
Due to interesting results from the Accuhaler™ formulation in Chapter 3, a 
study of aerosolization using the cyclone with blends containing different APIs with 
different grades of lactose was assessed. A variable IP/PS deposition was seen for 
SS and SX emitted from the Cyclohaler® and Accuhaler™, both in series with Cheng 
2, respectively (Chapter 3). The throat deposition was almost doubled for SX leading 
to a much reduced FPF than SS. Although the data were obtained when the Cheng 
2 was in place, which was supposed to retain only the large carrier particles, the 
APIs seemed to deagglomerate differently inside the conical section of the spacer. In 
order to understand the mechanism better, blends with either SX or SS were 
manufactured in-house with different grades of lactose and their aerosolization, was 
studied with the Cyclohaler® in the presence or absence of the Cheng 2 spacer at 2 
and 4 kPa. For the purpose of the study and to understand the different 
deagglomeration mechanism of SX and SS, the former was considered cohesively-
balanced when added to the lactose, due to its tendency to create agglomerates on 
SX:CL
Stage 5 cyclone
SS:CL SS:FL:CL
SX:FL:CL
SX:FL
SS:FL
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the carrier surface [104]. On the other hand, SS was considered due to its 
adhesively balanced behaviour when added to lactose as previously described [108]. 
This considerations were based on literature search. The concentration of the SS 
and SX was 1.48% w/w and they were blended with either FL (1:4), coarse lactose 
(1:67.5) or both (1:4:63.5). In the current chapter FPF and FPR1.5 were considered 
as metrics to undertstand the extend of deagglomeration of the blends and not for 
any clinical purpose (e.g. understanding the potential respirable fraction when using 
the spacer). This was decided due to the variability of the Cheng 2 with commercial 
blends. Therefore, comparison between blends when tested with or without the 
spacer was made only to propose a theory of different behaviour relating to the 
chemical entities (e.g. API) and the presence of fine carrier.  
The PSD (particle size distribution) of the APIs confirmed that the drugs were 
micronized (Figure 4.1 and Figure 4.2). Although the lactose was sieved in the 
fraction 63-90 µm, its Dv50 was 65.78 ± 0.44 µm. This is probably due to the 
presence of fine lactose on the surface of the carrier that affected the particle size. 
CL is well known to be used to improve aerosolization and flowability of micronized 
drug [108, 223].  However, a strong adhesion of the API to the carrier would 
decrease the drug dispersion[99, 110]. Therefore, ternary agents (or fine lactose) are 
usually added to the formulation to compete with the drug on the active sites of the 
carrier. Saturating the sites, the drug is detached easily from the carrier upon 
aerosolization [98, 100]. Many studies suggest an increase of fines would increase 
the FPF of the API because fines create agglomerates [99]. However, the different 
behaviour of the drug when mixed with the carriers must be kept in mind. Behara et 
al [113] showed that the presence of coarse carrier was not necessary as by 
increasing the concentration of fines, the agglomerate strength is reduced leading to 
a better aerosolization. Moreover, Islam et al [224] indicated that SX dispersion 
increased as the amount of FL increased. On the other hand,  Jones et al [203] 
demonstrated that the addition of fines does not always enhance the FPD. They 
tested the aerosolization of Bud and formoterol fumarate dihydrate in combination 
with erythriol or trehalose fines. They found that the FPD did not increase compared 
to the binary formulation of the drug with the carrier lactose (e.g. 18.6 ± 3.3 % vs. 
22.0 ± 1.2 % for budesonide binary formulation and budesonide/erythriol fines 
formulation, respectively). 
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In the current study, the emission from the Cyclohaler® alone did not differ 
between SS and SX formulations (88.20 ± 2.86% for SS:CL and 89.05 ± 2.12% for 
SX:CL at 4 kPa, p>0.05). However, it decreased when FL was added to the 
formulations (e.g. 89.05 ± 2.12% for SX:CL vs. 75.70 ± 2.00 for SX:FL:CL at 4 kPa). 
On the other hand, when the Cheng 2 was used, greater emission was seen for the 
SX blends than for the SS formulation (10.25 ± 3.85% for SS:CL and 22.86 ± 4.30 % 
for SS:FL:CL vs. 16.30 ± 3.25 % for SX:CL and 30.64 ± 10.44 for SX:FL:CL at 4 kPa, 
p<0.05). In the conical section of the Cheng 2, deagglomeration processes probably 
occur, leading to better emission of what could be stong agglomerates of SX from 
the spacer than SS. As previously suggested [224], adding FL in SX formulations 
(with CL) the SX deagglomeration occurred to a greater extend. This also led to a 
reduced IP/PS deposition for the blend with the ternary agent compared to when fine 
lactose was absent from the formulation (Table 4.3). Greater throat deposition was 
seen for SX blends than SS formulations. The same finding was reported when 
Cyclohaler/SS and Accuhaler/SX/FP were tested with Cheng 2 in Chapter 3.  
In Chapter 3, the retention of the drug within the cyclone was high shown to be 
high for all drugs. Here the cyclone retention was especially high for the blends with 
fine lactose only (e.g. 95.76 ± 0.67 % and 96.83 ± 0.34 % for SS and SX). This is 
probably due to the presence of small particles that have low inertia and therefore, 
experience low deagglomeration forces. Also, when only micronized particles were in 
the formulation (e.g. SS:FL or SX:FL), no throat deposition was detected when the 
Cheng 2 was in place, as the drug particles remained inside the spacer which has 
been shown not to work efficiently with only micronized material. Therefore, when 
hitting the spacer walls, the particles do not re-disperse in the air. In fact, as seen in 
Chapter 2 with the Symbicort/Turbuhaler®, when coarse carrier was absent from the 
formulation, the majority of the particles were collected within the conical section of 
the spacer. This confirms that the cyclone spacer did not function effectively with 
agglomerated micronized material alone. Fine lactose and cohesive micronized 
particles create agglomerates [113]. The absence of the coarse lactose affects the 
flowability of the formulation [96] and therefore, when entering the spacer, the 
agglomerates are subjected to more adhesion to the cyclone’s walls than the other 
type of formulations with a coarse carrier. In fact, the highest retention within the 
spacer was seen for SS:FL and SX:FL (64.14 ± 6.20% and 52.39 ± 4.73 % at 4 kPa, 
168 
 
respectively). This was confirmed by the SEM images (Figure 4.15) where particles 
were detected as agglomerates.  
The lower deposition in the IP/PS for SS than SX formulations when CL or 
FL:CL was used than SX formulation lead to a variable PSD between the 
formulations when the spacer was used. Interestingly, when the Cheng 2 was not 
employed, the blends showed an almost identical PSD at both flow rates (Figure 4.3 
and Figure 4.4). In fact, the same FPF (% ED) of the aerosol emitted from the inhaler 
alone was unchanged for both APIs (13.08 ± 1.29 % for SS:CL vs. 10.86 ± 1.31% for 
SX:CL, p>0.05 and 31.95 ± 4.76% for SS:FL:CL and 32.2 ± 5.08% for SX:FL:CL, 
p>0.05). FPF seems dependent on the composition of lactose used [225]. 
The presence of cohesively balanced particles, and therefore, high interaction 
forces between drug-drug, would lead to a reduced FPF of the drug upon 
aerosolization [104]. This was observed when Cheng 2 was employed. A reduced 
FPF (%sED) of SX:CL emitted from Cyclohaler into the spacer was observed than 
when SS:CL was assessed (Table 4.4). The SS, probably due to its stronger forces 
of interaction with the lactose [108] showed an higher FPF than SX (%sED) (65.83 ± 
8.99 % vs.45.83 ± 5.035 % for SS:CL and SX:CL, respectively at 2 kPa and 70.14 ± 
5.15% and 43.06 ± 6.88 %, for SS:CL and SX:CL, respectively at 4 kPa, p<0.05). It 
seems that the deagglomeration forces inside the conical section of the spacer have 
a greater impact on the formulation when the carrier is used. Interestingly, adding FL 
to the formulation led to an enhanced FPF (%sED) for formulations of both SS or SX 
with a much greater improvement for SS blends (e.g. 81.83 ± 4.11 % for SS:FL:CL 
vs 70.15 ±5.15 % for SS:CL at 4 kPa). Literature search suggests that SX exhibits a 
more cohesive behaviour than SS [99]. However, when added to the FL and CL, the 
fine particles competed with SX leading to a similar FPF of SS:FL:CL and SX:FL:CL 
(72.68 ± 16.83 % for SS:FL:CL and 71.76 ± 2.80% for SX:FL:CL at 2 kPa). 
Therefore, the CAB theory cannot be fully applied to the proposed project. However, 
it seems that the presence of the ternary agent improved the dispersion of the drug 
probably due to stonger FL deagglomeration forces that break up the weak mixed 
agglomerates [99].  
Due to the cut off size of the cyclone being < 2 µm, FPR1.5 were calculated 
dividing the FPF1.5 of the blends emitted from the spacer by the FPF1.5 of the same 
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formulation emitted from the Cyclohaler®. This was done as FPF1.5 could be used as 
a parameter to assess the extent of deagglomeration of the emitted dose within the 
spacer. It was calculated as a measure of classification of particles below the cut-off 
diameter. Although SS:CL had higher FPF than SX:CL, the latter exhibited a greater 
FPR1.5 (Table 4.4). The same trend was seen when FL was added to the 
formulations, with expected greater ratios for the formulation with fine lactose than 
with CL (2.01 ± 0.52 for SS:FL:CL vs. 2.82 ± 0.24 for SX:FL:CL at 2 kPa and 2.18 ± 
0.18 for SS:FL:CL vs. 3.44 ± 0.34 for SX:FL:CL at 4kPa). This was confirmed by the 
maximum gradient (slope in Figure 4.9) of SS:FL:CL and SX:FL:CL (in the easily 
dispersed fraction curve), indicating SX:FL:CL to have a greater gradient than 
SS:FL:CL. Therefore, a better deagglomeration seems to occur for SX particles as it 
should be expected also in the absence of the carrier (Figure 4.8, B) [99]. In Chapter 
3, the same trend was seen for SS formulation and SX formulation emitted from the 
Cyclohaler and Accuhaler, respectively in the presence of the spacer (1.96 ± 0.30 for 
SX and 1.30 ± 0.98 for SS at 4 kPa). Although the respirable fraction was higher for 
the SS formulation, the potential of enhanced deagglomeration of SX would lead to a 
more potential lung deposition in the small airways for this particular API, where a 
longer bronchodilation than SS would be required for severe asthmatic patients [226, 
227]. This is probably because SS alone is not present as agglomerates unlike when 
is in presence with the lactose. Moreover, SX presents agglomerates on the carrier 
surface (Figure 4.12), leading to a greater deagglomeration than SS blends (e.g. 
FPR1.5 in Table 4.4). From the SEMs, it is clear that SS:FL agglomerates, when 
mixed with CL, tend to re-distribute in the surrounding spacer of the carrier unlike 
SX:FL agglomerates when mixed with CL. 
Using laser diffraction techniques, the effect of the addition of either fine lactose 
or coarse lactose to the API was shown [224]. Studying the particle size distribution 
of SX with fine lactose, Islam et al [224] indicated that SX dispersion increased as 
the amount of FL increased. On the other hand, adding coarse carrier to the mixture 
shifted the distribution to a larger size range [224]. However, adding lactose with size 
between 45-63 µm, led to almost double the FPF (fine particle fraction), compared to 
when the coarse lactose with size > 63 µm. Particle size distribution using laser 
diffraction showed a greater fraction of particles with size < 5 µm when SS blends 
were emitted from the Cyclohaler® (Table 4.5). As already discussed in Chapter 3, 
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the cyclone spacer, Cheng 2, especially its conical section, behaves differently 
between formulations. Studying the deagglomeration process of the dispersed 
powder at different flow rates prior to entering the spacer is important to understand 
the outcome when a DPI is used to effect powder emission. Although this issue has 
featured widely in the literature, a few studies have investigated the deagglomeration 
trend of either the powder bed [213] or the aerosol emitted from a Rotohaler [220]. 
These studies proposed a quick methodology to assess deagglomeration of the 
formulation upon increasing flow rate or pressure drop.  Laser diffraction analysis 
such as Sympatec and Malvern instrument [213, 220] were used.  However, the 
studies seem to focus on the fine particles, rather than on the formulation with 
coarse carrier.  
 
High flow rates are required to deaggregate blends if lactose carrier is present, 
due to the adhesion of the micronized particle to its surface. Only several studies 
have investigated the powder dispersion when coarse lactose was employed [221, 
228]. The authors used Standardized Entrainment Tubes (SETs) to generate the 
aerosols using then cascade impactor (twin-stage liquid impinger and Andersen 
cascade impactor) to characterize the formulation at 60 Lmin-1 [221]. The FPF was 
then correlated to the SET shear stress and an equation proposed similar to the 
Langmuir adsorption isotherm, called the powder aerosol deaggregation equation 
(PADE) [221]. However, the study implies that a cascade impactor should be used to 
study the deagglomeration of the particles. The same issue of modifying the 
deagglomeration process with an inhaler was reported by Behara et al, [220] when 
the Rotohaler was used. The aim of the current chapter was to understand the 
deagglomeration behaviour of the formulation itself prior to entering the cyclone 
spacer. Therefore the models proposed by these studies were not used. Other 
studies investigated the interaction between individual particles using atomic force 
microscopy (AFM) [218, 219]. However, the technique does not quantify the 
adhesion force of the powder bed as it only measure the interaction between one 
particle or excipient and the probe of the AFM.  
Other techniques have been proposed to study the interaction between 
particles. For instance, inverse phase gas chromatography [229] showed potential to 
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understand the interaction between carrier and API, where the formulation is placed 
inside a packed columns and a gas (e.g. helium) is passed through it. The API with 
higher affinity to the carrier, would elute later than the one with less affinity. This is 
due to the higher surface energy between API particles and carrier. Studying the 
retention of a range of probes with different polarity and chemistry, the cohesion 
strength can be calculated [229]. Another technique to study the different behaviour 
of blends under applied forces are powder rheometry (where flow properties are 
studied by studying the movement of an impeller through blends under a specified 
force, such as torque) [230] and centrifugation of micronized material [231]. In this 
chapter only cascade impactor, laser diffraction and SEM techniques were used to 
propose a deagglomeration theory. 
When the APIs were dispersed using the Sympatec/RODOS for pressure drop 
titration, both SX and FL showed a bi-modal PSD at 0.5 Bar (Figure 4.5 A, B). The 
same trend was seen also for SS that exhibited a similar behaviour at 1 Bar too 
(Figure 4.5, C), suggesting a greater energy is required for the deagglomeration 
mechanism to occur for SS compared to SX and FL. However SS, SX and FL 
showed a bell-shaped distribution at higher pressure drops as confirmed in previous 
studies [96, 232]. When FL was added to the APIs, a more consistent distribution 
when increasing the pressure was seen for both drugs, although SS-FL 
deagglomeration at low pressure (0.5 Bar) did not occur completely (shoulder in the 
large particle size range in Figure 4.6, A). The same trend was seen by Jaffari et al 
[213] with SX, and by Behara et at for SS:FL [220]. However, the bi-modal 
distribution was not present for SS:FL at 1 Bar unlike for SS alone, probably due to 
the addition of the FL leading to disruption of SS agglomerates and enhanced 
deagglomeration [113]. 
 
When the formulations containing either CL or FL:CL were analysed, the 
lactose carrier showed a distribution in the 60-90 µm range (Figure 4.7 A). However, 
in blends also containing FL, a shoulder was seen in the micronized region due to 
the greater amount of fine particles present in the mixture (Figure 4.7, B). The 
formulations showed a bi-modal distribution due to the presence of easily-dispersible 
agglomerates (small shoulder in the respirable range) and a poorly-dispersible 
fraction of drug still attached to the carrier (big shoulder) [98, 213] that could be 
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explained by the bi-exponential trend when an increased pressure drop is applied 
(Figure 4.9). At high pressures there was an increase in the release of fine particles, 
corresponding to the increased FPF as seen in the cascade impaction study (Table 
4.4). The presence of ternary agent would help the detachment of the micronized 
API from the surface of the carrier, resulting in greater FPF than when the 
formulation was composed of CL only [101] (Table 4.4). Jones et al [203] confirmed 
it when also other ternary agents were added to a binary formulations showing and 
increased mode in the respirable fraction for Bud ternary formulation with erythriol 
fines. 
 
In accordance with Jaffari et al [213], formulations with fine particles only 
reached a plateau when the pressure drop was increased. The trend could be 
described by a mono-exponential function (equation 4.6) which is a modification from 
the Johnson-Mehl-Avrami-Kolmogorov (JMAK) equation [233]. The plateau size 
represents the maximum deagglomeration (“m” parameter in Table 4.7 define the 
positive asymptote of the curve) which varied with the type of particle (Table 4.7). 
The slope of the curve in Table 4.7, B represents the deagglomeration sensitivity 
(e.g. the maximum gradient). SS showed the lowest maximum gradient (indicating a 
deagglomeration process less sensitive to airflow) when pressure is applied 
compared to the other micronized materials (Table 4.7). The difference, especially at 
low pressure drops, suggests variability in agglomerate size (i.e. x0 in Equation 4.6) 
and strength between agglomerates [194, 214]. In order to compare the drugs and 
blends, the critical pressure point (CPP), the pressure point corresponding to 
reaching 95% of the maximum deagglomeration was calculated. SS started to reach 
the plateau at 1.25 ± 0.19 Bar, at a much greater pressure than SX or FL (Table 4.7). 
However, when FL was added to SS, the CCP95 was reached at lower pressure 
than when SS was analysed alone (0.84 ± 0.08 Bar, p< 0.05) and the greater 
maximum gradient was seen for FL than SS (Table 4.7).The maximum gradient is a 
vector of the derivative of the function. This indicates the rate of ascent of the curve, 
therefore, the rate of the degree of deagglomeration. If a small tangent is drawn in a 
selected point (in this case x0;y0), then the maximum gradient refers to the slope of 
the tangent.  
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The enhanced degree of deagglomeration seen for SS when FL was added 
could be explained by the fact that adding FL, agglomerates with potential low 
cohesive strength are created between fine carrier particles and drug that otherwise 
would not be overcome [113, 220]. Therefore, the force of adhesion between 
agglomerates of API is reduced. SX:FL had a poor deagglomeration compared to FL 
or SX, suggesting that maybe the addition of FL to very cohesive agglomerates does 
not improve the deagglomeration mechanism [203]. In accordance with this theory, 
Adi et al [104] showed that increasing the shear pressure to formulations of SX 
containing FL with different size range (3.0 and 7.9 µm) is required especially for 
formulation containing FL 3.0 µm. This might lead to segregation in the formulation, 
especially at high pressure drops, a phenomenon already reported with other 
formulations in Chapters 2 and 3. The parameters ‘x0’ and ‘n’ are dependent on 
each other. The parameter ‘x0’ has a similar meaning like the one proposed by 
Behara et al [220]. The authors used a Rotahaler with Spraytec to study the 
deagglomeration behaviour of either SS or FL. They suggested that the parameter 
was the dispersion energy required to overcome internal interaction of the 
agglomerates. In the current project we suggested that ‘x0’ could be seen as an 
inflection point and it is the pressure at which the deagglomeration attempts to reach 
the maximum point. In accordance with Behara et al [220], the blends with fine 
particles and FL alone showed similar ‘x0’ values (Table 4.7, p>0.05) with the 
exception of SS. The parameter ‘n’ is the trend of the first part curve between 0.1 
and x0 Bar. SS:FL exhibited the highest deagglomeration exponent whilst, SX:FL 
showed the smallest. This indicates a different deagglomeration mechanism when 
the fine lactose overcomes SS-SS and SX-SX interactive forces. Moreover, the 
blend structure plays a role. Adding the fine lactose would modify the adhesive 
strength between particles and enhance the detachment of the API (Table 4.7, 
maximum gradient was greater for SS:FL than SX:FL). 
 
When the blends containing coarse lactose or fine lactose and coarse lactose 
were analysed, they did not show a plateau size. The graph shows a bi-exponential 
distribution (Figure 4.9) that could be described by Equation (4.7) with the first part 
showing an easily dispersed fraction and a second part showing a less easily 
dispersed fraction. The trend of the latter seemed to be the same for all the 
formulations. However, the first part shows difference in the deagglomeration 
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behaviour of the blends. SS:CL seemed to have the steepest curve  than the other 
API:CL blends, expressed by the maximum gradient. As expected, API:FL:CL 
blends, showed a more rapid slope in the first fraction than API:CL blends (Figure 
4.9). They showed also a greater % of deagglomeration expressed by the parameter 
“A” in equation (4.7) reported in Table 4.8. This might explain the greater FPF seen 
for blends with FL when either the Cyclohaler or the Cheng 2 was used in the 
aerosolization studies (Table 4.4). Equation (4.7) shows the Heaviside function 
which is usually used in engineering to represent a parameter that changes abruptly 
at specified values of time t. For example, it is usually applied when a voltage is 
switched on or off in an electrical circuit at a specified value of time t. In many 
circuits, waveforms are applied at specified intervals other than t = 0 [234, 235]. In 
the current model the step function (or Heaviside function) was applied to the bi-
exponential trend. If noticed in Figure 4.9, between 1.0 and 2.0 Bar, between the end 
of the deagglomeration of the easily dispersed fraction and the beginning of the 
deagglomeration of the poorly dispersed fraction, there is a small plateau [235]. ‘H’ 
was applied to the deagglomeration mechanism of the blends with coarse carrier, 
where the “H” parameter of the function was 1 if x>xw, with xw being the pressure 
when the poorly dispersed fraction starts to deagglomerate (the delayed unit), or 0 if 
x<xw. All the formulations with the exception of SX:CL showed the plateau between 
the easily and the poorly dispersed fraction, with SS:CL showing the highest 
pressure value. This suggested that this particular formulation required the highest 
pressure to deagglomerate. The addition of FL led to a greater deagglomeration as 
the pressure (xw) decreased by 1 unit. Furthermore, the corresponding % 
deagglomeration to xw was the highest between all the formulations (Table 4.8). 
 
SEM was used to study the morphology of the APIs and blends. Unlike some 
studies have suggested [109, 213], SS did not exhibit a plate-like shape, whereas 
both APIs created elongated agglomerates without clear differentiation in their shape 
(Figure 4.10).  Moreover, When added to coarse lactose, no difference in the APIs’ 
distribution was seen on the surface of the carrier (Figure 4.11). This particle 
behaviour is different to what is proposed in the literature. Begat et al suggested that 
SS distributes evenly on the surface of the carrier [109], whilst SX that created 
agglomerates due to the fact that SX–lactose blends are dominated by SX cohesive 
interactions [99]. However, this is not showed in the current work. Nevertheless,  
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clearly different re-distribution of the APIs with the lactose was seen when FL was 
added to the mixture (Figure 4.12). The agglomerates of FL-SX were clearly not 
distributing homogenously on the lactose surface, presenting larger agglomerates on 
the extremities of the carrier compared to when FL was absent in the formulation. 
This was probably due to the weak adhesion of FL to the carrier surface, and 
therefore, its tendency to agglomerate with SX [98]. This suggests that SX-FL have 
stronger adhesion than FL:FL. The same tendency to create agglomerates was seen 
for FL-SS. The maximum gradient value for SS:FL (Table 4.7) was greater than 
SX:FL, suggesting that the deagglomeration of the former was enhanced in 
presence of the fine lactose that can be seen also when the coarse carrier is present 
(e.g. % relative deagglomeration in Table 4.8). The SX:FL agglomerates did not 
redistribute on the lactose surface, but in the spaces between carrier particles 
showing a greater amount of “free” agglomerates for SS:FL than SX:FL. This might 
explain the greater % deagglomeration seen for SS:FL:CL than SX:FL:CL (Table 
4.8) as less energy is required to release the agglomerates form the carrier surface. 
However, the adhesion between SS and lactose carrier does require higher flow 
rates to be overcome (xw= 3.0 ± 0.3 for SS:CL in Table 4.8). 
 
In order to understand impaction data and correlate to the empirical model 
proposed, SEM was also used on the powder deposited on specific stages of the 
NGI (device, Cheng 2, throat, pre-separator, stage 5). No great difference was seen 
between SS:CL and SX:CL when deposited in each stage between Cyclohaler® 
tested alone and when Cheng 2 was employed. However, slightly difference of the 
effect of the fine lactose when added to the formulation was seen for SX:FL:CL 
(Figure 4.15 and Table 4.8). It appeared that individual SX particles remain in the 
capsules compared to SS (Figure 4.13). The Cheng 2 is known to retain big 
agglomerates. This is shown by the SEM images (Figure 4.15) and cascade 
impactor studies (retention within Cheng 2 for 65.54 ± 10.08 for SS:CL and 67.82 ± 
10.24 for SX:CL at 4 kPa). This helps to decrease the IP-PS deposition of the 
formulation. However, as already seen in Chapter 3 with Cyclohaler/SS and 
Accuhaler SX/FP, SS:CL and SX:CL emitted from the Cheng 2 showed a different 
deposition in the throat and pre-separator stages (Table 4.3). This was confirmed by 
SEM, as shown in Figure 4.17. Small agglomerates of SX were detected in the USP 
throat with size less than 10 µm. Aersolization studies showed the IP/PS deposition 
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was doubled when SX:CL was emitted from the Cheng 2 than SS:CL (29.65 ± 4.82 
for SS:CL vs. 58.71 ± 8.30 for SX:CL at 4 kPa). The rotation of the capsules 
increases the deagglomeration process [164]. Large agglomerates tend to be 
deagglomerated better during aerosolization than small agglomerates as the contact 
surface is smaller. 
 
The addition of fines together with the presence of coarse carrier might 
increase the deagglomeration due to the fact the particle-particle collisions increase 
in these types of formulation rather than when only CL is present [203]. This was 
confirmed by both aerosolization studies and FPR1.5 (Table 4.4) of SX:FL:CL and 
SS:FL:CL emitted from Cheng 2. Collection of carrier particles was seen in the 
spacer (Figure 4.15), that prevented their deposition in the throat (Figure 4.17). 
Compared to SX:FL:CL, when Cheng 2 was employed, SEM showed the lack of 
agglomerates in the spacer for SS:FL:CL (Figure 4.15). This indicates the fine 
particles are removed from the carrier leading to slightly higher respirable fraction for 
this formulation rather than SX:FL:CL (81.83 ± 4.11 and 76.66 ± 1.35 at 4 kPa, 
respectively). This is in accordance with Adi et al [98] who showed less fine particle 
detachment from the carrier for low % of SX with FL. The particles adhered to the 
wall of the gelatine capsule and the inhaler used in the study, causing a low FPF of 
SX. Although, the difference in the SEM for stage 5 between devices and blends is 
not very clear, higher % deagglomeration for SS:FL:CL formulation was seen than 
SX:FL:CL (61.4 ± 2.6 vs. 48.7 ± 1.8, respectively, Table 4.8). Nevertheless, the 
FPR1.5 was greater for SX blends than SS blends (Table 4.4). However, when the 
fines (SX and FL) concentration was increased, a better detachment from the lactose 
and a greater amount of agglomerates was seen in stage 1 of the twin-stage 
impinger, because of saturation of the active sites on the carrier[98]. This led to a 
better interaction between SX and FL causing agglomeration and surface 
detachment. The authors proposed this is due to the fact that adhesion force 
between SX-CL was lower than SX-SX and SX-FL [98]. This potentially shows the 
strong cohesive behaviour of SX particles that is likely to create agglomerates. 
However, SEM was not a successful technique to help understand the 
deagglomeration extent of formulation, although it is was a useful tool for assessing 
particle morphology. 
177 
 
 
4.6. Conclusion 
This chapter has shown that the cyclone spacer Cheng 2 does behave in a different 
manner for different formulations, despite using the same inhaler to emit the blend. 
Higher deposition in the IP/PS stages was seen for SX:CL and SX:FL:CL when 
Cheng 2 was employed, leading to a lower FPF (%sED) than SS:CL and SS:FL:CL, 
but higher deagglomeration (FPR1.5). This was suggested by SEM studies only for 
SS:FL:CL which showed a greater number of free agglomerates in the formulation 
than SX:FL:CL, leading to higher dispersion of the micronized material. Moreover, an 
empirical model has been suggested as a fast approach to understand 
deagglomeration behaviour of the formulation that enters the spacer which could 
guide future mixture preparation and design of new cyclone geometry. The empirical 
parameterization described agglomerate structure and deagglomeration 
mechanisms. The micronized particles showed different deagglomeration processes 
to each other suggesting variability in agglomerate size and strength between 
agglomerates. On the other hand, the presence of the coarse carrier and fine lactose 
did modify the deagglomeration process suggesting that two different type of fraction 
of dispersed particles can be identified when increasing the pressure drop.  
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5.1. Development of a strategy to determine the influence of inter-patient variability 
on the product performance of dry powder inhalers 
 
5.1.1. The importance of device choice in patient disease management 
Although asthma and COPD (chronic obstructive pulmonary diseases) affect 
almost 6% of UK population, there is not exact definition for the former, whilst 
patients with COPD are affected also by heart problems and the cost of 
management is increasing due to the poor disease control [68]. The causes of poor 
management are many such as underestimated symptoms, lack of adherence of the 
patients or incorrect use of the available inhalers [74, 132, 135]. To overcome the 
adherence issue, a constant improvement of the device design has been recently 
made by pharmaceutical innovators and engineering design companies, such as 
GSK (Ellipta), Pfizer (Exubera), Novartis (Breezehaler) or Team Consulting 
(StarHaler). The main problem is that patients have difficulties in using the 
appropriate technique through their device [69, 74]. The majority of the patients is 
not aware of the different techniques in using MDIs (metered dose inhalers) or DPI 
(dry powder inhalers), resulting in the dose delivered to the lungs being 
compromised [69]. For an MDI a slow and deep manoeuvre is needed when inhaling 
the formulation, whilst for DPIs, a fast and deep inhalation is required in order to 
create turbulent energy for aerosolization of the dose [74]. 
 
5.1.2. Inspiratory airflow power and guidance for inhaler selection 
The ability of an individual to inhale with sufficient strength through an inhaler, 
especially dry powder inhalers (DPI), depends on both the lung function and device 
design [84]. The device design creates a resistance to the air that is almost a 
fingerprint for each inhaler and a wide range of resistances can be achieved [85]. 
Typically, high flow rates are achieved through DPIs such as Diskus and Aerolizer 
which have low resistance compared to high resistance DPIs such as Easyhaler, 
Turbuhaler and Handihaler [81, 85]. In vivo studies [84, 125, 236] suggested that 
prolonged peak inspiratory flow (PIF) is achievable with high resistance device, 
although some patient might find it uncomfortable. Many studies report both high 
inter and intra-patient flow rate variability that leads to a variable respirable dose and 
its particle size [12]. It has been shown that the delivered dose and the de-
180 
 
aggregation force depend on the full inhalation manoeuvre of the patients and not 
only on the peak inspiratory flow [126]. Using simulated patients’ inhalation profiles, 
Kamin et al. [12] tested the variability of the mass output and mass median 
aerodynamic diameter (MMAD) from two DPIs (Turbuhaler and Accuhaler). The 
Turbuhaler showed the highest variance in particle output with range of fine particle 
fraction (FPF) between 3.4% to 22.1% of label claim (at 30 and 75 Lmin-1, 
respectively), whereas the Diskus was less dependent on variations (10.6% to 
18.5% of label claim) [12]. 
 
Some studies [237, 238] have focused their aims on assessing the peak 
inspiratory flow (PIF) of a group of COPD (chronic obstructive pulmonary disease) 
patients through particular devices. Dewar et al. [238] suggested that some patients 
can inhale correctly through the device provided (e.g. Turbuhaler for COPD patients) 
and Janssens et al. [237] suggested that, especially in elderly patients, the flow rate 
achievable could be compromised probably due to the high resistance of the inhaler 
prescribed. Other groups [239, 240] have focused their work on creating or collecting 
inhalation profiles for in vitro testing of inhalers. Therefore, the inhalation manoeuvre 
is important to consider when choosing the appropriate device. Some studies in the 
US and in the EU have been completed [13, 241] on collection of inhalation profiles 
through specific devices. The authors used a pneumotrac spirometer attached to 
marketed devices and measured the inhalation profile using the inhalation manager 
(i.e. a computer-controlled flow-volume simulator). Although their methods gave 
interesting information regarding the inhalation profiles, it required multiple inhalers 
with placebo or medicine. Sometimes a propellant might be involved that can 
increase the risk of having aerosol impacting on the patient’s throat. 
 
5.1.3. Incorporating patient performance when assessing product performance 
The British and US Pharmacopoeia [147] stated that the aerosol deposition 
from an inhaler needs to be tested at a constant flow. This is mainly for quality 
control purposes. However, it does not represent the actual use of inhalers, as 
patients do not inhale with a constant flow. It has been reported [12, 13] that the 
inhalation manoeuvres of a patient consist of an initial flow acceleration, when the 
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dose is usually delivered [126], a maximum peak inspiratory flow that is the  
maximum flow that the patient achieves, and a deceleration of the flow, that indicates 
the manoeuvre is terminated. As the assessment of the dose deposition is important 
to be tested at constant flow, the full inhalation profile needs to be taken in 
consideration, too (e.g. Figure 5.1). 
 
Figure 5.1. Inhalation profile and peak inspiratory flow of a healthy volunteer through Cheng 2 
spacer-device. 
 
Studies showed that patients are able to maintain the PIF for longer when the 
resistance of the device is high [13, 125, 236] rather than when the resistance is low. 
Also, the dose is released rapidly for devices such as Diskus and Turbuhaler, 
although the dose emitted from capsule-containing devices such as the Cyclohaler is 
released over a longer period of time [242]. It has been shown that the powder 
emptying rate from inhalers appears to increase when the acceleration slope 
increases [243]. 
Parameters, such as flow acceleration, inhalation volume, time to reach peak 
inspiratory flow, post peak deceleration [13] need to be considered when testing 
aerosol deposition. The electronic lung device (ELD) has been used [126, 127, 244] 
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in order to determine the aerosol deposition using both inhalation profiles and steady 
flow. The dose dispersion from the inhaler is driven by the patients’ profiles that can 
be loaded into the ELD, whilst the steady flow allows the particle size determination 
into the impactor [244]. However, inhalation profiles are required. In Figure 5.1 an 
example of inhalation profile is shown. 
 
Some authors [245] attempted to predict the slope of the inhalation pressure 
profiles using the PIFs through inhalers. Correlation was seen between PIF and 
slopes for Diskus and Turbuhaler (13.5 ± 5.0 and 13.8 ± 4.7 kPa s-1, respectively) 
[245]. The authors suggested that PIF could be used to predict the inhalation slope if 
the inhaler resistance is known. However, they pointed out that for a given PIF, a 
wide range of slopes can be achieved. Previous studies recorded inhalation profiles 
through inhalers such as Turbuhaler and Diskus [246] to assess the ex-vivo 
performance of the inhalers. Variability was seen within inhalers. Diskus showed a 
more accurate and reproducible dose emission across the range of tested flow rates 
than Turbuhaler [152] and the latter trend was seen regardless of the inhalation 
profile used [246]. The Turbuhaler delivered only 68.1% of the labelled dose when 
inhalation profiles of COPD patients were used and a correlation between total 
emitted dose or fine particle mass with PIF showed that the Diskus performed 
independently of the PIF unlike the Turbuhaler [246]. Other authors have studied the 
change in the particle size when using a constant flow or an inhalation profile. Finlay 
et al [247] suggested that the aerosol particle size is unchanged when peak 
inspiratory flow is chosen instead of the breath simulated profiles as long as the flow 
rates are set as near as possible of the PIF achieved in the profile. 
 
5.1.4. Throat models for in vitro studies (AIT) 
The use of human mouth-throat cast models (e.g. Alberta Idealized Throat, AIT) 
have started to appear in published papers [183-186] as a substitute for the USP 
throat for aerosolization studies with cascade impactors. The AIT was first proposed 
ten years ago by the Aerosol Research Laboratory at the University of Alberta, 
Canada[248]. The cast has been validated on computed tomography (CT) scans of 
human throats. Using the AIT would help the prediction of real mouth and throat 
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deposition and enable  a real comparison between in vivo and in vitro data [185, 
186]. Zhang et al [185] showed a good correlation between in vivo deposition of 
particles emitted from the Turbuhaler®  (65.8 ± 10.1%) and in vitro deposition using 
an idealized throat (67.8 ± 2.2 %,). A further, more recent study [249] reported that a 
good correlation between in vitro and in vivo lung and throat deposition was seen for 
marketed inhalers such as Handihaler, Diskhaler, Easyhaler, Turbuhaler and 
Aerolizer. Lung deposition was reported to be 17.3 ± 1.2%, 22.6 ± 1.1%, 29.0 ± 
1.1%, 28.0 ± 3.0%, 21.7 ±1.2%, respectively. The throat deposition followed a similar 
trend [249]. Other studies tested the mouth-throat cast at different flow rates [188, 
189] suggesting that small particle deposition decreased under a slow flow rate due 
to a low particle inertia values. Delvadia et al [250] tested inhalers with simulated 
inhalation profiles using an equation based on the PIFs (peak inspiratory flows) to 
extrapolate the full profile. However, the state of the disease of the patient needs to 
be considered, including how this affects their inhalation strength. Consequently 
accurate inhalation profiles need to be collected from the patients through each 
device used. 
5.2. Aims 
The aim of this chapter was to investigate the potential influence of flow-rate 
control with DPIs on potential disease management in asthmatic patients and those 
affected by COPD. This involved the collection of preliminary data on the future 
applicability of a diagnostic tool to guide DPI choice based on inhalation profiles 
achieved by asthmatic and COPD patients. It also involved establishing a 
methodology to assess the impact of patient-focussed aerosolization testing to 
improve inhaled product development. In Chapter 4, the potential of a cyclone 
spacer to mitigate flow rate dependence of particle size and respirable fraction was 
examined, revealing different behaviour depending on formulation and API (active 
pharmaceutical ingredient) choice. However, the biorelevance of employing constant 
airflow for aerosolization of DPIs needs to be considered. This chapter further aimed 
to pilot a more patient-relevant testing regime during device and product 
development in an ex vivo pilot study.  
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The objectives of the current work were: 
- To establish and pilot an inspiratory manoeuvre testing system and protocol 
using clinically-employed spirometry through the Cheng 2 spacer with healthy 
volunteers 
- To design a statistically appropriate study protocol and obtain ethical and 
R&D approval for a full clinical spirometry study in the NHS 
- To identify appropriate asthmatic (moderate, severe) and COPD patients and 
establish metrics that stratify inter-patient and inter-device variability in dry 
powder inhaler use. 
- To assess the difference in aerosol deposition when employing the Cheng 2 
spacer with the standard metric of square wave peak inhalation flow 
compared to a full inhalation profile. 
5.3. Materials and methods 
 
5.3.1. Materials 
 
Micronized salbutamol sulphate (SS, batch number B027798) was purchased from 
GlaxoSmithKline Research and Development (Ware, UK). Salmeterol xinafoate (SX) 
was purchased from Vamsi Labs Ltd (Solapur, India). Lactose monohydrate, 
chromatography grade methanol, hydrochloric acid solution (HCl) 5M, sodium 
hydroxide and n-Hexane were purchased from FisherScientific (Loughborough, UK). 
Fine lactose (LH300) was purchased from Friesland Foods (Netherlands). 
Hipersolv® grade ammonium acetate was purchased from Lab3 Ltd (Northampton, 
UK). A Luna 3 μm C18 column (150 mm x 4.6 mm x 3 μm) was obtained from 
Phenomenex (Macclesfield, UK). Silicone oil - Dow Corning Corporation 200® fluid 
was obtained from Sigma-Aldrich (Gillingham, UK). A Cyclohaler® device was 
obtained from AAH Hospital Supplies (Coventry, UK). Size 4 hard gelatine capsules 
were obtained from Meadow Laboratories Ltd. (Romford, UK). The cyclone spacer 
(Cheng 2) was manufactured in-house (University of Cambridge, UK) from a 
Perspex block (Engineering & Design Plastics Ltd, Cambridge, UK); the exit duct 
was cut and polished from stock brass tubing (Engineering Department Storeroom, 
University of Cambridge, UK). The flow meter (model number DMF2), next 
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generation impactor (NGI), Breath Simulator (BRS 3000), Albert Idealized throat and 
a model HCP5 vacuum pump were all purchased from Copley Scientific Ltd 
(Nottingham, UK).  
 
The spirometer (Vitalograph Pneumotrac) with software IV, filters and mouthpieces 
were kindly donated by Vitalograph (Buckingham, UK). A Pneumotrac 
(MasterScreen™ Pneumo Spirometer) was purchased from CareFusion 
(Basingstoke, UK) and a mouthpiece containing a rotating disk that contained holes 
that mimic the resistance of MDI, Turbuhaler and Accuhaler was removed from the 
In-Check Dial (Clement Clarke International Ltd., Harlow, UK). Clement Clark 
International kindly provided two devices that mimic the resistances of Handihaler 
and Aerolizer. Filters purchased from CareFusion (Basingstoke, UK) were used 
between patients to avoid microbial contamination. 
 
Statistical analysis including one-way ANOVA and post-hoc Tukey’s test (multiple 
comparisons) or Student’s two-tailed t-tests (paired and unpaired as appropriate) for 
pair-wise comparisons was performed in Minitab or OriginLab. 
 
5.3.2. Performance of in vivo measurements with healthy volunteers 
 
5.3.2.1. Ethical review and study protocol 
An internal ethical approval (number PHAEC/12-77) was obtained from the 
ethics committee (Professor Brown, Dr O’Neill, Dr Trainor, Mr Caserta, Mrs Fuller) in 
order to assess inhalation profiles of 10 healthy subjects through a cyclone-spacer 
prototype using the Vitalograph Pneumotrac spirometer. The participants were 
requested to fill in a questionnaire about their demographic data (weight, height, 
gender, age, smoking habit, previous attack of asthma) in order to ensure the health 
of the volunteers. Once the volunteers were identified, they were requested to 
perform a full lung function test (Section 5.3.2.2) and to breathe through a cyclone 
spacer (Engineering & Design Plastics, Cambridge, UK) attached to a spirometer in 
order to record an inhalation profile (Section 5.3.2.3). The volunteers were fully 
trained before performing the test. Exclusion criteria for participants were: 
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- Had a chest infection or were recovering from it.  
- Patients with pneumonia unless fully recovered from the condition  
- Patients who smoked unless free from smoking for 24 hours 
- Patients with pneumothorax  
- Patients with myocardial infarction within 8 weeks preceding the test 
- Patient with abdominal, chest, throat or eye operations within 6 weeks 
preceding the test 
- Patients with any form of aneurism  
- Patient with uncontrolled angina 
- Patients with uncontrolled blood pressure 
- Patients with asthma or chronic obstructive pulmonary disease 
- Participants, who when screened presented with a lung function test indicating 
obstruction or restriction (i.e. FEV1/FVC ratio less than 70%; FVC less than 
80% and FEV1 less than 80%). However, spirometry was carried out if at least 
5 weeks have passed from the last antibiotic treatment for chest infection. 
 
5.3.2.2. Full lung function testing 
Prior to the start of the test, weight, height, gender and ethnic background were 
recorded in the software (Spirotrac) to confirm the health of the volunteer. Then, the 
subject exhaled into a disposable filter (to avoid contamination between volunteers) 
in order to measure slow vital capacity (SVC), forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF). A minimum of 
three tests were measured. In order to define healthy volunteers, the ratio between 
FEV1 and FVC had to be > 0.7 and PEF> 75 % of the predicted value. The FVC had 
to be > 80% and FEV1> 80% of the predicted value [11]. The values were assessed 
in accordance to ATS/ERS (American Thoracic Society/European Respiratory 
Society) criteria. 
 
5.3.2.3. Collection of inhalation profiles and Peak Inspiratory Flow through 
Cheng 2 
Following lung function screening, the volunteers inhaled through the cyclone spacer 
attached to the spirometer to assess the inhaled volume (IV) and the peak 
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inspiratory flow (PIF) through the device and in order to record the inhalation profiles. 
A disposable mouthpiece (sterile plastic tubing) was attached to the cyclone to avoid 
contamination between volunteers (Figure 5.2). A minimum of three tests were 
measured for each volunteer and exported as an MS Excel spreadsheet. PIF was 
measured using the ATS equation from the inhalation profiles. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Diagram of how the in-vivo study was performed 
 
5.3.3. Clinical study 
5.3.3.1. NHS protocol 
An ethical and R&D approval (REC number: 13/LO/0970 and Study ID: 122645) 
was obtained through the Royal Brompton Hospital (Asthma Clinic, London) in order 
to recruit 80 patients (20 COPD and 20 mild, 20 moderate and 20 severe asthmatics, 
all adults) that were identified through medical records. For the purpose of this 
chapter, the data from only 20 severe asthmatics and 20 COPD patients were 
analysed due to failure to recruit sufficient numbers of patient to reach statistical 
power. The protocol was designed to identify patients through a clinician at the 
hospital who performed a full lung function test on the volunteers as a routine check. 
The volunteers were requested to inhale through 
an airflow-restricting device that mimics the resistance to airflow of marketed in order 
for their inhalation profile to be collected (Table 5.1). 
 
 
 
Subject
Disposable plastic tubing
Cyclone-spacer
Spirometer
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Table 5.1 Devices and their resistance to the air tested with patients. 
Device Resistance (kpa0.5L-1min) 
MDI No resistance 
Aerolizer 0.020 
Handihaler 0.048 
 
 
 
Participants were permitted to practice an inhalation manoeuvre under training prior 
to the recorded inhalation. The study was designed in a way that the patients would 
inhale air when performing the study as showed in above. No placebo powder or 
active pharmaceutical ingredient was used. Exclusion criteria for the patient 
recruitment to the clinical phase of study were identical to Section 5.3.2.1, above. 
Lung function testing was also performed as described in Section 5.3.2.2. 
 
5.3.3.2. Sample size selection 
The study was designed as a cross-over cohort observational study. Two 
statistical packages were employed for analysis. G*Power Ver. 3 (University of 
Duesseldorf) was used to assess the response of statistical power to effect size and 
sample number. Minitab Ver. 16.2 was employed to calculate statistical power. The 
data generated were assumed to represent a normal distribution of values. Literature 
review of clinical studies was performed to enable sample size analysis. The mean (
x ) and standard deviation (s) values were taken into account. The measured 
(estimated) difference was calculated using Equation 5.1: 
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Assuming a normal distribution, the individual sample means (
21, xx ) were estimates 
of the true population means (µ1, µ2). Hence the estimate of the differences between 
the means was also a normal distribution with a mean (µd) and a standard error 
(SEd) and variance (SEd)
2. The standard error of the difference can be calculated in 
Equation 5.2: 
 
   
2
2
2
2
2
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n
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n
s
SEd     (5.2) 
 
For ∆ to reach significance, the test statistic of d/SEd should be greater than the 
critical value |uα|. Here uα is a value selected such that the standard normal 
distribution (mean 0, variance 1) > |uα| with probability α. For example u0.05 = 1.96. In 
accordance with Bland et al [251] and Whitley et al  [251, 252] statistical estimates of 
effect size were calculated from the differences (∆)  through the calculation of 
standardized differences (Cohen’s effect size, [253]), d, according to equation 5.3 . 
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In the first approach, the pooled standard deviation was calculated according to: 
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Where n1, n2 are the numbers of patients and s1and s2 are the standard deviations 
reported for study group 1 and 2, respectively, from the literature values. In the 
second approach the largest standard deviation (smax) from the reported studies (e.g. 
when comparing PIFR for asthmatics through Turbuhaler vs. PIFR for asthmatics 
through Accuhaler) was employed in Equation 5.3, to provide the most conservative 
estimate of effect size (dmax). 
 
The sample size was determined for at a significance level of 0.05 for a statistical 
power of 0.8 and 0.9 using Equation 5.5: 
 
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The function f(α,p) is defined as: 
   2)1(2, Puupf       (5.6) 
Where the values for the f(α,p) function were obtained from literature [251, 252].  
 
5.3.3.3. Collection of inhalation profiles as a function of device resistance 
After assessing the severity of the disease, the patients were required to inhale 
through an airflow-restricting device consisting of a rotating disk with holes that 
mimic the resistance to the air of marketed inhalers, within a sealed mouthpiece. By 
rotating the disk, each aperture diameter was selected in turn, thereby providing a 
range of resistances. The inhalation volume and full profile were recorded using 
spirometry for each patient over an inhalation period (measured in seconds), until the 
patient felt comfortable to inhale. A disposable mouthpiece was attached to the 
airflow-restricting device that was changed between patients to avoid cross-
contamination. After the study the patients were rewarded economically. 
 
5.3.4. Impaction studies with Cheng 2 using Next Generation Impactor at peak 
inspiratory flow 
The formulations of SS:FL:CL and SX:FL:CL, prepared for the study in Chapter 
4, were tested using the Cyclohaler® at the PIF values corresponding to the 
population undersize 10th, 25th, 50th, 75th and 90th percentiles with the Cheng 2 in 
place according to Section 4.3.5. Prior to performing the measurements with the 
NGI, the desired flow rate was adjusted with a flow meter. 15 ml of mobile phase 
was added to the central cup of the pre-separator. Eight capsules were actuated at 
each flow rate. In order to collect the drugs, the Cyclohaler, with the capsules, were 
washed with 20 ml of mobile phase. The bottom of the cyclone was washed with 100 
ml, whilst the mouthpiece and the AIT (Alberta Idealized Throat) were washed with 
25 ml of mobile phase.The upper section of the cyclone was washed with 10 ml. For 
collecting the drugs from the pre-separator 50 ml of mobile phase was used. The 
volumetric flasks were sonicated (Kerry, Germany) for 2 min. Mobile phase (5 ml) 
was added to each stage to recover deposited drug. All the stages were set on a 
laboratory rocker (Stirling Mixer, Sandrest Ltd, UK) and rocked for 2 min in order for 
the solvent to wash the entire surface. The concentrations of the drugs from each 
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stage were determined by HPLC assays as described in Chapter 2, Section 2.3.3 
and Chapter 3, Section 3.3.3. After performing the experiments, each stage and the 
NGI were thoroughly cleaned with Millipore water and the coating was removed with 
acetone before rinsing with methanol. 
 
 
5.3.5. Impaction studies with Cheng 2 using Next Generation Impactor with 
inhalation profiles 
 
The inhalation profiles collected from the healthy volunteers through the spacer were 
uploaded in the Breath Simulator 3000 (Copley, Nottingham, UK). Prior to the test, 
the PIF from each profile was set with a vacuum pump at the outlet of the breath 
simulator attached to the NGI. With an air compressor, the flow was then set to zero 
to avoid air leak between actuations (Figure 5.3).  
 
 
Figure 5.3. Breath simulator 3000 attached to a next generation impactor. 
 
 
The inhalation profiles which possess the PIF corresponding to the 10th, 25th, 50th, 
75th and 90th percentile of PIFs of the population were employed. The Cheng 2 was 
used attached to the Cyclohaler. The same method was used as described in 
Section 5.3.4. 
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5.4. Results 
5.4.1. Performance of in vivo measurements with healthy volunteers 
5.4.1.1. Full lung function testing 
All the volunteers utilized for the project were healthy (using the FEV1/FVC being 
> 0.7) as demonstrated by the SVC, FEV1 and PEF values in Table 6.2 (n=10). 
 
Table 5.2. Table of parameters used to define healthy volunteers (FEV1= forced expiratory volume in 
1 sec; PEF = peak expiratory flow, SVC =slow vital capacity). 
Parameters Values (mean ± SD) 
Female 5 
Male 5 
Smokers 0 
FEV1 % predicted 104.14 ± 8.51 
PEF % predicted 103.87 ± 9.15 
SVC 4.43 ± 0.87 
 
5.4.1.2. Collection of inhalation profiles 
The 10 volunteers were requested to inhale through the cyclone at maximal 
effort but not to cause discomfort [125]. Each volunteer repeated the inspiratory 
manoeuvre 3 times and the average result was 72.07 ± 12.03 Lmin-1 with an inhaled 
volume of 2.96 ± 0.64 litres (n = 30). Cumulative frequency analysis (Table 5.3 and 
Figure 5.4) showed that one quartile of the volunteers was able to breathe through 
the spacer with a PIF greater than 79.93 Lmin-1whilst the lower quartile used a PIF of 
65.55 Lmin-1or less. However, half of the volunteers managed to breathe with a PIF 
greater than 72.65 Lmin-1. A wide range of flow rates were achievable with the 
Cheng 2 in the healthy population. In Figure 5.5 representative inhalation profiles 
through the Cheng 2 are shown. 
 
Table 5.3. Values of peak inspiratory flow through the cyclone for 10%, one quartile, three quartile, 
half and 90% of the volunteers. 
10% 25% Median 75% 90% 
52.83Lmin-1 65.55 Lmin-1 72.65 Lmin-1 79.93 Lmin-1 89.1Lmin-1 
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Figure 5.4. Cumulative frequency distribution of peak inspiratory flow rates achieved through the 
cyclone (n=30). 
 
Figure 5.5. Representative inhalation profiles of a healthy volunteers through the Cheng 2 spacer-
device. 
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5.4.2. Statistical design to measure inspiratory performance through dry powder 
inhalers using a clinically-applicable spirometry tool. 
In order to establish an appropriate sample size a survey was conducted of 
previous similar studies from the literature where inhalation by patients through 
various devices was studied. The majority of the data were reported as mean ( x ), 
standard deviation (s) and sample size (n) (Table 5.4). As the study was a cross-
over cohort observational study the differentiating power was increased by allowing 
paired comparisons both within homogeneous groups and between heterogeneous 
groups. The study does not rely on independent group comparisons. A single metric 
from the inhalation profile (peak inspiratory flow rate, PIFR) has been used to assess 
the appropriateness of an emitted aerosol for inhalation therapy. Therefore the PIFR 
and the fine particle mass/fraction (i.e. that portion of the dose which is suitable for 
inhalation) were examined to assess the statistical power and an appropriate sample 
size for comparisons of relevance. The data from review of the cited studies are 
presented in Table 5.4. 
 
The study’s aim was to recruit equal numbers of patients for study in each 
group. Furthermore, it was clear from comparison of previous studies (Table 5.4), 
that variance in the sample estimates was not identical between study groups or 
conditions. Therefore, to provide the most conservative estimate of SEd for sample 
size determinations, the largest value of the s of any two groups being compared 
was chosen (e.g. PIFR for asthmatics through Turbuhaler compared to PIFR for 
asthmatics through Accuhaler). The differences (∆) from published reports as 
estimates of the anticipated differences in the current study along with their SEdiff, 
Cohen’s effect size (d) and the most conservative effect size (dmax) are presented in 
Table 5.5 and the sample size and study power were determined for a significance 
level of s = 0.05. 
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Table 5.4. Sample mean values (?̅?), standard deviation (s) and sample number (n) from previous 
literature reports into inhalation performance through inhaler devices.  COPD: chronic obstructive 
pulmonary disease, PIFR: peak inspiratory flow rate, FPM: fine particle mass following aerosolization 
and FPF: fine particle fraction following aerosolization. 
   𝒙 s n 
Combined asthma & COPD, PIFR through devices [13]    
  Turbuhaler 65.1 (Lmin
-1
) 21.1 262 
  Accuhaler 103.3 (Lmin
-1
) 42.0 341 
Uncategorized COPD, PIFR through devices [81]
 
   
  Turbuhaler 47.8 (Lmin
-1
) 14.7 163 
  Accuhaler 57.5 (Lmin
-1
) 17.9 163 
  Handihaler 28.6 (Lmin
-1
) 10 163 
Uncategorized asthma, PIFR through devices [254]
 
   
  Turbuhaler 76.8 (Lmin
-1
) 26.2 20 
  Accuhaler 94.7 (Lmin
-1
) 32.9 20 
PIFR for Turbuhaler, comparing diagnosis [13, 254]
 
   
  Asthma 76.8 (Lmin
-1
) 26.2 20 
  COPD 47.8 (Lmin
-1
) 14.7 163 
PIFR for Accuhaler, comparing diagnosis [13, 254]    
  Asthma 94.7 (Lmin
-1
) 32.9 20 
  COPD 57.5 (Lmin
-1
)  17.9 163 
PIFR for grouped asthmatics & COPD [245]
 
   
  Turbuhaler 76.1 (Lmin
-1
) 13.8 58 
  Accuhaler 108.3 (Lmin
-1
) 20.4 58 
PIFR for Turbuhaler: 4-year olds compared to 8-year olds 
as a surrogate measure for lung function/capacity [255]
    
  4 years 53.0 (Lmin
-1
) 23.0 18 
  8 years 76.0 (Lmin
-1
) 10.0 20 
PIFR for Accuhaler: 4-year olds compared to 8-year olds as 
a surrogate measure for lung function/capacity [255]
    
  4 years 70.0 (Lmin
-1
) 23.0 18 
  8 years 105.0 (Lmin
-1
) 14.0 20 
FPM when inhalation profiles tested ex vivo for Accuhaler: 
4-year olds compared to 8-year olds as a surrogate 
measure for lung function/capacity [255]
 
   
  4 years 
15.0 (µm) 
2.0 18 
  8 years 18.0 (µm) 2.0 20 
FPM when inhalation profiles tested ex vivo for Turbuhaler: 
4-year old compared to 8-year olds as a surrogate measure 
for lung function/capacity [255]
 
   
  4 years 21.0 (µm) 10.0 18 
  8 years 32.0 (µm) 9.0 20 
Uncategorized asthma, FPM when inhalation profiles 
tested ex vivo [254]
    
  Turbuhaler 20.4 (µm) 4.8 20 
  Accuhaler 23.1 (µm) 12.9 20 
Table 5.5 . Measured difference (d) and standard error of the difference (SEdiff) and effect sizes (d 
and dmax) for literary comparisons in peak inspiratory flow values (PIFR). COPD is chronic obstructive 
pulmonary disease. 
   Δ SEdiff D dmax 
To compare PIFR between Turbuhaler 
& Accuhaler in asthmatics & COPD 
patients [13] 
38.2 (Lmin
-1
) 2.6 1.11 0.91 
To compare PIFR between two 
devices in uncategorized COPD 
patients [81]
 
    
 Turbuhaler vs Accuhaler 9.7 (Lmin
-1
) 1.8 0.59 0.54 
 Turbuhaler vs Handihaler 19.2 (Lmin
-1
) 1.4 1.53 1.31 
 Accuhaler vs Handihaler 28.9 (Lmin
-1
) 1.6 1.99 1.62 
To compare PIFR between Turbuhaler 
& Accuhaler in uncategorized 
asthmatics patients [254]
 
17.9 (Lmin
-1
) 9.4 0.62 0.54 
To compare PIFR between Turbuhaler 
& Accuhaler for patients with 
uncategorised lung disease [256]
 
32.2 (Lmin
-1
) 3.2 1.87 1.58 
To compare PIFR between asthmatics 
and COPD patients for a specific 
device [81, 254] 
    
 Turbuhaler 29.0 (Lmin
-1
) 6.0 1.79 1.11 
 Accuhaler 37.2 (Lmin
-1
) 7.5 1.87 1.13 
To compare PIFR between lung 
function for a specific device [242] 
     
 Turbuhaler 23.0 (Lmin
-1
) 5.9 1.36 1.00 
 Accuhaler 35.0 (Lmin
-1
) 6.3 1.91 1.52 
 
 
From Table 5.5, it is clear that the required sample size for group comparative 
studies ranges is subject to a wide degree of variability in estimated effect size from 
a low of 0.54 [81] to a high of 1.62 [81]. This was expected to lead to a disparity 
between the estimated sample size required for some comparisons when the various 
studies are examined. The response of sample power to effect size was determined 
for total sample sizes ranging between 80 and 160 patients (Figure 5.6). In the 
current study, it was proposed that 20 patients would be recruited for each category 
of lung disease (i.e. a total of 80 patients). It is clear that for the lowest effect size 
(dmax = 0.54) a large sample size of >55 patients per treatment arm would be 
required to achieve statistical power of 80 % with an independent comparison of 
mean PIFR for two devices. However, the cross-over design ensures 80 patients in 
each measurement arm (equivalent to a total of 160 patient comparisons). Pooling 
standard deviation when comparing two different devices in the same patient 
population may not be a suitable approach due to the potential for vastly different 
variability in the data (cf. SEdiff in Table 5.5). To account for this and provide the most 
discerning test for difference, the mean PIFRs for two devices in the heterogeneous 
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patient group are compared as independent means. From Figure 5.6, when the 
assumption was applied to the 80 patient-comparison, the study design provides for 
in excess of 80 % power at the 5 % confidence interval even with the low d = 0.54. 
 
 
Figure 5.6. Simulation of effect size (Cohen’s d value) on the statistical power at a confidence level of 
α = 0.05 for a two-tailed independent t-test comparing mean PIFR between two different devices total 
sample of 80 (red), 90 (blue), 100 (green) 100 (yellow), 120 (purple) and 130 (cyan) patients. 
The design of the current study employs a paired analysis, thereby offering 80 
uncategorised patients per device (i.e. 20 mild, 20 moderate, 20 severe, 20 COPD). 
From Figure 5.7, it is clear that the 80 patients achieved by pooling patients from all 
four groups together would achieve a power in excess of 90 %. Within a 
homogeneous treatment group, it would be expected that the effect of changing 
device would be lowest for mild asthmatics, but highest for severe asthmatic 
patients. The simulation performed assuming the lowest effect size  of any of the 
reported studies (dmax=0.54) was chosen to represent the mild asthmatic group and 
also to account for the fact that the COPD group to be recruited is likely to be 
heterogeneous in their disease state. In considering the effect of changing the device 
on PIFR (Figure 5.7, red) it is clear that a sample size of 26 patients would be 
sufficient to determine differences at 75 % power within the classified groups. 
However, cross comparison of all three studies indicates that in actual fact a dmax> 
0.54 is to be expected in a homogeneous patient group and therefore recruiting 20 
subjects in each disease severity category would provide for sufficient statistical 
power using the proposed design. 
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Figure 5.7. Simulation of effect sample number on the statistical power at a confidence level of α = 
0.05 for a two-tailed paired t-test comparing mean PIFR between two different devices for an effect 
size of sample of 0.54 (red), 0.64 (blue), 0.74 (green), 0.84 (yellow) and 0.94 (purple). 
 
The change in PIFR when using the same device in a sample of asthmatics 
compared to a sample of COPD patients is presented in Table 5.5. It can be seen 
that even comparing two heterogeneous patient populations (i.e. uncategorised 
asthma and uncategorised COPD), the disease state is predicted to have a large 
effect on the PIFR. Employing the lowest dmax value (1.11) would result in a power > 
99 % (Figure 5.7) for comparing a group of 20 asthmatics with 20 COPD patients in 
the current study. The strength of the latter observations suggests that a sample size 
of 20 patients in each disease group would provide for a sufficiently powered study 
to assess differences between disease state and PIFR for a particular device. The 
stratification of patients into homogeneous groups defined by disease severity was 
assessed using a surrogate marker for lung function/capacity (i.e. age) is considered 
for children (Table 5.5), since the latter population shows highly variable inhalation 
abilities [255]. In this instance the lowest effect size observed was 1.00 (comparing 
the same device between two age groups) and a sample size of 20 patients in each 
group would provide a power of 86.9 % when comparing independent means. Thus 
classification of patients into categories of disease severity (i.e. mild, moderate, 
severe asthmatics and COPD patients) provides a sufficient statistical power for the 
most conservative estimates of effect size (d & dmax), both for paired group (device-
199 
 
device) and unpaired group (disease condition-disease condition) comparisons when 
studying inhalation profiles in asthmatic patients. 
 
5.4.2.1. Inhalation performance and parameterisation of patients with lung 
disease 
The full lung function testing (FEV1, forced expiratory volume in 1 s, FVC, 
forced vital capacity and the ratio of the two values) are reported in Table 5.6.  
 
Table 5.6. Forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC) and ratio between 
FEV1 and FVC for COPD and severe asthmatics patients involved in the study (mean ± SD, n=20). 
Parameters COPD Severe asthma 
FEV1 (% pred) 54.79 ± 26.61 63.21± 27.09 
FVC (% pred) 87.79 ± 27.87 80.89 ± 24.27 
FEV1/FVC (%) 62.13 ± 18.19 77.52 ± 23.51 
 
In Figure 5.8 (A, B) a representative inhalation profile for each ‘device’ resistance is 
presented for the two groups of patients.  
 
 
Figure 5.8. Representative inhalation profiles against time through resistance simulating a low 
resistance device (red), the medium resistance device (blue) and the high resistance device (green) 
devices  a COPD patient (A) and a severe asthmatic patient (B).  
 
The majority of the patients demonstrated inappropriate technique when inhaling 
through the low resistance device as shown in Figure 5.8 (black line). On the other 
hand, when testing the device with resistance of 0.04 kpa0.5L-1min a more prolonged 
flow was observed (Figure 5.8, blue line).  In Table 5.7, metrics recorded from the 
inhalation profiles of the patients and used for statistical analysis are reported. 
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Table 5.7. Values of peak inspiratory flow (PIF), inhaled volume (IV), time of 
inhalation, time to reach the PIF, PIF at 50,70, 90%, acceleration measured for two 
groups of patients through three inhalers (mean ± SD, n=20) 
 
Metrics 
Resistances 
(kpa
0.5
L
-1
min) 
COPD Severe asthma 
PIF (l/min) 
No resistance 147.57 ± 43.71 141.72 ± 53.21 
0.02 133.33 ± 43.30 133.44 ± 41.19 
0.04 82.51 ± 28.64 77.89 ± 28.05 
IV (L) 
No resistance 2.39 ± 0.95 2.09 ± 0.72 
0.02 2.51 ± 0.96 2.06 ± 0.73 
0.04 2.09 ± 0.86 1.59 ± 0.68 
Time of inhalation (sec) 
No resistance 3.06 ± 1.36 1.89 ± 1.01 
0.02 3.02 ± 1.90 1.85 ± 0.97 
0.04 4.12 ± 1.88 2.78 ± 1.81 
Time to PIF (sec) 
No resistance 0.72 ± 0.73 0.71 ± 0.44 
0.02 0.83 ± 1.89 0.64 ± 0.54 
0.04 0.82 ± 0.95 0.78 ± 1.09 
Time above 50% (sec) 
No resistance 1.22 ± 0.50 1.03 ± 0.44 
0.02 1.14 ± 0.43  1.02 ± 0.30 
0.04 1.58 ± 0.62 1.41 ± 0.54 
Acceleration50 (l/sec
2
) 
No resistance 7.26 ± 5.15 7.45 ± 5.91 
0.02 8.35 ± 5.22 8.59 ± 5.44 
0.04 4.04 ± 2.33 4.65 ± 2.64 
Acceleration70 (l/sec
2
) 
No resistance 7.37 ± 4.92 7.35 ± 5.47 
0.02 6.97 ± 3.51 8.29 ± 5.07 
0.04 2.92 ± 1.55 4.21 ± 2.27 
Acceleration90 (l/sec
2
) 
No resistance 6.08 ± 3.46 5.98 ± 3.97 
0.02 8.09 ± 4.39 6.83 ± 4.90 
0.04 3.74 ± 2.04 3.40 ± 1.80 
Acceleration (l/sec
2
) 
No resistance 4.87 ± 2.90 4.52 ± 2.68 
0.02 5.42 ± 3.15 5.32 ± 3.82 
0.04 2.47 ± 1.32 2.83 ± 1.67 
 
 
The PIFs achieved for the low resistance device were high compared to the DPIs 
used due to the patients’ poor inhalation technique. However, for within disease 
group comparisons, patients inhaling through the medium resistance device (e.g. 
Aerolizer), achieved a greater PIF and IV than following inhalation through the high 
resistance device (e.g. Handihaler, paired t-test, p<0.05, Table 5.7). No significant 
difference was seen when any specific inhaler was compared between asthmatics 
and COPD patients (unpaired t-test, p>0.05, Figure 5.9). A similar trend to the PIF 
was observed for the high IV achieved by the patients for a medium resistance 
device compared to high resistance device. Unlike the PIF, a significant difference 
was seen for IV between disease groups for the medium and the high resistance 
device (unpaired t-test, p<0.05, Table 5.7).  
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Figure 5.9.Statistical analysis of PIF (peak inspiratory flow) on MDI (A), Aerolizer (B) and Handihaler 
(C) between groups of patients (mean ± SD, n=20). 
 
Interestingly patients affected by COPD had a longer inhalation time for all the 
inhalers than asthmatic patients (p<0.05, Table 5.7) and, in addition, a longer 
inhalation manoeuvre for the highest resistance device (p<0.05, Table 5.7). No 
statistical difference was observed for the % of PIFs (Table 5.7, p>0.05) between 
diseases, although the % of PIFs were greater for the no resistance device 
compared to the medium resistance device and then high resistance inhaler within 
the same patient group. The same trend was observed when the acceleration was 
analysed, although no statistical significance was observed for inter-disease group 
comparisons for any specific device and inter-device comparisons for a particular 
patient group for time to reach the PIF (p>0.05, Table 5.7). Moreover, higher 
acceleration was observed during the inhalation profiles for both groups of patients 
when the resistance of the device decreased (Table 5.7). 
 
5.4.3. Aerosolization studies with Cheng 2 at peak inspiratory flow 
Aerosolization studies of SX:FL:CL and SS:FL:CL were performed using the 
NGI with the AIT at the PIF of the 10th – 90th percentile of the population. The PIF 
identified were 52.83 Lmin-1 for 10 %, 65.55 Lmin-1 for 25 %, 72.65 Lmin-1 for 50 %, 
79.93Lmin-1 for 75 % and 89.1 Lmin-1 for the 90th percentile. The Cyclohaler was 
used in series with the Cheng 2. The recovery was within the pharmacopoeial limits 
COPD patients Severe asthmatics
MDI
A
COPD patients Severe asthmaticsB
Aerolizer
COPD patients Severe asthmaticsC
Handihaler
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for both drugs at each flow rate (e.g. 75.16 ± 0.34% – 76.34 ± 2.04 for SS:FL:CL and 
77.57 ± 2.44 % - 76.25 ± 1.29 % for SX:FL:CL% between 10th – 90th percentile of the 
PIFs). Similar to previous observations (Chapter 4) the emission from the Cheng 2 
was higher for SX:FL:CL (range: 16.02 ± 7.13 % to 16.51 ± 1.42 %) between the flow 
rates tested. For SS:FL:CL the % emission ranged from between 12.59 ± 0.95% to 
12.14 ± 0.94%. Although the emission form the Cheng 2 was higher for SX:FL:CL, 
the FPF (%sED) was lower for this blend than SS:FL:CL, due to a higher AIT 
deposition for the SX formulation (21.66 ± 3.02% at the 10th percentile) than SS 
where AIT deposition was not detectable at any flow rate tested. On the other hand, 
%FPF (ED) was almost unaltered between blends, whilst the FPD (especially for 10th 
and 90th percentile PIFs) showed differences between blends (Table 5.8). 
Table 5.8. Fine particle fraction (FPF) and fine particle dose (FPD) for salbutamol sulphate (SS): fine lactose 
(FL): coarse lactose (CL) and salmeterol xinafoate (SX): FL: CL emitted from the Cheng 2 in series with the 
Cyclohaler® at the peak inspiratory flow at 10
th
, 25
th
, 50
th
, 75
th
, 90
th
 percentile of the population (mean ±SD, n = 
4). 
Blends 
% of 
population 
Peak 
inspiratory 
flow (Lmin-1) 
% FPF 
(ED) 
% FPF 
(%sED) 
FPD 
(µg/ml) 
SS:FL:CL 
10 52.83 13.38 ± 2.63 86.71 ± 16.02 14.18 ± 0.44 
25 65.55 14.14 ± 5.58 99.93 ±0.08 13.29 ± 6.59 
50 72.65 14.71 ± 2.38 99.97 ± 0.03 15.62 ± 2.28 
75 79.93 18.57 ± 4.64 99.85 ± 0.15 16.33 ± 3.77 
90 89.10 16.96 ± 1.99 99.90 ± 0.03 16.28 ± 1.34 
SX:FL:CL 
10 52.83 17.05 ± 2.12 74.09 ± 5.12 15.96 ± 8.14 
25 65.55 16.25 ± 3.11 69.23 ± 3.75 18.70 ± 4.02 
50 72.65 19.23 ± 3.93 72.39 ± 3.92 21.50 ± 4.52 
75 79.93 17.78 ± 3.52 71.91 ± 1.97 20.34 ± 3.88 
90 89.10 14.72 ± 0.72 73.00 ± 3.05 15.52 ± 1.36 
 
The FPF (%ED) was calculated as a fraction of the particles emitted from the 
Cyclohaler entering the spacer. The almost unchanged FPF (%ED) was already 
seen for the Cheng 2 spacer in Chapter 4, Section 4.4.4. On the other hand, if FPF 
(%sED) is analysed, a difference is seen in the formulations (Table 6.8, SX < SS for 
low flow rate profiles), due to the deagglomeration process that occurs in the 
cyclone-spacer, already proposed in Chapter 4. 
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5.4.4. Aerosolization studies with Cheng 2 using inhalation profiles 
The inhalation profiles of healthy volunteers were collected through the Cheng 2 and 
tested in the NGI for SX:FL:CL and SS:FL:CL. The comparison of the aerosol 
deposition with the impactor was made when inhalation profiles were tested vs. PIF. 
The recovered dose was within the pharmacopoeial limits for both formulations (e.g. 
77.96 ± 2.44% for SS:FL:CL for the 10th percentile and 84.40 ± 5.93% for SX:FL:CL 
at 90th percentile). 
Table 5.9.% Emission (%sED) from the Cyclohaler in series with Cheng 2 and % AIT/PS Alberta 
idealized throat/pre-separator) deposition for salbutamol sulphate (SS): fine lactose (FL): coarse 
lactose (CL) and salmeterol xinafoate (SX):L fine lactose (FL): coarse lactose (CL)at the peak 
inspiratory flow (PIF) and inhalation profiles (IP) corresponding to the 10
th
, 25
th
, 50
th
, 75
th
, 90
th
 
percentile of the population (mean ±SD, n = 4). 
Blends % 
% Emission 
(%sED) from IP 
% Emission 
(%sED) from 
PIF 
AIT/PS 
deposition 
(%)from IP 
AIT/PS 
deposition 
(%)from PIF 
SS:FL:CL 
10 2.55 ± 1.00 12.59 ± 0.95 0.00 ± 0.00 0.00 ± 0.00 
25 5.46 ± 1.62 10.52 ± 4.09 0.00 ± 0.00 0.00 ± 0.00 
50 6.67 ± 3.75 10.66 ±1.52 0.00 ± 0.00 0.00 ± 0.00 
75 4.20 ± 1.29 13.62 ± 3.21 0.00 ± 0.00 0.00 ± 0.00 
90 2.13 ± 0.23 12.14 ± 0.94 0.00 ± 0.00 0.00 ± 0.00 
SX:FL:CL 
10 6.25 ± 2.01 16.02 ± 7.13 37.86 ± 6.93 21.66 ± 3.02 
25 3.46 ± 0.46 17.89 ± 2.98 25.41 ± 2.69 27.89 ± 3.32 
50 6.16 ± 0.56 20.89 ± 4.04 45.06 ± 1.27 30.14 ± 1.73 
75 8.00 ± 1.39 19.58 ± 3.46 40.45 ± 5.86 26.48 ± 2.04 
90 6.59 ± 1.06 16.51 ± 1.46 44.53 ± 0.99 25.45 ± 3.08 
 
The emission of the SX blend was higher than SS formulation (Table 5.9) when 
inhalation profiles were used. However, for both formulations, the % emission was 
dramatically reduced compared to when PIF were used. This probably occurred as, 
during the inhalation profiles, steady flow is not present. Instead, there are 
acceleration and deceleration phases. Therefore, there is probably lower force 
involved to aerosolise the particles. On the other hand, the IP/PS deposition for 
SX:FL:CL was higher when the inhalation profiles were used (p<0.05). Therefore, 
when the Cheng 2 was assessed with reproduced ‘real’ inhalation manoeuvres, the 
flow rate dependency of the throat deposition was not mitigated for low flow rates 
(10th and 25th percentiles, p<0.05). However, for flow rates above 70 Lmin-1, the 
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deposition on the throat did not vary between flow profiles. The % cumulative 
undersize collected form the PSD decreased when inhalation profiles were tested 
rather than when peak inspiratory flows were used for both formulations (Figures 
5.10 and 5.11). This is correlated with the difference in the % emission seen already 
(Table 5.9).  
 
Figure 5.10. Cumulative aerodynamic undersize (%) of SS:FL:CL of emitted dose from Cheng 2  
using inhalation profiles (A, Black: 10
th
, Red: 25
th
, Blue: 50
th
, Pink: 75
th
, Green 90
th
 percentile) and 
using peak inspiratory flow (B, Black: 10
th
, Red: 25
th
, Blue: 50
th
, Pink: 75
th
, Green 90
th
percentile) 
(mean ± SD, n = 4) 
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Figure 5.11. Cumulative aerodynamic undersize (%) of SX:FL:CL of emitted dose from Cheng 2  at 
inhalation profiles A, Black: 10
th
, Red: 25
th
, Blue: 50
th
, Pink: 75
th
, Green 90
th
 percentile) and using 
peak inspiratory flow (B, Black: 10
th
, Red: 25
th
, Blue: 50
th
, Pink: 75
th
, Green 90
th
percentile) (mean ± 
SD, n = 4) 
 
The FPF (%sED) were higher when PIF were tested compared to when 
inhalation profiles were used for both formulations (Table 5.10). The SX formulation 
showed a slightly higher FPF compared to SS:FL:CL when square wave flow profiles 
were used, although for the inhalation profiles of the 25th and 50th percentile PIF, SS 
showed a greater FPF than SX (Table 5.10). A similar trend was seen for the FPD, 
the dose respirable by the patients (Table 5.10). Clearly, the physico-chemical 
properties of the APIs affect the deagglomeration mechanism inside the Cheng 2. 
Furthermore, using a constant flow (e.g. PIF) would lead to a constant energy 
provision for the aerosolization of the particles, whilst, when employing a flow rate 
loop (e.g. an inhalation profile) the flow is no longer constant, as acceleration and 
deceleration are present. This would lead to decreased values for FPF and FPD 
when inhalation profiles are used. The Cheng 2 showed variable FPF and FPD 
especially at highest flow rates (75 and 90%, Table 5.10). As previously reported 
(Chapter 3 and 4), at high flow rates some uncontrolled vortex instability occurs 
inside the cyclone. 
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Table 5.10. Fine particle fraction < 5 µm (FPF5µm), Fine particle dose < 5 µm (FPD5µm), and Mass 
median aerodynamic diameter (MMAD) of salbutamol sulphate (SS)  and salmeterol xinafoate (SX) 
formulation with fine lactose (FL) and coarse lactose (CL) emitted from the Cyclohaler in sequence 
with the Cheng 2 at the peak inspiratory flow (PIF) and inhalation profiles (IP) of the % of the 
population (mean ± SD, n = 4). 
Blends 
Inhalation profiles of 
population (%) 
% FPF 
(ED) 
FPD 
(µg/ml) 
MMADs 
(µm) 
SS:FL:CL 
10 3.67 ± 1.46 3.42 ± 1.28 1.54 ± 0.23 
25 7.20 ± 1.85 6.70 ± 1.62 1.25 ± 0.08 
50 8.01 ± 3.89 8.04 ± 4.63 1.11 ± 0.29 
75 5.54 ± 1.75 5.44 ± 1.67 1.25 ± 0.07 
90 2.93 ± 0.23 2.33 ± 0.39 1.28 ± 0.13 
SX:FL:CL 
10 4.83 ± 2.00 5.70 ± 2.38 1.46 ± 0.11 
25 3.20 ± 0.37 3.88 ± 0.61 1.33 ± 0.10 
50 4.15 ± 0.45 5.63 ± 0.49 1.48 ± 0.02 
75 5.73 ± 1.35 7.06 ±  2.12 1.46 ± 0.13 
90 4.52 ± 1.12 4.78 ± 0.26 1.38 ± 0.02 
Blends PIF (Lmin-1) 
% FPF 
(ED) 
FPD 
(µg/ml) 
MMADs 
(µm) 
SS:FL:CL 
52.83 13.38 ± 2.63 14.18 ± 0.44 1.02 ± 0.09 
65.55 14.14 ± 5.58 13.29 ± 6.59 0.98 ± 0.12 
72.65 14.71 ± 2.38 15.62 ± 2.28 0.79 ± 0.06 
79.93 18.57 ± 4.64 16.33 ± 3.77 0.94 ± 0.07 
89.10 16.96 ± 1.99 16.28 ± 1.34 0.93 ± 0.04 
SX:FL:CL 
52.83 17.05 ± 2.12 15.96 ± 8.14 1.63 ± 0.38 
65.55 16.25 ± 3.11 18.70 ± 4.02 1.35 ± 0.08 
72.65 19.23 ± 3.93 21.50 ± 4.52 1.15 ± 0.17 
79.93 17.78 ± 3.52 20.34 ± 3.88 1.14 ± 0.03 
89.10 14.72 ± 0.72 15.52 ± 1.36 1.05 ± 0.08 
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When MMADs are considered (Table 5.10), Cheng 2 decreased the aerodynamic 
diameter of the emitted particles upon increasing the flow rates only for SX:FL:CL. 
When Inhalation profiles were used, the MMADs for the formulation did not change. 
On the other hand, unaltered MMADs was seen for SS at PIFs unlike when 
inhalation profiles were used. 
 
5.5. Discussion 
 
The design of the inhaler plays a major role on its resistance to airflow and this 
influences the correct inhalation technique through the device [132]. In vitro studies 
showed that, when testing a dry powder inhaler (DPI), increasing the flow rate would 
increase the FPF (fine particle fraction) of the aerosol deposited in the cascade 
impactor body [148, 153]. Although a constant flow is used for in vitro studies of 
aerosol deposition as requested from regulatory agencies, it cannot be solely 
employed to recreate the realistic scenario that occurs in the clinics. Researchers 
have started taking into account the inhalation manoeuvre from patients [126, 240, 
256]. However, authors have used devices containing propellant or placebo to collect 
inhalation profiles through inhalers from patients affected by lung diseases [13, 257]. 
This would be difficult to implement routinely in clinical settings and provide 
meaningful information to prescribers about the suitability of devices for their 
patients. The aim of this chapter was to understand metrics collected from real 
inhalation profiles when inhalers with different resistances to airflow were used with 
patients. This was achieved in three principal studies: (1) a pilot study assessing the 
feasibility of modified spirometry to collect inhalation profiles from healthy volunteers, 
using an inhalation device (i.e. the cyclone spacer); (2) to apply the spirometry 
method to record inhalation profiles from real patients in the clinic suitable to assess 
patient-use issues; and (3) to employ recorded profiles understand the potential in 
vivo performance aspects during development of inhalation devices and formulations 
(i.e. a generic spacer for DPIs). 
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For quality control the BP and USP  [147] state that airflow through an inhaler 
corresponding to 4 kPa is required to test a new device. Moreover, either 4 L (BP) or 
2 L (USP) of air are required to calculate the time for each actuation of the inhaler 
when testing using a cascade impactor. However, a new monograph in the 
Pharmacopoeia mentioned the used of the breath simulation to test the emitted dose 
of nebulizers. Although the constant flow is an appropriate metric to measure the 
particle size distribution and the deagglomeration process of the emitted aerosol, it 
cannot be solely employed to recreate the realistic scenario that occurs in the clinic. 
This is due to the fact that patients do not use a constant flow to inhale the 
medication emitted from an inhaler. Therefore, a more accurate and realistic 
assessment of the aerosol deposition is required, not only in the research field, but 
also in the industry guidance for inhalation. When a patient inhales, an acceleration 
of inhalation first occurs, followed by attaining a maximum flow achievable and it 
terminates with a deceleration to conclude the manoeuvre [12, 13]. Typically, the 
dose is delivered before the maximum peak flow is reached [126]. Some authors 
showed that patients are able to maintain a prolonged inhalation time for devices 
with high resistance, and this was confirmed in Section 5.4.2.1 [13, 125, 236]. The 
use of realistic as well as predicted inhalation profiles has been recently reported 
[152, 245, 246]. 
 
Previously it was shown that the Cheng 2 spacer enhanced the 
deagglomeration of mixed drug agglomerates containing lactose (Chapter 4), 
although the nature of whether blends are potentially adhesively- or cohesively-
balanced may play a major role in the deagglomeration process both in aerosol 
clouds entering the spacer, and for agglomerates present within the spacer (Chapter 
4). Healthy volunteers were recruited to enter a pilot study where their inhalation 
profiles were collected through the Cheng 2. The spacer showed high resistance to 
airflow in the range of Turbuhaler and Handihaler (Chapter 4). However, it was 
suitable for the pilot study as the participants were not affected by impaired lungs. 
De Boer et al [258] showed that the volunteers in their study preferred a medium to 
high resistance device when DPIs with different resistance were tested due to the 
prolonged inhalation profile. Also, the dose is released rapidly for devices such as 
Diskus and Turbuhaler (the latter presents high resistance), although the dose 
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emitted from capsule-containing devices such as the Aerolizer (resistance: 0.02 
kpa0.5L-1min) is released over a longer period of time [242]. The range of PIFs 
achievable when inhaling through the spacer was large; between 52.8 Lmin-1 to 89.1 
Lmin-1 were achievable by the population recruited, whilst a narrower distribution 
was seen for patients for the high resistance device (Table 5.7). The feasibility of 
employing modified spirometry to record inhalation profiles through devices in a rapid 
manner was demonstrated in the pilot study, which enabled the development of a 
protocol for translation to the clinical environment.  
 
The clinically-based study was designed to collect inhalation profiles using a 
rotating disk with five holes that mimic the resistance of marketed inhalers from 80 
patients, in  the chapter only 40 patients (20 COPD and 20 severe asthmatics) were 
analysed and three inhalers (Aerolizer, MDI and Handihaler) were taken into account 
for statistical analysis. The study was designed to provide a sufficient number of 
participants in each of four study groups to investigate the presence of any 
significant differences in inspiratory flow characteristics through inhalation devices 
depending on the disease state of the individual. Several studies were identified 
which addressed the inhalation of patients/volunteers through devices [13, 81, 254, 
256, 259]. The majority of the latter studies did not characterize the full inhalation 
profile. In addition, the results for patients stratified according to the disease severity 
were only reported in a single study [260]. However, the latter study did not report 
the data in a manner suitable for statistical design of the experiment (i.e. no 
tabulated data). Peak inspiratory flow rate (PIFR) through a device has been 
correlated previously to the severity of lung disease, as well as to the 
appropriateness of an emitted aerosol for inhalation therapy. Therefore the PIFR was 
examined in the sample size measurement to estimate an appropriate sample size 
for the patient populations in question. The data in Table 5.4 confirm that variance 
was dissimilar between studies and, between study treatments (for a given study 
group). In only one study was it possible to calculate a pooled variance for both 
study groups for the PIFR in uncategorized asthmatics [254]. The purpose of the 
current study was to recruit equal numbers of patients in each of four groups. The 
data reported in Table 6.4 demonstrated the PIFR, FPF and FPM and a similar 
finding was reported with respect to the Forced Expiratory Volume in 1 second 
(FEV1) which is the directly opposite metric (exhalation) to the PIFR measurements 
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reported by Bland et al [251]. The measured (estimated) difference (  ) between 
reported metric means was calculated and the standardized differences (referred to 
as the effect size throughout) were calculated using the method of Cohen [253].Two 
approaches were used to calculate the effect size. In the first, approach the pooled 
standard deviation of two independent means was employed (referred to as d, 
below). In the second approach the largest standard deviation of the two compared 
studies was employed to provide the most conservative estimate of effect size 
(referred to as dmax, below). Sample sizes and statistical power at a significance level 
of 0.05 were calculated using values of the f(α,p) function obtained from literature 
[251, 252]. In all cases the sample size numbers were increased to the nearest 
whole patient number. The absolute magnitude of difference in PIFR between 
devices would be anticipated to be larger when comparing devices which differ more 
in their resistance. This is seen in Table 5.5, for example by comparing Turbuhaler 
vs. Accuhaler and Accuhaler vs. Handihaler comparisons. 
 
In heterogeneous patient populations with high measurement variance [13] the 
effect size (d, dmax) was observed to be large. An equally large effect size was 
calculated from the reports of Broeders et al. [256]. When examining a more 
homogeneous group of patients (i.e. COPD only [81]) the effect sizes calculated 
were medium-to-large (e.g. dmax 0.54 – 1.62). However, the latter study did not 
stratify the COPD patients according to disease severity. Similarly, the PIFR was 
compared in uncategorized asthmatic patients [254] for two different devices. In this 
instance the dmax values corresponded to a moderate effect level. In attempting to 
estimate the required sample number for the proposed study, the approach was 
taken of using the lowest identified effect size (dmax= 0.54 [191]). The response of 
sample power to effect size was determined for total sample sizes ranging between 
80 and 120 patients (Figure 5.6).The simulation performed assuming the lowest 
effect size of any of the reported studies (dmax = 0.54) was chosen to represent the 
mild asthmatic group and also to account for the fact that the COPD group to be 
recruited is likely to be heterogeneous in their disease state. It can be seen that even 
comparing two heterogeneous patient populations (i.e. uncategorized asthma and 
uncategorized COPD), the disease state is predicted to have a large effect on the 
PIFR. Employing the conservative value of effect size for the latter comparisons 
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(dmax = 1.11) would result in a power > 99 % (Figure 5.7) for comparing a group of 20 
asthmatics with 20 COPD patients in the current study. The strength of the latter 
observations suggests that a sample size of 20 patients in each disease group was 
appropriate to provide a sufficiently powered study to assess differences between 
disease state and PIFR for a particular device. 
 
Several studies have collected the inhalations of patients/volunteers through 
devices [81, 242, 256, 261, 262]. As already reported [81] the PIF achieved by the 
patients though a high resistance device (e.g. 0.048 kpa0.5L-1min) were low 
compared to low resistance inhaler (Table 5.7). It  has been shown that slow flow 
rates were achieved by COPD patients and that it was proportional to the severity of 
their lung disease [81]. Although some authors suggested that a low to medium 
resistance device is a suitable option for those types of patients [81, 246], other 
authors recommended a high resistance device as a more prolonged flow is 
achievable [125, 236, 249]. The latter statement is in accordance with the data 
collected using the Handihaler (resistance 0.048 kpa0.5L-1min, Figure 5.5). 
 
As previously reported [125], the patients showed a prolonged breath profile 
with the Handihaler and this can be beneficial as longer inhalation time could lead to 
better coarse particle deagglomeration. This is in accordance with the current study 
where the inhalation time was double for COPD patients than asthmatics when 
inhaling to the highest resistance device (0.048 kpa0.5L-1min, Table 5.7). Moreover, 
the expected flow rate was achieved for that particular inhaler (e.g. 40 Lmin-1 for the 
Handihaler) suggesting that potentially air was still drawn in the lungs during 
inhalation. It has been suggested [164, 166] that when flow is applied to a modified 
device with the same resistance of the Handihaler the turbulence through the inhaler 
increases, enhancing the potential deagglomeration of the emitted dose. De Boer et 
al [258] showed that the volunteers in their study preferred the medium to high 
resistance device when DPIs with different resistance were tested due to the 
prolonged inhalation profile. Janssens et al. [237] showed that the majority of the 
patients with COPD were able to achieve flow rates > 45 Lmin-1 when the In-Check 
Dial was used. The In-Check Dial is a device that mimics the resistance of marketed 
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inhalers such as Aerolizer, Diskus, Turbuhaler and MDI. When the Aerolizer was 
used, 87.5% of the population achieved inspiratory flow > 45 Lmin-1 as well as at 30 
Lmin-1. In the current study the patients inhaled with a much higher flow rate for the 
medium resistance device representing the Aerolizer (Table 5.7). Moreover, when 
patients inhaled through the spirometer with the mouthpiece that mimics the 
resistance of the MDI inappropriate technique was recorded (Figure 5.8) [74]. The 
rapid manoeuvre was achieved owing to the poor perception of flow rate against the 
low resistance. The MDI is an ultralow-resistance device, which means that it is 
relatively easy to generate too great an inspiratory flow, which is a common error in 
the use of MDIs [74]. The PIFs achieved for the MDI were higher the previously 
reported data for patients with good technique [85], although patients with poor 
technique do inhale as rapidly as 240 Lmin-1 [263]. The inhalation volume achieved 
by the asthmatic patients through both Aerolizer and Handihaler are in agreement 
with the data shown by Delvadia et al. [249], although the authors generated 
empirically the inhalation profiles from healthy volunteers. Moreover, as previously 
suggested [125, 236, 249], patients to inhale longer for a high resistance devices 
(Table 5.7), although inter-patient variability is still shown.  
 
The aerosol deposition of strongly (SX:FL:CL) and weakly (SS:FL:CL) 
agglomerating blends in the cascade impactor was assessed using both inhalation 
profiles and peak inspiratory flows collected from the volunteers. The emission from 
the spacer was higher for the SX blends than SS formulations (16.02 ± 7.13 % for 
SX vs. 12.59 ± 0.95% for SS), which led to a greater throat deposition for the former 
and a greater FPF (%sED and %ED) for the latter, although unchanged with 
increasing flow rate (Table 5.8). When comparing PIF vs. inhalation profiles, the % 
emission had the same trend, although was lower for both formulations when using 
the inhalation profiles. The particle size distribution (PSD) differed between the 
inhalation profiles and PIF (e.g. compare the ranking of the distributions for the 90th 
(green) and 75th (pink) percentiles (Figure 5.10 and 5.11) for both SS:FL:CL and 
SX:FL:CL. It has been suggested [247] that the particle size of the aerosols is 
unchanged when constant flow or breath simulated profiles are employed, as long as 
the flow rates are set as near as possible the PIF achieved in the profile. When 
employing PIFs a lower FPF (%sED) was observed (p<0.05) for SX:FL:CL (e.g. 
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72.39 ± 3.92% for the 50th percentile PIF) than SS:FL:CL (e.g. 99.97± 0.08% for the 
50th percentile PIF).  
 
In Chapter 4, the aerosolization of SS was dominated by impaction events in 
the cyclone unlike SX blends. The contrasting behaviour for SS and SX when 
comparing PIF to inhalation profiles presumably occurs as, during the inhalation 
profiles, the steady flow is not present. Instead, due to the acceleration and 
deceleration it is hypothesized that lower force is applied to aerosolize the particles 
[12, 13]. This would also explain the variable % emission when comparing the two 
metrics.  An interesting result, when using the inhalation profiles as metric to assess 
the aerosol distribution, was that the AIT/PS deposition for the formulations was not 
constant when increasing the flow, unlike when the PIF was used. The flow rate 
dependence of the throat deposition was not mitigated with the Cheng 2 in place 
especially at low inhalation profiles. Less AIT/PS deposition was observed when the 
Cheng 2 was used with PIFs, but not when the profiles were used, instead. 
Interestingly, this phenomena did not happen at  flow rates above 70 Lmin-1, 
probably due to more control of the volunteers at maintaining the flow through a high 
resistance device [125].  
 
As previously showed in Chapter 4, SX blends showed a greater throat 
deposition than weakly agglomerated particles. Interestingly, the throat deposition 
was doubled when the IP was used due to the low acceleration during the inhalation 
profile than when PIF was used. The respirable fraction of SX formulations were 
slightly higher than SS blends (Table 5.10) when low inhalation energy was supplied 
(e.g. at inhalation profiles and at low PIF). This is probably due to both physico-
chemical properties of the APIs (e.g. the deagglomeration process is affected due to 
different agglomeration strength of SS and SX particles with lactose, respectively) 
and to the use of a constant energy that enhanced deagglomeration of the weakly 
agglomerated SS blends (e.g. PIF). Together with the % emission, also the FPD 
values were decreased when the inhalation profiles were used compared to the PIF. 
The Cheng 2 showed relatively consistent MMADs but variable FPDs, especially at 
low flow rates and inhalation profiles (Table 5.10).  This is probably due to the fact 
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that at low energy the capsule does not spin in the device, releasing a lower dose 
than when high flow rates are employed [175]. The current project showed that the 
PIF was probably not an adequate metric to assess inter-subject variability in fine 
particle delivery from the cyclone spacer. 
5.6. Conclusions 
This chapter has developed, piloted and implemented a rapid screening 
modified spirometric method for rapid identification of the ability of patients to inhale 
through inhalation devices with a wide range of resistances to inhalation. The study 
showed no significant difference for the majority of the metrics of inhalation 
performance (e.g. the peak inspiratory flow) between patient disease groups when 
examining specific inhalation device resistances, although within groups, patients 
achieved low flow rates and longer inhalation time for a device with high (0.048 
kpa0.5L-1min) resistance to airflow (i.e. Handihaler) than a device with 0.020 kpa0.5L-
1min resistance to the air (Aerolizer). Significant difference was seen in the IV, 
instead, suggesting the using only the PIF as a sole metric is not appropriate. 
Variability in the flow achievable by the patients is still an issue. This is expected to 
lead to variable lung deposition, oropharyngeal impaction and a high particle size of 
the dose. It is apparent that strategies to mitigate against the variability are therefore 
required, analogous to the use of spacer devices for metered dose inhalers. 
Accordingly the pilot study conducted with inhalation profiles collected from healthy 
volunteers were employed in patient-centred device testing. The full assessment of 
spacer functionality showed that a simulation of real-life inhalation conditions is 
required to understand the device performance. The crucial dependence of drug 
delivery performance on physico-chemical properties of the formulation (e.g. 
cohesive vs. adhesive balance) was revealed by the mismatch between fine particle 
delivery when square wave peak inspiratory flows were tested compared to the 
profiles of real volunteer inhalations, as acceleration and inhaled volumes are 
parameters to consider. The observation that, by using the cyclone spacer, the 
variability in the aerodynamic diameter and fine particle delivery were consistently 
minimized alongside the reduction in throat deposition, represent highly positive 
finding of relevance to realistic application to patient therapy. 
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6 Chapter 6: General Discussion 
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Asthma and COPD (chronic obstructive pulmonary disease) are considered 
diseases of major burden worldwide. The WHO (World Health Organization) 
estimated that 64 million people have COPD, 3 million people died of COPD and 235 
million people suffer from asthma. These diseases could be a cause of death 
worldwide in the near future [264]. Moreover, they are common in both high income 
and developing countries. In the latter, between 6.5 to 7.7 % of the population suffers 
from chronic bronchitis due to open-fire cooking with high child mortality [16]. In the 
UK, the NHS  registered more than 1,200 deaths per year from asthma [11] and 
increased rates of hospitalization for both asthmatic and COPD patients [67]. 
Metered dose inhalers (MDIs) and dry powder inhalers (DPIs) have been used 
widely with consistent improvements in the user-friendliness and efficiency of 
delivered dose for these portable therapies over the last fifty years. However, poor 
response to inhaled medicine is still common probably due to underestimated 
symptoms, poor adherence of patients or due to incorrect inhalation technique. This 
thesis has sought to address several poorly investigated issues relating to poor 
management of lung disease using DPIs. The latter issues were: physical capacity to 
use inhalers correctly; specificity of lung deposition of inhaled formulations; and 
reduction of oropharyngeal deposition as a potential strategy to improve compliance.  
 
Poor management of asthma leads to a progression of the disease and needs to 
be controlled as exacerbations lead to poor quality of life. It has been reported [11, 
68] that patients are not familiar with the prescribed medications and/or are not well 
aware of their symptoms. This leads to a poor adherence/concordance of the patient 
to/with their inhalation therapy and, subsequently poor disease control. Moreover, 
due to their inexperience, a poor inhalation technique is displayed [11, 68, 69]. The 
medical staff is frequently unaware of the patient’s poor technique and the incorrect 
inhaler may be prescribed. Especially when MDIs are used, patients do not inhale 
properly through the device (i.e. slow and deep inhalation) [74]. In the current study 
the highest peak inspiratory flows recorded for asthmatic patients through an MDI 
were 287 Lmin-1 and 248 Lmin-1 for COPD patients.  The issue of high flow rates 
through the MDI as an incorrect inhalation technique was previously reported [263]. 
Patients, often do not differentiate the inhalation technique from an MDI and a DPI 
(i.e. “inhale as fast and as deep as you can” manoeuvre). The  inhalation strength 
required for DPIs is to create turbulent energy for aerosolization of the dose [74]. 
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Failing to achieve that,  the dose delivered to the lungs can be compromised [69]. 
Moreover, due to the different types of asthma and lung diseases, high inter-patient 
variability in the achieved peak  flow rate is reported [77, 85]; although considering 
only the peak flow rate ignores the potential source of variability. In fact, the 
variability seen between patients lies mainly in the first, acceleration part of the 
inhalation manoeuvre, and many studies reported that the medication is inhaled 
before the peak inspiratory flow in reached [12, 125, 126]. 
 
The achieved airflows and profiles variability lead to low deposition of the 
emitted dose of the medication in the specific lung regions for therapeutic effect. 
Also, due to the low inhalation strength of the patients during therapy, most of the 
emitted powder impacts on the throat. This leads to side effects with corticosteroid 
medications. Available already in the market, there are some training tools to help 
the patients understand the appropriate technique to use when inhaling through a 
device, such as the Flo-Tone or the Novolizer. These device emit signals that either 
inform the patients of the appropriate inhalation technique used or whether sufficient 
drug has been delivered to the lungs [145]. Pharmaceutical companies are also 
moving forward in the design technology, leading to inhalers that liberate fine 
particles suitable to deep lung deposition. Some example are the Airmax® [92, 93] 
that has a design similar to MDI and the Conix® [91, 146] that contains a miniature 
reverse airflow cyclone to capture coarse carrier that might impact in the patient 
throat during inhalation. Although similar technologies have addressed and 
attempted to overcome the main issues of DPI delivery of carrier particles, inter-
patient variability in the particle size and delivered dose is still observed. Moreover, 
the technology is applied only to specific branded inhalers and not necessarily the 
required drug substance for a patient. 
 
The primary aim of this PhD thesis was to investigate strategies to minimize the 
flow rate-derived variability of performance when using DPIs. This was achieved 
using prototype reverse airflow cyclones that were intended to function as a spacer 
(Cheng 1 and Cheng 2) for DPIs in order to collect large agglomerates during dose 
emission. This study focused on characterizing the spaces using both marketed and 
in-house formulations and varying flow rates and flow regimes. The secondary aim 
was to formulate a patient-centred testing approach using both healthy volunteers 
218 
 
and patients with obstructive lung disease to understand their inhalation profile 
variability when inhaling against different resistances to airflow. 
 
Each inhaler available in the market has its own typical resistance to inhaled 
airflow. Typically, high flow rates are achieved through DPIs such as Diskus and 
Aerolizer which have low or medium resistance compared to high resistance DPIs 
such as Easyhaler, Turbuhaler and Handihaler [81, 85]. In collaboration with the 
Department of Engineering at Cambridge University, a prototype cyclone spacer 
called Cheng 1 was manufactured to be used with DPIs. The cyclone spacer was 
engineered to retain particles down to a micron-scale size range with the aim of 
creating an classifier with cut off diameter <2 µm. Cascade impactor testing was 
performed at 3 flow rates (30, 45 and 60 L min-1) using a Cyclohaler® and 
aerosolizing the formulation collected from the Ventolin/Accuhaler™. In Chapter 2 a 
much lower throat deposition in the Next Generation Impactor (NGI) was observed 
when the Cyclohaler® was used in series with the Cheng 1 spacer. However the 
spacer did not improve the FPD (fine particle dose) for the ‘inhalable’ aerosol when 
the Cheng 1 was present except at low flow rates. This is possible as at low flow 
rates, lower deagglomeration forces occur and during aerosolization the axially 
downward-flowing vortex and the secondary axially upward-flowing vortex in the 
Cheng 1 might not work properly. This led to high retention of the emitted powder in 
the conical section of the spacer (~ 60% of the emitted powder) and subsequently 
reduced throat deposition [173]. Interesting, the conical section of the Cheng 1 did 
collect the big agglomerate as seen during laser diffraction analysis (Figure 2.11). 
Particles of large mass and inertia are retained in the cone, and only the finest 
particles (e.g. < 5 μm) can escape the cyclone for inhalation [91]. Data shown in 
Chapter 2 suggested that the spacer might reduce the FPD flow rate dependency; 
although without improvement.  
 
An improved FPF of the aerosol that escapes the cyclone (% sED) can be seen 
with the spacer in place. It has been reported that with the Cyclohaler, a cyclonic 
turbulent flow is predominant, increasing the collisions between particle-particle and 
particle-device wall. This would enhance deagglomeration of the emitted dose and, 
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therefore, the FPF [95, 163]. Such deagglomeration was continued and enhanced 
inside the conical section of the Cheng 1 [159]. 
 
When considering the Cyclohaler alone, the FPFs of the emitted SS increased 
from 30 to 60 L min-1 (p value>0.05, Table 2.8) with consequently decreased in the 
IP/PS deposition [163]. Another feature of the cyclone was that the MMAD (mass 
median aerodynamic diameter) was halved for SS and mitigated at 45 and 60 Lmin-1 
suggesting the potential of an enhanced deagglomeration process with the spacer. 
However, because the emitted aerosol size was lower than one expects during 
inhalation therapy (e.g. 0.76 ± 0.04 µm at 60 L min-1 with Cheng 1), the spacer 
needed some engineering improvement. However, it has to be taken into 
consideration that the engineering of the spacer was only proposed to collect big 
agglomerates, without knowledge on potential creation of sub-micronized particles.  
 
CFD revealed near-wall velocity and integral scale strain rates with enhanced 
aerodynamic separation and impaction forces [159]. Moreover, CFD studies [159] 
suggested that impaction on the cyclone wall due to centrifugal forces occurs when 
flow rate is applied at the outlet of the cyclone and therefore, the velocity of the 
emitted particles from the Cyclohaler® would increase the particle-particle and 
particle-wall collisions inside the Cheng 1. However, the resistance of the Cheng 1 
was excessive (0.0805 kPa1/2 /L min-1) and not acceptable for use in patients with 
obstructive lung disease. Moreover, when using a carrier-free product (e.g. 
Turbuhaler/Symbicort), no difference in aerosol emission using the Cheng 1 was 
observed with laser diffraction techniques. On the other hand, large agglomerates 
were observed escaping the Cheng 1 at 60 Lmin-1 as a bi-modal particle size 
distribution was detected by laser diffraction. 
Therefore, a second prototype (Chapter 3) with a much reduced resistance 
(0.04 kPa1/2 min L-1) was manufactured modifying the outlet orifice diameter from a 
circular to an oval shape. The device resistance was within the range of existing 
DPIs (Tubuhaler®, 0.03 kPa1/2 min L-1 and Handihaler®, 0.05 kPa1/2 min L-1) 
acceptable by patients even with severe COPD [125, 168]. This was an improvement 
as patients with lung disease should be able to achieve a reasonable flow rate 
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through the prototype. The new design was also engineered to allow a higher cut off 
diameter (e.g. < 5 µm) than Cheng 1 (which was in the region of 1.0 µm). However, 
due to manufacturing issues, this was not achieved, resulting in a cut off diameter 
which was also very low, although it was higher than Cheng 1 (1.19 – 1.55 µm for 
Cheng 2 and 0.46 – 0.90 µm for Cheng 1). In Chapter 3 the impaction testing using 
Cheng 2 was performed to ensure that the spacer could still mitigate the 
dependence of the respirable dose and of the MMADs on the inhalation flow rate 
using marketed inhalers. The SS was still recovered from the Ventolin/Accuhaler™ 
and emitted through the Cyclohaler® for comparison. The Cheng 2 was then tested 
with: Cyclohaler/SS®, Easyhaler/Budesonide (Bud™ 400 µg/dose) and 
Seretide/Accuhaler™ (Salmeterol xinafoate, SX) 50 µg/dose and fluticasone 
propionate, FP) 500µg/dose). SS was considered as it is reported that it forms 
adhesively-balanced blends when added to lactose [194], Bud is reported to form 
cohesively- balanced blends [195], and SX/FP was considered due their therapeutic 
use as a combination of anti-inflammatory and bronchodilator [196]. In the study, 2 
and 4 kPa were used to aerosolise the formulation in order to represent low and high 
pressure drop achievable by patients and to represent different formulations. 
The engineering issue in designing the Cheng 2 led its axial velocity to be lower 
than Cheng 1. This led to high near wall tangential velocities in the latter allowing 
greater impaction and deagglomeration forces for emitted masses passing through 
the spacer. This potentially may have allowed large agglomerates to exit the cone as 
seen during laser diffraction testing (Figure 3.8). The near wall tangential velocity 
was 3-fold lower for Cheng 2 than Cheng 1 leading to higher impact mass though the 
former. The greater integral strain rate of Cheng 1 led, in fact, to a greater fine 
particle detachment then when Cheng 2 was used.  For instance, the FPF (%ED) for 
SS when Cheng 1 was used was 14.48 ± 5.84 µm at 30 L min
-1, whilst when Cheng 
2 was used for the same API, the FPF (%ED) was 12.90 ± 4.43 µm at 37 L min-1. 
The same trend was observed when the flow rate increased (e.g. 33.42 ± 5.86 µm at 
60 L min-1 when Cheng 1 was employed and 11.39 ± 0.64 µm at 51 L min-1 when 
Cheng 2 was used). Cheng 2 showed lower impaction forces and lower integral 
strain rate by the inlet and at the vortex cone base than Cheng 1 [193]. 
Nevertheless, similar to Cheng 1, high retention of the formulations was detected in 
Cheng 2 possibly due to electrostatic charges occurring in plastic spacers, but also 
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due to the retention of large agglomerates and carrier-bound drug particles. In fact, 
the % emission calculated for the emitted dose of APIs emitted from the inhalers 
when Cheng 2 was employed was low (e.g.  24.51 ± 1.68 % and 19.33 ± 0.46 % for 
Bud and SX respectively at 2 kPa). The low emitted fractions were due to the high 
retention within the spacer (almost 80% of the emitted drug) as seen already for the 
Conix™(80 %) [91]. This would allow decreased in vivo throat deposition [174]. The 
trend of reduced throat deposition seen already for Cheng 1 was observed also for 
Cheng 2 in Chapter 3 for all the formulations tested. However, there was a 
formulation dependency in the performance behaviour with the cyclone in place. For 
instance, the IP/PS deposition for SX and FP was twice that of the Bud or SS (e.g. 
18.44 ± 2.79 % for SS, 15.19 ± 1.74 % for Bud, 36.01 ± 9.77 % for SX and 29.63 ± 
5.85 % for FP at 4 kPa). Harrison et al [146] and Needham et al [91] showed similar 
findings when testing SX/FP formulation and SS  formulation emitted from the 
Conix™. SX and FP cohesive behaviour when blended with coarse carrier might 
lead to a less efficient deagglomeration process than SS when emitted from a device 
as their interaction to the carrier has higher energy than SS  [202]. In accordance 
with data shown in Chapter 2, neither cyclone retention nor IP/PS deposition was 
affected by the flow rate for the SS formulation, nor for any of the drug-device 
formulations tested. Although the extent of IP/PS deposition and cyclone retention 
did depend on the drug formulation/product type (Table 3.9), the potential for flow-
rate independence of oropharyngeal drug deposition for a specific formulation was a 
promising finding towards overcoming inter-patient variability in DPI deposition 
profiles. 
While the cyclone was designed to emit a similar fine particle fraction to the 
inhaler for SS to improve in vitro drug delivery (Chapter 2), it was seen to fail in tis 
aim, since a lower fraction was emitted for SS, and the FPDs of the tested drugs 
decreased compared to the inhalers tested alone with the exception of 
Bud/Easyhaler™ (Table 3.10). Although, the FPDs were lower with the Cheng 2 in 
place than without, the consistency of FPD (and MMAD) between flow rates 
confirmed that the spacer might mitigate the flow rate dependence of the emitted 
aerosol for all formulations. Although the spacer did not perform with 
pharmaceutically equivalence to the inhalers regarding the FPD (i.e. FPDs changed 
when the spacer was used) and very fine particles (e.g. MMADs) were emitted due 
to the less-than-desirable excessively low cut off diameter, the difference in the 
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IP/PS deposition between SS and SX or BUD and FP (that lead to similar difference 
in the FPFs, Table 3.10) was worth being investigated. Therefore, in Chapter 4, in-
house made blends were prepared using what the literature suggested being 
cohesive balanced blends (SX/Lactose) and adhesive balanced blends (SS/lactose).  
 
Similar to when commercial products were tested, variable IP/PS deposition 
and respirable fractions were observed when Cheng 2 was assessed with in-house 
manufactured blends of strongly agglomerating- (SX) and weakly agglomerating- 
(SS) particles with different grades of lactose when Cyclohaler® was used. Although 
the data obtained when the Cheng 2 was in place suggest retention of large 
agglomerates, the APIs seemed to deagglomerate differently inside the conical 
section of the spacer. In Chapter 4, it was observed that the presence of FL would 
improve the emission of both strongly agglomerated- (SX) and weakly agglomerated- 
(SS) particles in presence of the spacer  (10.25 ± 3.85% for SS:CL and 22.86 ± 4.30 
% for SS:FL:CL vs. 16.30 ± 3.25 % for SX:CL and 30.64 ± 10.44 for SX:FL:CL at 4 
kPa, p<0.05). This is probably due to the fact that SS is still attached to the lactose 
and has low impaction forces in the spacer. On the other hand, the creation of small 
SX agglomerates may lead to greater % of emitted dose. However, the SX 
agglomerates seemed not to break-up as the FPF (%sED) was lower than the SS 
FPF (%sED): e.g. 76.66 ± 1.35 % for SX:FL:CL vs. 81.83 ± 4.11 % for SS:FL:CL at 4 
kPa). The same difference was observed in the IP/PS deposition with SX blends 
having higher impaction in this particular stage then SS (65.83 ± 8.99 % vs. 45.83 ± 
5.04 % for SS:CL and SX:CL, respectively). It seems that the deagglomeration 
forces inside the conical section of the spacer have a greater impact on the 
formulation when a large particle size carrier is used.  
 
Studying the deagglomeration process of the dispersed powder as a function of 
the flow rate prior to entering the spacer is important to understand the outcome 
when a DPI is used for the powder emission. Fine particle formulations showed an 
exponential trend in the deagglomeration process when a pressure drop was 
applied, reaching a plateau point of maximum deagglomeration. On the other hand, 
when coarse lactose was added to the micronized material, a bi-exponential trend 
was observed without a maximum deagglomeration. As expected, API:FL:CL blends, 
223 
 
showed a greater % of deagglomeration than API:CL formulation. This might explain 
the greater FPF seen for blends with FL when either the Cyclohaler or the Cheng 2 
was used in the aerosolization studies (i.e. because of enhanced mixed agglomerate 
liberation from the formulation prior to entering the cyclone. This was confirmed by 
SEM (scanning electron microscopy) study. SX:FL:CL showed agglomerates on the 
lactose surface and a greater quantity of "free agglomerates" than SS:FL:CL, 
explaining the greater % deagglomeration seen for SS:FL:CL than SX:FL:CL (Table 
4.8), as lower energy was required to release the agglomerates form the carrier 
surface. 
 
The data shown in Chapters 2, 3 and 4 were obtained using constant (square-
wave) airflow. However, in reality, patients breathe using an inhalation loop with 
acceleration and deceleration of the flow. Therefore, a patient-centred study 
approach was developed and performed using the Cheng 2 with healthy volunteers, 
and a mouthpiece air-restrictor that can vary the resistance to inhalation airflow with 
asthmatics and COPD patients. This was performed to collect inhalation profiles 
through multiple devices and obtain a measure of inter-patient variability. Using a 
breathing simulator, inhalation profiles of healthy volunteers were used for in vitro 
testing. A wide range of flow rates were achieved by the volunteers through the 
Cheng 2. Aerosolization studies of SX:FL:CL and SS:FL:CL were performed using 
the NGI with the idealized throat at the PIF (peak inspiratory flow) and inhalation 
profiles for those corresponding PIFs in the range 10 – 90% of the population PIF 
distribution. The Cyclohaler® was used in series with the Cheng 2.  
 
The particle size distribution (PSD), differed between the inhalation profiles and 
PIF for both SS:FL:CL and SX:FL:CL. It had been suggested [256] that the particle 
size of an aerosol is identical for a constant flow and an inhalation profile provided 
the constant flow rate approximates the PIF achieved in the profile. Although 
emission of SX from the spacer was higher than the SS formulation when inhalation 
profiles were used, the % emission was dramatically reduced compared to when 
PIFs were used instead. The throat deposition for SX blends was similar for all the 
PIFs tested (e.g.27.89 ± 3.32% for the 25th percentile PIF and 25.45 ± 3.08% for the 
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90th percentile PIF). Interestingly, when employing PIFs a lower FPF (%sED) was 
observed (p<0.05) for SX:FL:CL (e.g. 72.39 ± 3.92% at 50th percentile PIF) than 
SS:FL:CL (e.g. 99.97± 0.08% at 50th percentile PIF). In Chapter 3 and 4, the data 
showed that aerosolization of weakly agglomerated SS blended with lactose was 
dominated by impaction events in the cyclone unlike aerosolization of small but 
strongly coherent agglomerates of SX. The contrasting behaviour for SS and SX 
when comparing PIF to inhalation profiles presumably occurs as, during the 
inhalation profiles, the steady flow required to release SS from the carrier is not 
present. Instead, due to the acceleration and deceleration, it is hypothesized that 
lower force is applied to aerosolize the particles. Therefore, it is evident that the PIF 
was not an adequate metric to assess inter-subject variability in fine particle delivery 
from a dry powder inhaler. 
 
The study used spirometer technology to collect inhalation profiles from 
patients in an attempt to identify metrics to quantify inter-patient variability in 
inhalation for use in patient-centred testing designs. The study was performed in 
respiratory clinics through a mouthpiece air-restrictor that mimic the resistance of 
inhalers available in the market. Data suggested that when patients inhaled though a 
very low resistance device such as an MDI, patients tended to inhale rapidly, which 
is an incorrect technique for MDIs but may be appropriate for low resistance DPIs 
[74]. This led to flow rate above 200 Lmin-1 being achieved, however the duration of 
inhalation was typically shorter than recommended. Interestingly, when a high 
resistance mouthpiece was used, patients, especially COPD volunteers, tended to 
inhaler longer than through low resistance device, suggesting that air was still 
entering into the distal lung regions (e.g. alveoli) [125, 236, 249]. Therefore, although 
some authors suggested that a low to medium resistance device is a suitable option 
for those types of patients [81, 246], probably a higher resistance device should be 
preferred due to the longer inhalation time allowing the formulation to deaggregate 
better and reach the lower regions of the lung during the lengthy inhalation[125, 236, 
249]. 
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The work of this thesis has shown, in vitro, that a prototype spacer based on 
reverse airflow cyclone technology offers some potential to mitigate the flow rate 
dependency of aerodynamic particle size. However, the respirable dose represented 
by the FPD did decrease with the spacer. This was unexpected, as was the 
enhanced delivery of sub-micron particles which may not be suitable for inhalation 
therapy – and certainly could not be considered pharmaceutically equivalent. Also, 
consideration regarding the physicochemical properties of the API in the formulation 
needs to be made prior using the spacer. The thesis has also shown that considering 
only the PIF is not a realistic metric when attempting to address the bio-relevance of 
in vitro aerosolisation performance studies, despite the acceptance of square-wave 
PIFs in quality control testing. Inhalation profiles should be taken into account with 
compendial testing in order to achieve a more realistic scenario and data for 
interpretation during inhaled product design. Therefore acceleration, inhalation 
volume and other parameters that account for the full inhalation profiles should be 
considered during in vitro study. Aerosolisation studies in the future must take into 
account the inhalation profiles achieved by those patients being treated. This thesis 
has also shown the necessity to develop appropriate and reliable tools for clinicians 
to facilitate prescribing of a product which maximizes specific lung deposition for 
their patients, and which addresses the preponderance for throat deposition, an all-
too-frequent cause for poor patient compliance with inhaled therapies. 
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